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1. REVIEW OF THE RELATED LITERATURE 
1.1 Pain Mechanisms 
1.1.1 Historical Account 
Pain is one of the most common experiences of man and the expla-
nations of its nature probably one of his oldest preoccupations. 
Throughout the years, several theories have been proposed to explain 
the phenomenon of pain; as research evidence began to accumulate all 
these theories have been shown to be inadequate. 
One of the earlier writers on pain, Aristotle, considered pain 
to be a manifestation of the soul, an emotion, and the epitome of un-
pleasantness (Aristotle [330 B.C.?] cited by Hardy et al., 1952). 
Man was thought to continuously fluctuate between two emotional states 
of pleasure and pain; thus, pain was equated with the unpleasantness 
one experiences throughout his/her life (Aristotle [330 B.C.?] cited 
by Hardy et al., 1952). 
The view of pain as an emotional state was championed until the 
end of the eighteenth century when Darwin proposed the Intensive The-
ory of pain (Darwin, 1794, cited by Hardy et al., 1952). The Inten-
sive Theory considered pain to occur whenever any of the "sensorial 
emotions" namely heat, touch, sight, taste, or smell were stronger 
than usual (Darwin, 1794, cited by Hardy et al., 1952). Although the 
Intensive Theory was popular for a long time, evidence now demon-
1 
strates that in some cases pain is in itself a particular form of 
sensation (Sweet, 1959; Dash and Deshpande, 1976). 
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The twentieth century saw the Intensive Theory of pain replaced 
by the Specificity Theory which until recently was the theory taught 
in medical schools (DeSousa and Wallace, 1977). The Specificity The-
ory implies a straight-through transmission system from somatic pain 
receptors via specialized pain fibers and a pain pathway to a "pain 
center" in the brain (Sweet, 1959). Evidence today, however, suggests 
that the perception of pain cannot be directly related to the neural 
activity in any particular anatomical structure (Melzack and Wall, 
1965). Furthermore, pain is influenced by many psychological vari-
ables such as attention, anxiety, suggestion, and prior conditioning; 
thus, the perception of pain includes a very pervasive psychological 
component (Melzack and Wall, 1965). 
Recently, research concerning pain has moved in the direction of 
investigating the plasticity and modifiability of events in the cen-
tral nervous system (CNS) through various physiological and psychol-
ogical techniques; these techniques will be reviewed briefly; perti-
nent physiological and anatomical descriptions also will be presented. 
In addition, the involvement of the cholinergic, serotonergic, and 
endogenous opioid systems in the rhenomenon of pain will be reviewed. 
However, before proceeding any further, it is necessary to define some 
relevant terms which will be employed throughout this dissertation. 
1.1.2 Definitions 
Just as there have been many theories proposed to explain the 
phenomenon of pain, many definitions have been proposed. Analysis of 
the current literature suggests that the term "pain" must be defined 
in terms of psychology rather than physiology, and therefore is only 
applicable for use when describing the human experience. Merskey 
( 1978) has proposed the following definition of pain: "pain is an un-
pleasant experience which we primarily associate with tissue damage 
or describe in terms of tissue damage or both". 
Next, the term "nociception" is defined as potentially tissue-
damaging thermal, mechanical, or chemical energy impinging upon spe-
cialized nerve endings called nociceptors (Fordyce, 1978). In this 
3 
scheme, the pain experience must be perceived in order for it to be 
said to have occurred. However, nociceptive input for pain needs not 
occur since man may perceive pain even in the absence of noxious 
stimuli such as in phantom limb pain. Similarly, the presence of nox-
ious stimuli does not insure the experience of pain since various 
neurological defects, the administration of drugs, or other factors 
make it possible for noxious stimuli to exist without being perceived. 
Thus, the terms pain and nociception although related to one another 
clearly are not interchangeable. 
Finally, the terms "analgesia" and "antinociception" are defined 
as the failure of an organism to exhibit pain- and nociceptive-induced 
behaviors, respectively; behavior is defined as observable, measurable, 
4 
overt, verbal and non-verbal actions of an organism (Fordyce, 1978). 
In regards to pain and. nociception, the essence of the problem is that 
there are pain- and nociceptive-induced behaviors. It is these part-
icular behaviors such as the various autonomic responses and voluntary 
or reflex muscular movements in laboratory animals as well as the 
verbal and non-verbal descriptions by humans which are observed and 
quantitated in the study of nociception and pain. 
1.1.3 Psychological Factors Influencing Pain 
Presently, there exists a large and increasing body of evidence 
which suggests that pain is influenced by a variety of psychological 
factors (Sternbach, 1978). To understand pain first one must take 
into account its interaction with the overall total personality. 
Since an individual's personality is shaped from birth, a develop-
mental analysis might prove useful in demonstrating the importance of 
early childhood events in shaping the pain experience. Pozanski 
(1976) demonstrated that children (age 5 to 16 years) who exhibit 
recurrent pain syndromes, for which there is no evident organic cau-
sation, such as chronic abdominal pain, headache, and limb pain come 
from families in which the parents themselves were more prone to 
exhibit pain behaviors. Pozanski (1976) suggests that the models 
presented by parents influenced pain associated behaviors in their 
children. 
Second, pain also has a very important cultur~l dimension. 
People respond to pain not only as individuals but also as members of 
their cultural heritage. While differences in pain behavior among 
cultural and ethnic groups are not well understood, consistencies 
within a particular group suggest that members of the group model 
normative standards for both the degree and way in which suffering 
is perceived and exhibited (Craig, 1978). Cultural specific attitudes 
towards pain can be summarized as follows: Yankees are apathetic, 
matter of fact, doctor-help oriented; Jews are concerned about im-
plications of pain and distrust pain relief procedures; Italians 
readily express desire for pain relief; Irish block both expressions 
of suffering and concern for the implications of pain (Craig, 1978). 
Third, some reinforcing, environmentally situated events may be 
pain contingent; that is, certain reinforcing events will not occur 
unless preceded by pain behaviors. Pain medications prescribed on 
5 
a "take only as needed" basis may be effective reinforcers or posi-
tive consequences of pain-related behavior or pain percetion if the 
patient feels better when sedated or analgetic (Fordyce, 1978). Sim-
ilarly, accident victims or wounded war heroes who are in pain may 
receive love,· attention, and .affection as rewards for pain behavior 
(DeSousa and Wallace, 1977). Finally, pain behavior is often rewarded 
financially; monetary compensation after successful litigation is an 
excellent reinforcement causing people to remain in pain (DeSousa and 
Wallace, 1977). 
Indirect reinfo=cement of pain behavior may occur when pain be-
havior leads to avoidance of some aversive or unpleasant consequence 
such as avoiding an unpleasant job, a threatening social encounter, 
or an aversive set of duties and responsibilities (Fordyce, 1978). 
Paraphrased, "when I am in pain, bad things don't happen which other-
wise would (Fordyce, 1978)". 
Fourth, in order for any stimulus to produce pain it must affect 
either the arousal or selective aspects of the patient's attention. 
Since an individual possesses a finite attention capacity, it follows 
that involvement of attention in one area will be accompanied by re-
moval of attention from another area. In fact, almost any situation 
that attracts intensive maintained attention will diminish or abolish 
pain perception (Melzack, 1961). 
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Strong relationships between pain and mood have been demonstrated. 
Anxiety is generally recognized as inceasing pain; thus, anything 
which diminishes anxiety may be expected to diminish pain (Merskey, 
1978) . Even the mere presence of the word pain during instructions 
in an experimental situation decreased the level of electroshock pain 
in patients as compared to a group of patients in which the mention of 
pain was not made during the instructional process (Hall and Stride, 
1954). On the other hand, excitement or aggression may leave subjects 
totally oblivious.even to serious trauma. Most notable examples are 
(i) football players and other sportsmen who suffer traumatic blows 
during competition but do not notice any pain until the contest is 
completed and (ii) severely wounded soldiers performing heroic tasks 
in spite of apparently incapacitating injuries (Merskey, 1978). 
Overall, a most important psychological component of pain has 
been amply demonstrated. The next section reviews the many pertinent 
physiological and anatomical aspects of pain. 
1.1.4 Physiological and Anatomical Correlates 
1.1.4.1 Nociceptors 
7 
Specific somatic receptors, called nociceptors, which convey 
neural impulses arising from a noxious stimuli have been identified 
and characterized as follows: (i) nociceptors are much more resistant 
to damage from noxious input than the low threshold mechanical and 
thermal receptors (ii) nociceptors have higher thresholds with respect 
to all stimuli in comparison to other sensory receptors of the same 
tissue and (iii) unlike other receptors, nociceptors undergo the 
process of sensitization; that is, repeated stimulation reduces the 
threshold for activation and increases the £requency of discharge per 
unit of stimulus (Perl, 1976). 
Nociceptors can be classified by measuring the discharge f:::-e-
quency of isolated peripheral nerves in response to a variety of nox· 
ious and innocuous stimuli applied to the skin (Besson and Perl, 1969). 
Briefly, (i) "mechanical nociceptors" respond to strong mechanical 
stimuli but are not at all excited by noxious thermal stimuli, (ii) 
"mechanical and thermal nociceptors" respond to both strong mechanical 
and noxious cold, and (iii) "polymodal nociceptors" respond to noxious 
mechanical, cold, and heat stimuli (Angel, 1977). In addition, a 
fourth group of nociceptors called "chemosensitive nociceptors" has 
been identified in the anesthetized skin of leprosy patients; the 
application of several algesic substances to blistered skin produced 
pain as measured by the patients verbal reports; noxious thermal and 
mechanical stimuli were ineffective (Dash and Deshpande, 1976) .. 
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The morphological structure of nociceptors has not been iden-
tified unequivocally. Attempts to describe the morphological substrate 
for nociceptors have been based upon delineation of the receptor 
function of a spot of skin with subsequent fixation, excision, and 
histological examination, or by the functional isolation of a known 
structure and accurate determination of its adequate stimulus (Angel, 
1977) . Research in this area has been concentrated on the receptor 
structure in the human tooth since most authorities believe that only 
the sensation of pain is felt when any form of stimulation is applied 
to the dental pulp (Scott and Maziarz, 1976). 
For many years, free nerve endings were considered to be noci-
ceptors. However, most receptors in mammalian hairy skin are of this 
type indica~ing that such endings probably subserve sensations other 
than pain (Weddell et al., 1955). In addition, the cornea lS inner-
vated exclusively by free nerve endings but mediates sensations of 
touch, pressure, and temperature as well as pain (Lele and Weddell, 
1956). Although no morphological differe~ces are seen among free 
nerve endings, the possibility of physiological specificity remains. 
1.1.4.2 Primary Afferent Nerve Fibers 
Nerve impulses generated by stimulation of nociceptors in the 
body tissues are transmitted along primary afferent nerve fibers to 
various destinations in both the spinal cord and brain (Melzack, 
1973). The peripheral nerve contains a heterogeneous mixture of 
primary afferent fiber types which can· be classified by utilizing a 
knowledge of nerve fiber diameter and impulse conduction velocity. 
A simple classification scheme is summarized as follows: the "A" 
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fiber group consists of five subgroups of myelinated fibers designated 
in order of diminishing fiber diameter (20 to 1 ~m) from alpha (a) 
through epsilon (s); the conduction rate of nerve impulses (120 to 
4 m/s) varies directly with the diameter of the axon (Angel, 1977). 
"C" fibers are unmyelinated, have diameters of 0.3 to 1.5 ~m, and 
conduction rates of 0.4 to 2.0 m/s (Angel, 1977). 
Clark et al. (1935) demonstrated that for the cat C fibers con-
ducted to the CNS neural impulses which elicited autonomic responses 
similar to those produced by noxious stinulation; A fibers were in-
effective. 
In humans, electrical stimulation of A a fibers has been correl-
ated with pricking pain sensations whereas stimulation of A-delta (o) 
and C fibers produced prolonged, chronic, dull, sometimes burning pain 
sensations (Torebjork, 1974; Torebjork and Hallin, 1974; Willer et 
al., 1978). 
Clinical observations do not completely support the role played 
by these small diameter primary afferent fibers in pain perception; 
for instance, two peripheral neuropathies, namely Fabry's Disease 
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and a hereditary sensory disease both result in a decrease of the 
number of small diameter primary afferent fibers found in the pe-
ripheral nerve, but are associated with increased and decreased pain 
sensations, respectively (Wall, 1978). However, since pain perception 
involves numerous higher brain centers as well as primary afferent 
fibers it would be difficult to speculate about the changed state of 
pain perception in neuropathies on the basis solely of the state of 
the primary afferent nerve fiber. 
Finally, Applebaum et al. (1976) demonstrated that 50% of the 
small unmyelinated fibers in the ventral roots arise from dorsal root 
ganglion and are sensory fibers. Furthermore, many of these fibers 
are selectively responsive to noxious cutaneous mechanical and ther-
mal stimuli (Clifton et al., 1976). Thus, these fibers may also par-
ticipate in the transmission of neural impulses arising from noxious 
stimulation. 
1.1.4.3 Spinal Cord Involvement 
The cytoarchitectonic investi~ations of Rexed (1952) established 
that neurons of the dorsal horn of the spinal cord are arranged in a 
series of six clearly defined laminae. The surface of each lamina is 
roughly parallel to the dorsal and ventral surfaces of the cord; 
laminae are numbered consecutively I through VI from the extreme 
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dorsal aspect to the center of the spinal cord. 
Christensen and Perl (1970) demonstrated that lamina I neurons 
are excited by intense thermal and mechanical cutaneous stimulation. 
This finding has been confirmed in several laboratory animals includ-
ing the rat (Giesler et al., 1976). Although experiments involving 
recording from lamina II cells have not been performed extensively, 
Perl (1976) has shown that some lamina II cells were excited by high 
intensity thermal and mechanical stimuli. 
Neurons in lamina V can be excited by noxious thermal and mechan-
ical stimuli (Price and Mayer, 1975). These neurons in contrast to 
lamina I neurons also respond to innocuous thermal and mechanical 
stimuli; their firing rates increase as the stimulus increases through-
out a range of innocuous to noxious intensities; these neurons have 
been called "wide dynamic range neurons" (Price and Mayer, 1975; 
Giesler et al., 1976). 
Neurons located in laminae III and IV show excitatory responses 
to innocuous touch and pressure movements and pressure stimulation; 
however, these neurons were not excited by noxious pressure stimu-
lation(Giesler et al., 1976). 
In summary, it appears that there are two populations of neurons 
in the dorsal horn which are responsive to noxious stimulation: (i) 
lamina I, marginal, neurons and (ii) lamina V, wide dynamic range 
neurons. 
12 
1.1.4.4 Ascending Transmission Systems 
Three anatomically distinct pathways convey sensory information 
from the periphery to the cerebral cortex; they include (i) the 
dorsal column-lemniscothalarnic system, (ii) the spinocervical-lem-
niscothalarnic system, and (iii) the spinothalamic system which con-
sists of spinoreticular, paleospinothalarnic, and neospinothalamic 
components (Angel, 1977). It appears that all three ascending trans-
mission systems participate in the transmission of neural impulses 
arising from noxious input (Dennis and Melzack, 1977). 
For years the dorsal columns has been viewed as carriers only 
of innocuous touch and proprioceptive information. While this still 
appears to be the case for primary afferent fibers ascending in the 
dorsal columns it can no longer be said of the secondary afferent 
fibers. Petit (1972) determined that 9.3% of fibers examined in the 
dorsal columns originated from spinal neurons. The frequency of 
evoked tonic discharge in these secondary afferent fibers increased 
accordingly to the strength of applied heat and mechanical stimulus 
even when the stimulus was brought well into the noxious range (Petit, 
1972). Thus, the dorsal column-lemniscothalamic system has the cap-
acity to transmit nociceptive information. 
Neurons which demonstrate increased discharge frequencies in 
response to noxious mechanical and thermal stimuli have been shown 
to be present in the spinocervical tracts of the cat (Price and Brown, 
1975) and monkey (Bryan et al., 1974). In addition, some of these 
cells respond exclusively to noxious mechanical stimulation (Bryan 
et al., 1974) . 
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The spinothalamic system is believed to be the principal path-
way for conveying nociceptive information in man and primates 
(Willis, 1976). Trevino et al. (1974) demonstrated that many spino-
thalamic neurons have their origins in spinal cord laminae known to 
be associated with the transmission of nociceptive information such 
as laminae I, IV, and V (see section 1.1.4.3). 
Price and Mayer (1975) demonstrated that 50% (41 out of 82) 
of the cells studied in the anterolateral quadrant of the spinal 
cord responded to both innocuous and noxious mechanical stimuli 
while 12% (10 out of 82) of the cells studied responded only to 
noxious mechanical stimuli. Similar results in studies of the 
projections to various midline and intra-laminar thalamic nuclei 
(Willis, 1976) via the spinothalamic tract as well as to the medul-
lary reticular formation (Fields et al., 1975) via the spinoretic-
ular tract also have been obtained. 
Finally, it should be pointed out that specific central struc-
tures (such as the nuclei of the lateral diencephalon) which receive 
neural input via the rapidly conducting dorsal column, spinocervi-
cal, and ~eospinothalamic tracts are activated prior to other 
central sites (such as midline and intralaminal thalamic nuclei 
and brain stem reticular formation) to which the slowly conducting 
paleospinothalamic and spinoreticular tracts ascend, respectively 
(Bowsher, 1976). Dennis and Melzack (1977) suggest that the rapidly 
conducting systems convey phasic information about pain whereas the 
slowly conducting systems carry tonic information. 
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Overall, it appears that all of the ascending tracts discussed 
above participate in the transmission of nociceptive information to 
various higher centers in the CNS. The heterogeneity of the ascending 
systems in terms of termination sites as well as the rate at which 
neural impulses are transmitted suggest that specific ascending 
systems may selectively activate not only anatomically specific brain 
sites but also physiologically specific mechanisms. 
1.1.4.5 Supraspinal Associated Structures 
Various supraspinal structures such as the reticular formation, 
thalamus, and cortex have been implicated in processing information 
concerning noxious stimulation (Kerr and Wilson, 1978). 
Casey et al. (1974) have demonstrated that 57% (59 out of 104) 
of the units studied in the medullary nucleus reticularis giganto-
cellularis responded to innocuous and noxious mechanical stimuli; in 
addition, 25% of these units responded exclusively to noxious mechan-
ical stimuli. Investigations of the nucleus ventralis of the medulla 
have also demonstrated that a majority of cells (70%) respond to nox-
ious heat and mechanical stimulation; some of these cells respond ex-
clusively to noxious stimulation (Benjamin, 1970). 
Imprecisely defined regions in the pontine reticular formation 
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(Eickhoff et al., 1978), mesencephalic reticular formation (Young and 
Gottschaldt,l976;Eickhoff et al., 1978), and mesencephalic central 
grey region (Eickhoff et al., 1978) also contain cells which respond 
to noxious stimulation. Again, the majority (>70%) of the units test-
ed in each study responded to innocuous as well as noxious heat and 
mechanical stimuli; some (>16%) of the units tested respond exclu~ 
sively to noxious stimulation. 
The thalamic posterior group of nuclei (PO) contain neurons which 
resp?nd to noxious stimulation of the skin; 30% of 258 neurons studied 
were determined to be nociceptive; 16% responded exclusively to nox-
ious mechanical stimuli while 14% of the cells responded differentially 
to both noxious and innocuous mechanical stimulation (Dong and Wagman, 
1976). 
Similarly, neurons in the medial thalamus particularly the nu-
cleus parafasicularis, respond to noxious mechanical stimuli; however, 
more than half of the nociceptive neurons in the medial thalamus, 
unlike the nociceptive cells in the PO, did not respond to innocuous 
mechanical stimulation (Dong et al., 1978). Thus, the thalamus partic-
ipates in the nociceptive phenomenon. 
Cerebral cortical involvement in the appreciation of nociceptive 
input has been suggested by the following experiments. First, ablation 
of the secondary somatosensory cortex, the anterior ectosylvian gyrus, 
and its bordering sulci increased the escape threshold to noxious elec-
tric shock in cats; ablation of the primary somatosensory cortex was 
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ineffective (Berkely and Parmer, 1974). 
Second, specific evoked potentials (EPs) have been demonstrated 
to arise from noxious tooth pulp stimulation in man; tooth pulp-
evoked potentials were not present when devitalized teeth of normal 
patients were stimulated or when an individual congenitally insensi-
tive to pain was used as the subject (Chatrian et al., 1975). Re-
cently, Chen et al. (1979) demonstrated that the amplitudes of spe-
cific components of the EP waveform were directly related to the stim-
ulus intensity and subjective pain response as measured by the sub-
ject's verbal reports. 
1.1.4.6 Descending Systems 
Anatomically, the brain stem reticular formation receives input 
fibers from a number of higher centers. Axon degeneration studies 
have demonstrated that fibers originating in all parts of the cere-
bral cortex, especially the motor cortex, descend to terminate in the 
brain stem reticular formation; the majority of these fibers end in 
two fairly well defined areas, the pontine nucleus pontis oralis, and 
the medullary nucleus reticularis gigantocellularis (Rossi and Brodal, 
1956) . Electrical stimulation of intralaminar and midline thalamic 
nuclei has been shown by intracellular recording techniques to depo-
larize cells located in pontine and medullary reticular formation 
(Mancia et al., 1974a). The existence of intrareticular connections 
within the brainstem itself wh~ch produce primarily ascending inhibi-
tory effects also have been demonstrated by intracellular recording 
techniques (Mancia et al., 1974b). 
Neuron degeneration studies show that reticulospinal fibers 
from the medial portions of the pontine and medullary reticular for-
mation descend to terminate in cervical and thoracic spinal cord; 
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more than half of the cells in specific reticular nuclei namely pontis 
caudalis, oralis, gigantocellularis, ventralis, and lateralis project 
to the spinal cord (Torvik and Brodal, 1957). 
Recently, descending reticulospinal projections from medullary 
reticular nuclei were studied with autoradiographic methods; the nu-
cleus reticularis gigantocellularis projects primarily to motor re-
lated areas such as laminae VII and VIII; the nuclei raphe magnus and 
reticularis magnocellularis project primarily to laminae with known 
nociceptive input such as laminae I, II, III, and V (Basbaum et al., 
1978; see section 1.1.4.3). 
Overall, the brain exhibits the anatomical capacity to influence 
sensory input at several levels of the CNS. An analysis of how these 
descending systems affect nociception will be discussed in sections 
l. 3 • 4 and 1. 4 . 4 . 
1.1.5 Gate Control Theory 
The Gate Control Theory of pain developed by Melzack and Wall in 
1965 has attracted its share of criticism; nevertheless, it remains 
the most readily accepted theory of pain today. The basic proposals 
of this theory as set forth by Melzack and \vall (1965) will be pre-
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sented as follows. 
First, the transmission of nerve impulses by primary afferent 
nerve fibers to spinal cord transmission cells (T cells) is modulated 
by a spinal gating mech~nism in the dorsal horn. The substantia gel-
atinosa, laminae II and III, is considered to be the site of the spi-
nal gating mechanism. 
Second, the spinal gating mechanism is influenced by the relative 
amounts of activity in large, Aa fibers and small diameter Ao and C 
fibers; activity of large fibers tend to inhibit transmission (close 
the gate) while activity in the small fibers tend to facilitate trans-
mission (open the gate) . The mechanism of this effect is that large 
Aa fibers have a brief excitatory effect on spinal T cells but then 
close the gate by inhibiting transmission from Aa, Ao, and C fibers 
through activation of interneurons in the substantia gelatinosa. On 
the other hand, Ao and C fibers prevent this inhibitory effect by in-
hibiting the inhibitory interneurons, thus opening the synaptic gate 
and increasing excitatory input to the T cells. However, clinical 
observations do not completely support this hypothesis (see section 
1.1.4.2). 
Third, the spinal gating mechanism is influenced by nerve impuls-
es that descend from the brain. As described previously, various 
cognitive factors such as attention, anxiety, etc. influence pain 
responses. The brain stem reticular formation as well as reticula-
spinal projections inhibit transmission from the spinal T cells. Since 
fibers from the cortex project to the reticular formation as well as 
directly to the spinal cord by means of corticospinal fibers this 
provides a system by means of which cognitive processes are able to 
influence spinal T cell activity. 
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Fourth, a specialized system of large diameter, rapidly conduct-
ing fibers (the central control trigger) activates selective cogni-
tive processes which then influence, by way of descending fibers, the 
modulatory properties of the spinal gating mechanism. The dorsal 
column medial lemniscal and dorsolateral systems could fulfill the 
function of the central control trigger (Melzack and Dennis, 1978). 
The fifth proposal is that when the output of the spinal cord T 
cells exceeds a critical level, it activates those neuronal areas 
which subserve the complex, sequential pattern of pain related be-
havior. 
A final aspect of the Gate Control Theory is referred to as the 
central biasing mechanism (Melzack and Dennis, 1978). Here, brain-
stem areas which are known to exert an inhibitory control over trans-
mission in the pain signalling system receive inputs from widespread 
parts of the body and in turn project to widespread parts of the spi-
nal cord and brain. Stimulation of the small diameter afferents can 
increase input to this central biasing mechanism resulting in the 
closing of the gates to noxious inputs from selected body areas. The 
cells of the midbrain reticular formation are known to have large 
receptive fields and electrical stimulation of reticular formation 
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can produce analgesia in discrete areas of the body. It is possible 
then, that particular body areas may project especially to some re-
ticular areas, and these in turn would close the gate to input from 
particular parts of the body. This model could be used to explain 
aspects of hyperstimulation analgesia of which acupuncture and trans-
cutaneous electrical stimulation are but two examples. 
1.1.6 Brain Mechanisms 
It is obvious that the phenomenon of pain cannot be viewed solely 
in terms of sensory perception without r3garding motivational affect-
ive and cognitive processes. Melzack and Casey (1968) proposed a 
three dimensional psychological scheme to include (i) sensory-discrim-
inative, (ii) motivation-affective, and (iii) cognitive-evaluative 
components of pain. A brief summary of their proposal follows. 
First, the neospinothalamic tract, the spinocervical tract, and 
postsynaptic elements in the dorsal column-medial lemniscal system all 
project at least in part to the ventral basal thalamus which shows a 
discrete somatotopic organization. Since all of these ascending sys-
tems appear to be involved in the transmission of nociceptive infor-
mation, these rapidly conducting tracts have the capacity to process 
information concerning the spatial, temporal, and magnitude proper-
ties of the nociceptive input. Therefore, this system may subserve the 
sensory-discriminative dimension of pain. 
Second, the spinoreticular and paleospinothalamic tracts project 
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to the brainstem reticular formation and limbic system. Since the 
reticular formation and limbic system have been shown to participate 
in the pain process, the powerful motivational drive and unpleasant 
affective characte~istics of pain may be influenced by activities in 
those particular brain regions which are affected primarily by the 
slowly conducting spinal systems. 
Third, various cognitive activities such as cultural values, 
attention, and anxiety all have a profound effect on the pain expe-
rience. These cognitive functions must be able to act selectively on 
the sensory and motivation systems in order to influence the pain re-
sponse. The dorsal column-medial lemniscal system and dorsolateral 
projection pathways rapidly carry impulses directly and indirectly to 
the cerebral cortex. Influences that descend from the cortex are known 
to act at the level of the ventrobasal thalamus as well as dorsal horn 
cells. Therefore, these rapidly conducting ascending and descending 
systems appear to have the capacity to influence pain related infor-
mation being transmitted over the more slowly conducting pathways and 
thus account for the fact that psychological processes play an impor-
tant role in determining the quality and intensity of pain. 
Melzack and Casey (1968) suggest that these three psychological 
processes interact with one another to provide perceptional infor-
mation regarding the location, magnitude, and spatiotemporal proper-
ties of the noxious stimulus; motivational tendency toward escape; and 
cognitive information based upon past experience and probability of 
outcome of the various response. All three components then influence 
the appropriate motor mechanisms which produce the overt behaviors 
characterizing the pain response. 
1.1.7 Importance of Pain 
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Pain is of crucial biological importance; true value of this can 
be seen in congenitally insensitive individuals who suffer excessive 
tissue damage such as burning a hand or arm on a heated stove, chewing 
off the end of their tongues, or chopping a knee with an axe all be-
cause of the inability to experience pain which would have protected 
them from these various occurrences (Swanson et al., 1965). Although 
pain does serve as a warning of injury to the individual and is of 
great diagnostic value to the physician it may also be an unnecessary 
evil at times when its warning effect is useless such as in terminal 
cancer or phantom limb pain. 
1.1.8 Treatment of Pain 
1.1.8.1 Pharmacological Intervention 
The ideal analgesic agent should be effe9tive when given orally, 
rapidly active after ingestion, and sufficiently strong to produce an 
appropriate level of analgesia; it should not produce tolerance, ad-
diction, or respiratory depression; its actions should be specific and 
associated with few side effects; finally, an antidote should be avail-
able. In other words the ideal analgesic should control pain without 
producing any undesirable side effects and dependence (Villaverde and 
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MacMillan, 1977). 
The narcotic analgesics are the group of drugs which, among anal-
gesics available today, fulfill the above criteria most closely, even 
though they are far from being ideal; most of them are opium deriva-
tives while others are synthetic or semisynthetic products; morphine and 
meperidine are the principal members of these two groups, respectively. 
Besides producing analgesia the narcotics also produce, even when 
used in therapeutic doses,undesirable side effects such as sleepiness, 
nausea, vomiting, and respiratory depression. Among serious problems 
associated with the narcotics is that of the tolerance which develops 
to the analgesic effects upon repeated administrations; that is, con-
tinually increasing doses of narcotic must be administered to produce 
a sufficient analgesia. Unfortunately, in the chronic pain patient the 
doses of narcotic required are often extremely high increasing the 
frequency and severity of the associated side effects. In addition, 
as tolerance further develops there is no dose of narcotic which will 
produce analgesia short of ~ausing death. 
In addition to tolerance, physical dependence, i.e. addiction, 
develops with repeated use of narcotics; the abuse liability and possi-
bility of developing psychological dependence on the effects of these 
compounds is one of the major limitations for their clinical use. How-
ever, in patients with painful terminal illnesses, this factor should 
not prevent the physician from alleviating the patient's pain and dis-
comfort. 
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The principal use of the narcotics is for the treatment of severe 
pain which cannot be alleviated by other analgesics, such as in can-
cer, traumatic accidents, burns, fractures, and severe visceral 
lesions. 
The salicylates, most notably acetylsalicylic acid (aspirin), 
constitute a second major group of analgesics. The overall analgesic 
effect of the salicylates is inferior to that achieved by the nar-
cotics; salicylates do appear to be more effective against integumental 
than visceral pain. 
While used in therapeutic doses, the salicylates do not produce 
respiratory depression or sleepiness, prolonged salicylate use may 
cause hyperventilation, tinnitus, and mental confusion. Gastro-
intestinal distress, nausea, and vomiting, are the most common side 
effects. Salicylates are recommended for treatment of headache, 
arthritis, dysmenorrhea, and neuralgia. 
Para-aminophenol derivatives such as phenacetin and acetamino-
phen and pyrazalon derivatives such as antipyrine and aminopyrine 
and their modern congeners such as indomethacin all produce an equiv-
alent level of analgesia as do the salicylates and consequently these 
compounds are employed in the treatment of similar types of pain as 
are the salicylate drugs. It should be emphasized that with many of 
these drugs their analgesic effect may depend on their peripheral 
antiinflammatory action. Thus, they may be useful in arthiritis and 
gout. 
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In addition, high doses of phenacetin produce methemoglobinemia, 
nephropathy and hepatic necrosis while high doses of acetaminophen 
may cause thrombocytopenia and nephrotoxicity. However, in recommen-
ded therapeutic doses, phenacetin and acetaminophen are well toler-
ated. 
Aminopyrine and possibly antipyrine produce severe blood dyscra-
sias such as thrombocytopenia and agranulocytosis; consequently, these 
compounds are reserved for use in cases that do not respond to sali-
cylates or para-~~nophenol derivatives. 
Antimalarials, most notably quinine, whose main use is for the 
treatment of malaria also produce analgesia. As analgesics, however, 
their effects are weaker than those of the salicylates. Quinine is 
used only with considerable caution due to the potential nephrotoxic 
and hemolytic idiosyncratic reactions. 
Finally, certain groups of drugs are used for specific types of 
pain as follows: (a) local anesthetics such as procaine, lidocaine, 
and dibucaine are used primarily to produce surface and infiltration 
anesthesia in localized parts of the body; (b) vasodilators such as 
nitroglycerine and amyl nitrate are used for the treatment of angina 
pectoris, both as a preventive and for relief of the acute attack; 
(c) corticoids such as cortisone, hydrocortisone, and prednisone are 
employed in the treatment of pain associated with inflammation, ar-
thritis and bursitis; and (d) muscle relaxants such as meprobamate are 
used to treat pain associated with muscle spasms in rheumatic disease 
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or following trauma. 
While numerous analgesic agents are employed for the relief of 
pain, the narcotic analgesic compounds constitute the most effective 
and most potent analgesics available today. In view, however,·of 
their side actions and addictive liability, improvements in the pharma-
cological manipulation of pain, particularly chronic pain, are requir-
ed. 
1.1.8.2 Neurosurgical Ablative Techniques 
Various neurosurgical ablative procedures such as dorsal rhizo-
tomy, chemical sympathectomy, percutaneous chordotomy, and chemical 
hypophysectomy have been employed, without a great deal of success, 
in the management of chronic pain. 
Dorsal rhizotomy, sectioning of the dorsal roots, failed to pro-
duce long term (6 month} analgesia in the majority of cases (Loeser, 
1974}. Aside from imperfect surgical procedures, several other 
explanations may account for this lack of success. First, the source 
of pain may not lie in the periphery, therefore, deafferentation would 
not isolate the brain from the pathology (Melzack and Loeser, 1978}. 
Second, deafferentation may itself generate abnormal firing patterns 
which the patient senses as painful (Loeser, 1974}. Finally, primary 
afferent sensory nerve fibers associated with nociceptors are known 
to exist in the ventral roots (Applebaum et al., 1976}; the presence 
of these fibers also may account for the failure of dorsal rhizotomy 
to relieve pain (Clifton et al., 1976}. Overall the best prognosis 
for the patient offered dorsal rhizotomy for the relief of chronic 
pain is poor. 
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Similarly, the localized injection of phenol (6.7% in water) into 
the sympathetic chain, chemical sympathectomy is useful only when 
the disease is confined within the visceral cavity; it therefore is 
rarely successful in pain of malignant disease in which the cells at 
any early stage invade neighboring structures innervated by the so-
matic nerves of the body wall (White, 1974). Furthermore, chemical 
sympathectomy suffers from a high incidence of associated complica-
tions such as pneumothorax, kidney puncture, and intravascular injec·-
tions as well as a postoperative neuritis in the groin area and thigh 
regions of a large number of patients (14.6%; Reid et al., 1970). 
Radiofrequency currents are used to produce lesions in the antero-
lateral quadrant of the spinal cord for the relief of chronic pain. 
Initially pain relief is excellent for 90% of the patients (n=l,279); 
however, an abrupt decrease in efficacy occurs three months after the 
operation and continues to decrease thereafter so that only 40% of 
the patients continue to report adequate pain relief one year after 
the operation (Rosonoff, 1974). In addition, complications such as 
muscle weakness, sphincter paralysis, and localized burning sensations 
have also been reported (Mullan et al., 1963). One explanation which 
may account for this procedural failure is that ascending tracts con-
vey impulses arising from noxious stimuli are not restricted to the 
anterolateral quadrant of the spinal cord (see section 1.1.4.4). 
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Chemical hypophysectomy, neuroadenolysis, is achieved by the lo-
calized injection of absolute ethanol into the pituitary gland (Morrica, 
1974). This procedure was initiated in cancer patients with diffuse 
bone and/or visceral matastesis arising from hormone-dependent tumors 
(Morrica, 1974). Miles and Lipton (1976) reported that cancer pain 
arising from other nonhormone-dependent tumors was also relieved by 
chemical hypophysectomy. However, since ethanol injected into the 
pituitary has been shown to spread to the hypothalamus, it may act 
there to interfere with pain perception (Miles and Lipton, 1976; 
Yanagida et al., 1979). Finally, the severe complications associ~ted 
with chemical hypophysectomy such as diabetes insipidus, hypoadrenal-
ism, hypothyroidism, decreased libido, hyperthermic crisis, hyper-
phagia, and anhydrosis suggest that this procedure be used only after 
other treatment procedures have failed to relieve pain (Morrica, 1976). 
Overall, the neurosurgical ablative techniques have the disadvan-
tages of being restricted to a specific part of the body, gradual re-
turn of pain with time, or more seriously, various permanent neurol-
ogical complications. Thus, these methods for pain relief are grad-
ually being replaced by other related methods namely nerve stimulation 
techniques. 
1.1.8.3 Stimulation Produced Analgesia (SPA) 
Reynolds (1969) first employed electrical stimulation of the mid-
brain periaqueductal grey matter (PAG) to render rats sufficiently 
antinociceptive to pe:form abdominal surgery. Since then, PAG stimu-
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lation-induced analgesia (SPA) in laboratory animals has been reported 
to block behavioral responses such as extreme pinch (Reynolds, 1969), 
tissue damaging heat (Mayer and Liebeskind, 1974), electric tooth pulp 
stimulation (Oliveras et al., 1974), and the application of various 
algesic substances (Melzack and Melinkoff, 1974). Electrical stimu-
lation of other central sites such as the septal nuclei, dorsolateral 
thalamic nuclei were effective with regard to only certain types of 
noxious stimuli (Mayer and Liebeskind, 1974); stimulation of the ven-
trobasal complex of the thalamus and lateral hypothalamus was com-
pletely ineffective (Mayer and Liebeskind, 1974). 
In humans, electrical stimulation of various areas in the CNS 
such as the dorsal columns (Shealy et al., 1967), internal capsule 
(Adams et al., 1974), and PAG (Richardson and Akil, 1977a, b) pro-
duced analgesia. However, the occurrence of undesirable side effects 
such as nystagmus, nausea, vertigo, reports of enhanced pain sensa-
tions as well as the lack of prolonged effectiveness of treatment has 
limited the clinically effective target site to an area between the 
nucleus parafasicularis and third ventricle at the level of the pos-
terior commisure (Richardson and Akil, 1977a, b). 
SPA can be measured after only a few seconds of central stimu-
lation (Mayer et al., 1971) and the post stimulation duration of ef-
fectiveness in the rat lasts for minutes to hours (Mayer and Liebeskind, 
1974). Similarly, 30 minut~s of stimulation afforded 3 to 4 hours of 
pain relief in humans (Hosobuchi et al., 1977). Thus, SPA provides 
an alternative approach for the control of chronic intractable pain. 
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Evidence suggests that SPA, morphine-induced antinociception, and 
the endogenous opioid system all may be interrelated. The mechanism 
involved in SPA as well as the role played by the endogenous opioid 
system in antinociception and analgesia will be reviewed subsequently 
(see sections 1.3.4 and 1.4.4). 
1.1.8.4 Psychological Manipulations 
The first nonphysical method employed in the treatment of chronic 
pain utilizes placebos, pharmacologically inert agents. Placebo-in-
duced analgesia reduced pain by about half of its original intensity 
in a variety of clinical situations for about 30% of the patients stud-
ied (Evans, 1974). On the other hand, placebos reduced experimentally-
induced pain in only 3 to 16% of the experimental populations (Evans, 
1974). Thus, placebos relieve pathological pain more effectively than 
they relieve experimental pain. It should be pointed out here that 
the placebo was at least half as effective as the assumed strength of 
the analgesic drug being administered under double blind conditions 
regardless of what analgesic was administered (Evans, 1974). This 
finding holds true for aspirin (Evans, 1974), morphine (Evans, 1974), 
and transcutaneous electrical stimulation (Thorsteinsson et al., 1978). 
Overall, the judicious use of placebo-induced analgesia for a 
specific group of patients appears to be useful and in some cases may 
be more clinically effective than specific drugs. In addition, cer-
tain variables within the doctor patient relationship such as trust, 
belief, and the drug giving ritual appear to produce powerful curative 
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effects and therefore should be emphasized as a foundation on which 
all other therapeutic procedures concerning the treatment of chronic 
pain be built. 
A second nonphysical method used for the treatment of chronic 
pain is called hypnosis-induced analgesia. The usefulness of hypnosis 
in the relief of pain was demonstrated early in the 19th century when 
limb amputations and other major operations were performed apparently 
painlessly with hypnosis as the only analgesic-anesthetic agent 
(Esdaile, 1957 cited by Hilgard, 1978). Since hypnotizability is seen 
as a personality trait which an individual possesses rather than a 
skill which may be improved with time (Perry, 1977), the range of 
patients in which hypnosis-induced analgesia would likely be effective 
is severely restricted. 
Since naloxone fails to antagonize hypnosis-induced analgesia 
(Goldstein and Hilgard, 1975), it does not appear that the endogenous 
opioid system is involved in mediating this effect. Hilgard (1978) 
suggests that hypnosis-induced analgesia occurs primarily at higher 
cognitive levels which include cortical involvement. 
The final nonphysical technique used in the treatment of chronic 
pain employs operant conditioning methods. Pain behavior, like other 
ope=ants, while initially elicited by an antecedent stimulus may come 
under the control of consequences (Fordyce et al., 1973). When an 
operant is followed by a positive consequence such as praise, atten-
tion, money, or food that behavior is likely to occur in the future. 
Alternatively, when an operant is followed by a negative consequence 
such as criticism or loss of valued rewards that behavior is likely 
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to occur less in the future. Thus, in a specific group of patients, 
pain behavior may occur only because it is followed by positive con-
sequences. Fordyce et al. (1973) successfully employed the operant 
conditioning technique in a study utilizing a selected group of pa-
tients who suffered from chronic pain which was thought to occur from 
factors other than tissue pathology. The results of this study demon-
strated (i) a significant decrease in medication required and (ii) 
significant increases in walking and nonreclining activities. 
1.2 Cholinergic System in Antinociception and Analgesia 
1.2.1 Central Cholinergic System 
Central actions of cholinergic agonists and antagonists, anti-
cholinesterases, and acetylcholine (ACh) itself must be considered 
in terms of the presence and distribution of cholinergic synapses o~ 
cholinoceptive neurons or both, as well as in terms of cholinergic 
pathways. 
A variety of histochemical and biochemical techniques and bind-
ing studies have been utilized to investigate brain neuronal mecha-
nisms in which ACh is t~:ought to be the neurotransmitter. Acetyl-
cholinesterase (AChE) has been investigated utilizing histochemical 
procedures (Shute and Lewis, 1967; Lewis and Shute, 1967) while ACh 
(Cheney et al., 1975), choline acetyltransferase (CAT; Kobayashi et 
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al., 1975), and high affinity choline uptake (Kuhar et al., 1973a, 
1975) have been investigated by various biochemical tests. More 
recently, binding studies as well as studies of muscarinic and nico-
tinic cholinoceptivity have been used to determine the distribution 
of muscarinic (Kobayashi et al., 1978a; Krnjevic, 1974) and nicotinic 
(Hunt and Schmidt, 1978) binding sites. Since all of the afore-
mentioned parameters are considered to be functionally components of 
cholinergic neurons and synapses, indirect evidence from these studies 
concerning the distribution of cholinergic synapses and pathways can 
be obtained. 
Shute and Lewis (1967) demonstrated that AChE accumulated at the 
proximal end of sectioned nerves whereas it disappeared distal to the 
division. Utilizing histochemical procedures, Shute and Lewis (1967) 
and Lewis and Shute (1967) mapped the cell bodies and axons of cholin-
ergic neurons in the CNS. Two principal cholinergic pathways emerged 
from these studies. First, the ascending reticular system arises from 
reticular and tegmental nuclei of the brainstem and projects via dor-
sal and ventral tegmental pathways to virtually all cortical and sub-
cortical structures. Second, the cholinergic limbic system consisted 
of septa-hippocampal connections as well as hippocampal afferent 
projections to the medial sortex, nuclei connecting with the ascending 
cholinergic reticular system, and subfornical and supraoptic crest. 
Electrolytic lesions of the medial septal area decreased ACh 
levels, CAT activity, and high affinity choline uptake in the hippo-
campus (Kuhar et al., 1973a). Identical effects were observed in the 
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interpeduncular nucleus area when the medial habenular areas was le-
sioned (Kuhar et al., 1975). This provides additional evidence for 
cholinergic septa-hippocampal and habenular-interpeduncular tracts. 
Utilizing mass fragmentography and gas chromatography, Cheney et 
al. (1975) demonstrated that a high ACh/CAT ratio which is indicative 
of cholinergic terminals was found in (i) olfactory structures, (ii) 
preoptic nuclei, (iii) several hypothalamic and thalamic nuclei, (iv) 
habenular and mammalary nuclei, (v) various midbrain nuclei, (vi) 
locus coeruleus 7 and (vii) nucleus interpositus of the cerebellum. 
In addition, high content of CAT has been demonstrated in certain cra-
nial nerve nuclei including III, IV, VII, and XII as well as nuclei 
salvitorius, tractus solitarius and caudate putamen of the rat brain 
stem (Kobayashi et al., 1975). 
Utilizing a binding assay, Kobayashi et al. (1978a) found a 
high density of cholinergic muscarinic binding sites in the hippo-
campus, caudate-putamen, nucleus accumbens and cerebral cortex; septal 
areas, interpeduncular nuclei, habenular nuclei, and medial thalamus 
exhibited a less dense population of binding sites; least dense bind-
ing site distribution was observed in the spinal cord and cerebellum. 
The distribution of cholinergic nicotinic binding sites has also 
been investigated utilizing binding assays (Hunt and Schmidt, 1978). 
Binding sites were predominantly found with central areas of the brain 
associated with direct sensory input such as olfactory bulbs, superior 
colliculus, cochlear nuclei, the substantia gelatinosa, and the prin-
cipal trigeminal sensory nucleus (Hunt and Schmidt, 1978). Certain 
limbic areas such as the hippocampus, amygdala, mammallary bodies, 
and dorsal tegmental nucleus also contain nicotinic binding sites 
(Hunt and Schmidt, 1978). 
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Presynaptic localization of a neurotransmitter substance must be 
considered in terms of the concept of the synaptic vesicle. Accord-
ingly, ACh has· been shown to be contained in synaptic vesicles ob-
tained from the synpatosomal fraction of cerebral cortical tissue 
(Whittaker and Sheridan, 1965) and of other brain tissues. Altogether, 
localization of ACh-containing 'resicles agrees with that of other mark-
ers of the cholinergic system. It must be added in this context 
that ACh-containing vesicles are morphologically specific and differ 
from those containing GABA or catecholamine(Karczmar, 1976). 
Localized injections of ACh and subsequent recordings from various 
cholinoceptive neurons have provided additional information concern-
ing the central cholinergic system. Most cholinoceptive cells in the 
CNS were excited and depolarized; occasionally inhibitory, hyperpolar-
izing responses were observed (Krnje-vic, 1974) . The :nost common excit-
atory action of ACh in the CNS has muscarinic characteristics;_ it is 
relatively slow in onset and very prolonged and is readily blocked by 
atropine; the ionic mechanism of depolarization is probably a reduc-
tion in potassium conductance(Krnjevic, 1974). Other excitatory ef-
fects occur at nicotinic sites: ACh has a very quick and rapidly revers-
ible effect on some CNS neurons such as the Renshaw cell; dihydro-
beta-erthroidine and mecamylamil".e blocked this effect (Krnjevic, 1974) . 
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Finally, inhibition of some CNS neurons caused by a specific increase 
in potassium permeability is mediated by muscarinic receptors 
(Krnjevic, 1974). 
It should be pointed out that the presence of cholinoceptive 
neurons, ACh and AChE by themselves do not insure proof of cholin-
ergic transmission. For instance, the cerebellum contains AChE con-
taining cells and fibers but no specific pathway in the cerebellum has 
been shown to act by release of ACh (Krnje~ric, 1974). 
Finally, ACh was the first neurotransmitter substance collected 
following stimulation of different CNS preparations (Pepeu, 1973) . 
The original method of Mitchell (1963) for studying ACh release from 
the cerebral cortex utilized the cortical cup; ACh content was deter-
mined by bioassay on the dorsal muscle of the leech. Investigations 
of ACh release from subcortical structures were made possible by the 
push-pull cannula described by Gaddum (1961). In either case, ACh re-
lease studies were only possible if 95% of the AChE present had been 
previously inhibited (Lancaster, 1971). ACh release has been demon-
strated in such brain areas as sensory motor, auditory, parietal, and 
visual cortex; caudate nucleus; ventrobasal complex of the thalamus; 
thalamic nuclei ventralis, lateralis, and posterior; hypothalamus; 
medulla; and spinal cord (Pepeu, 1973). In addition, ACh release from 
central brain sites depends upon the presence of calcium ions (Randic 
and Padjen, 1967). Overall, the release studies provide additional 
evidence and information concerning the distribution of the central 
cholinergic system. 
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In summary, what emerges is the concept that cholinergic synapses 
and pathways are present in many CNS structures;the major central 
cholinergic system comprises a diffuse ascending tegmental-mesenceph-
alic-cortical system; the most notable pathways included here are 
the ventral and dorsal tegmental pathways, habenulo-interpeduncular 
tract, septohippocampal tract, and thalamocortical tract. 
1.2.2 Interactions with Other Neurotransmitter Systems 
Next, the interaction between the cholinergic, catecholaminergic, 
and serotonergic neurotransmitter systems throughout the CNS has been 
demonstrated (Karczmar, 1975). Cholinergic agonists and antagonists 
affect levels and/or turnover rates of brain catecholamines and sero-
tonin (5-HT) ; the effect on the 5-HT system is most pronounced 
(Karczmar, 1976). Diisopropyl phosphofluoridate (DFP) increased 5-HT 
levels in the rabbit midbrain, thalamus, hippocampus, and medulla 
(Barnes et al., 1974); effects were reversed by atropine (Barnes et 
al., 1975). DFP recently has been shown to increase both 5-HT levels 
and turnover in several rat brain regions; effects were reversed by 
atropine (Barnes et al., 1978). 
Furthermore, DFP increased levels of dopamine (DA) in several 
rabbit brain parts including the thalamus, hypothalamus, midbrain, and 
hippocampus (Glisson et al., 1972, 1974). Alternatively, DFP decreased 
norepinephrine (NE) levels in the same four rabbit brain regions dis-
cussed above (Glisson et al., 1972, 1974). The effect of DFP on NE 
arises from central actions while the DFP effect on DA depends in part 
on peripheral actions; atropine methyl nitrate, the quaternary ana-
logue which does not readily penetrate the blood brain barrier (BBB) 
blocked the DFP effect on DA but was ineffective against NE (Glisson 
et al., 1974). 
38 
Concerning reciprocal relationships, ACh-5-HT interactions may be 
bidirectional. 5-hydroxytryptophan (5-HTP), the metabolic precursor 
for 5-HT, significantly increased the level of ACh following pretreat-
ment with the serotonergic neurotoxin 5,6-dihydroxytryptamine in mice 
(Barnes et al., 1973a, b). On ~~e other hand, ACh brain levels were 
not affected by the catecholamine neurotoxin, 6-hydroxydopamine or by 
the metabolic precursor for catecholamines, 1-dopa (Barnes et al., 
1973c) . 
The pharmacological evidence described above demonstra~es that 
the interaction between various neurotransmi~ter systems in the CNS 
is widespread. The exact mechanism of these effects, in terms of 
neurotransmitter turnover rates and pertinent circuitry remains to be 
established. In addition, the results discussed above suggest that 
it may be difficult to obtain a predictable cholinergic effect that 
would depend solely on cholinergic synapses and pathways and/or cho-
linoceptive neurons. However, specific effects of cholinergic drugs 
on behavior are obtained as discussed in the following sections. 
1.2.3 Antinociception and Analgesia 
1.2.3.1 Compounds Which Affect the Cholinergic System 
Several cholinomimetic compounds such as dibromopyruvic acid 
(Martinet al., 1958), tremorine (Chen, 1958), arecoline (Herz, 
1961), oxotremorine (Harris et al., 1968), carbachol (Metys et al., 
1969), and pilocarpine (Houser and Van Hart, 1973); various anti-
cholinesterase agents such as physostigmine (Harris et al., 1968) 
and DFP (Koehn and Karczmar, 1978); and ACh itself (Pedigo et al., 
1975) produce antinociception when administered to mice and rats. 
Recently, physostigmine (Sitaram et al., 1977) and arecoline 
(Sitaram, 1979, personal communication) have caused an analgetic 
action in normal human volunteers. 
Scopolamine, an anticholinergic agent, produced antinociception 
when administered to monkeys (Pert, 1975). The discrepancy between 
findings in the monkey and all other species including man concern-
ing the involvement of the cholinergic system in nociception cannot 
be explained at present. 
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The antinociceptive and analgesic states produced by the com-
pounds mentioned above will henceforth be referred to as cholinergic-
induced antinociception and analgesia, respectively. 
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Prostigmine (Slaughter and Munsell, 1940), pilocarpine (Saxena 
and Gupta, 1958), DFP (Bhargava and Way, 1972), and ACh (Pedigo et 
al., 1975) potentiate narcotic-induced antinociception in laboratory 
animals. In addition, some partial agonists of narcotics such as 
cyclazocine, cyclorphan, nalorphan, and pentazocine are converted from 
inactive to active antinociceptive agents in the mouse in the presence 
of physostigmine (Harris et al., 1967). 
Some of these various agents which affect the central cholinergic 
system proved to be more potent on a milligram basis than morphine; 
for instance, oxotremorine was 3000 times more potent than morphine 
in the mouse (Leslie, 1969). Finally, oxotremorine but not morphine 
could produce antinociception when administered to frogs (Nistri et 
al., 1974). 
Several anticholinesterase agents such as pyridostigmine 
(Slaughter, 1950) physostigmine (Floodmark and Wrammer, 1945) 
and neostigmine (Hand and Audin, 1944; Christensen and Gross, 1948) 
potentiate narcotic-induced analgesia in humans. In fact, the com-
bination of neostigmine with a narcotic analgesic was considered to be 
more effective than the narcotic analgesic used alone as the dose of 
the narcotic employed to produce analgesia could be reduced, hence 
lessening the severity of associated side effects, most notably nausea 
and somnolence (Hand and Audin, 1944). 
1.2.3.2 Central Muscarinic Nature 
Cholinergic-induced antinociception and analgesia result from 
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actions involving central cholinoceptive sites of the muscarinic type 
as suggested by the following. First, tertiary anticholinergic-anti-
muscarinic agents such as atropine sulfate and scopolamine which cross 
the BBB antagonize cholinergic-induced antinociception and analgesia; 
quaternary anticholinergics such as atropine methyl nitrate and methyl-
scopolamine which do not cross the BBB are ineffective (Herz, 1961; 
Handley and Spencer, 1969; Pedigo et al., 1975; Sitaram et al., 1977; 
Koehn and Karczmar, 1978). On the other hand, various anticholinergic 
drugs which block central cholinoceptive sites of the nicotinic type 
such as dihydro-13-erythroidine(Herz, 1961), various alpha substituted 
acetylcholine derivatives (Dewey et al., 1975), nicotine and hexa-
methonium (Pert, 1975), and·mecamylamine (Pedigo et al., 1975) do not 
affect cholinergic-induced antinociception. It may be added that in 
monkeys, only those anticholinergic agents such as scopolamine which 
cross the BBB are effective antinociceptive agents when administered 
systemically; methylscopolamine was ineffective (Pert, 1975). 
Second, muscarinics, but generally not nicotinics (see however, 
below), do exert antinociceP.tion. For instance, carbachol, a quater-
nary cholinomimetic which also possesses some activity at nicotinic 
receptors, produces antinociception when administered intracerebro-
ventricularly (Icvt); effects were reversed by atropine (Metys et al., 
1969). 
Drug interactions with muscarinic receptors in peripheral tissues 
appear to be stereospecific; (+) isomers of beta-substituted methyl-
choline mimick the action of muscarine; (-) isomers were inactive 
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(Ellenbroek and Van Rossurn, 1960). Chemical derivatives of beta-
substituted methylcholine which exhibit muscarinic action stereospe-
cifically antagonized ACh-induced antinociception in mice; (+) isomers 
were active while the (-) isomers were inactive (Dewey et al., 1975). 
Thus, cholinergic-induced antinociception appears to be stereospecif-
ically mediated by muscarinic receptors in the CNS. 
It must be added that while most laboratories have failed to 
demonstrate antinociceptive activity for compounds which interact with 
nicotinic cholinergic receptors (Herz, 1961; Metys et al., 1969; Pert, 
1975; Pedigo et al., 1975), Phan et al. (1973) showed that nicotine 
produced antinociception when administered to rodents; the effect was 
blocked by mecamylamine but atropine was ineffective. However, more re-
search concerning this effect is required before two independent chol-
inergic systems can be implicated in the production of antinociception 
and analgesia. 
Pharmacological evidence concerning specific central sites for 
cholinergic modulation of the antinociceptive state comes from many 
sources. Intraventricular (Ivt) administration of carbachol (Metys 
et al., 1969), oxotremorine (Handley and Spencer, 1969), ACh (Pedigo 
et al., 1975), and scopolamine (Pert and Maxey, 1975) suggest the in-
volvement of structures immediately around the ventricular system 
since the time course of the antinociceptive state and diffusion prop-
erties of these drugs limit their potential sites of action to those 
particular areas. In addition, Ivt administrations of oxotremorine 
and arecoline into the septal area, mesencephalic reticular formation, 
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hypothalamus, and medial thalamic nuclei produce significant antinoci-
ception; applications into the striate or hippocampus were ineffective; 
effects were reversed by atropine (Metys et al., 1969). 
The close anatomical proximity of the ascending cholinergic re-
ticular formation and the paleospinothalamic and spinoreticular tracts 
which carry nociceptive information (see section 1.1.4.4), as well as 
the fact that Ivt applications of cholinomimetic agents into these 
areas produced antinociception led Sitaram et al. (1977) to postulate 
that physostigmine produced analgesia by virtue of its action mediated 
by the ascending reticular activating system. 
In any case, the specific sites and pathways involved in mediat-
ing and modifying cholinergic-induced antinociception and analgesia 
remain to be further identified. 
1.2.3.3 Mechanisms 
The mechanisms of effects concerning cholinergic-induced anti-
nociception are not known. The following evidence suggests as well as 
refutes various possible explanations.· 
First, the production of antinociception and elevation of ACh 
levels may be correlated for some centrally acting cholinomimetics 
such as oxotremorine (Harris et al., 1969). Morphine which produces 
a potent level of antinociception also increases brain ACh levels 
(Hano et al., 1964). However, various partial narcotic agonists and 
antagonists such as nalorphine, naloxone, pentazocine, and cyclazocine 
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(Howes et al., 1969) as well as several CNS depressants such as methyl-
parafynol, hydroxydione, pentobarbital, and reserpine (Giarman and 
Pepeu, 1962) do not produce antinociception but increase brain ACh 
levels. Therefore, no correlation exists between the ability of a 
compound to produce antinociception and increase brain ACh levels. 
Thus, cholinergic-induced antinociception needs not be directly attri-
butable to enhancement of brain ACh levels. 
Alternatively, oxotremorine and morphine decrease the turnover 
rate of brain ACh (Norberg and Sundwall, 1977); this action of mor-
phine appears to be due to its antirelease effect (Domino et al., 
1976). However, pentobarbital also decreases brain ACh turnover 
(Norberg and Sundwall, 1977). Again, no correlation exists between 
the ability of a compound to produce antinoci~eption and decrease ACh 
turnover. 
It should be pointed out that correlations between the antinoci-
ceptive state and whole brain or brain region neurochemistry may be 
misleading. It may be that the pertinent neurochemical changes associ-
ated with antinociception are restricted to nondetectable brain sites. 
Alternatively, the compounds which affect the cholinergic system may 
interact with other neurotransmitter systems to produce antinocicep-
tion. Since the various agents which affect the central cholinergic 
system influence the levels and turnover rates of other neurotrans-
mitters in the CNS, nociception and pain are probably mediated by a 
complex interplay of neurotransmitters (see section 1.2.2). To 
identify the neurotransmitter or neurotransmitters involved, various 
pharmacological manipulations were attempted as follows. 
Pretreatment with reserpine which decreases brain DA, NE and 
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5-HT levels, antagonized the antinociceptive states produced by physo-
stigmine (Pleuvry and Tobias, 1971) and tremorine (Sethy et al.,l971). 
Since reserpine decreases both catecholamines and indoleamines (Shore 
and Brodie, 1957), the following procedures were utilized to differ-
entiate the involvement of the various neurotransmitters. 
Concerning the involvement of DA and NE, diethyldithiocarbamate, 
which reduces brain NE levels by inhibiting dopamine-beta-hydroxylase 
(DBH), antagonized the antinociceptive state produced by tremorine 
(Sethy et al., 1971), physostigmine and oxotremorine (Pleuvry and 
Tobias, 1971), while alpha-methylparatyrosine (AMPT), a tyrosine hy-
droxylase inhibitor, 1-dopa, the metabolic precursor for DA and NE, 
and pimozide, aDA receptor blocker, were ineffective (Paalzow and 
Paalzow, 1975). These data suggest that NE may play a role in cholin-
ergic-induced antinociception but that DA probably does not. 
Various manipulations which affect the serotonergic system exert, 
on the whole, inconsistent effects on cholinergic antinociception. 
For instance, precursor loading with 5-HTP enhances physostigmine-
induced antinociception in mice (Pleuvry and Tobias, 1971) but not in 
rats (Paalzow and Paalzow, 1975). Para-chlorophenylalanine (PCPA) 
which decreases brain 5-HT levels by inhibiting tryptophan hydroxyl-
ation, antagonizes physostigmine-induced antinociception in mice 
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(Pleuvry and Tobias, 1971) and rats (Bhattacharya and Nayak, 1978); 
however, PCPA had no effect on oxotremorine (Pleuvry and Tobias, 1971; 
Paalzow and Paalzow, 1975) or DFP-induced antinociception (Koehn and 
Karczmar, 1978) in rats. Overall, reports from various authors con-
cerning the involvement of the serotonergic system in cholinergic-
induced antinociception are contradictory and inconclusive. The in-
volvement of the serotonergic system in antinociception and analgesia 
will be discussed in more detail in section 1.3. 
Endogenous opicid system may constitute another system that could 
be involved in cholinergic-induced antinociception (see also section 
1.4). Naloxone, a pure narcotic antagonist, antagonized the anti-
nociceptive state produced by physostigmine and oxotremorine (Harris 
et al., 1969), ACh (Pedigo et al., 1975) and DFP (Koehn and Karczmar, 
1978). Furthermore, antagonism of DFP-induced antinociception by 
stereoisomers of some narcotic antagonists was shown to be stereo-
specific (Koehn et al., 1979). On the other hand, Pedigo et al.(l975) 
demonstrated that inactive (+) isomers of partial narcotic agonists 
antagonized ACh-induced antinociception; (-) active isomers were in-
effective. 
Since one of the major characteristics of morphine-induced anti-
nociception is the tolerance which arises on chronic treatment, stud-
ies utilizing a cross tolerance design were performed to discern a 
possible common mechanism of cholinergic- and morphine-induced a~ti­
nociception. Invariably, cross tolerance did not develop between mor-
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phine-induced antinociception and antinociceptive state produced by 
oxotremorine (Howes et al., 1969), physostigmine (Pleuvry and Tobias, 
1971), scopolamine (Pert and Maxey, 1975), or DFP (Koehn et al.,l979). 
The results do not nullify the idea that morphine and the various 
compounds which affect the cholinergic system may be acting on opiate 
sensitive systems to produce their antinociceptive states since tol-
erance may not develop at sites at which the cholinomimetics and anti-
cholinesterases act to produce antinociception. Overall, the data 
suggest the possible involvement of an endogenous opioid system in 
cholinergic-induced antinociception. The involvement of the endoge-
nous opioid system in antinociception and analgesia will be discussed 
in greater detail in section 1.4. 
In summary, the exact neurochemical mechanisms involved in me-
diating or modifying cholinergic-induced antinociception remain only 
poorly understood at this time. 
1.2.4 Locomotion and Exploration 
Cholinergic agonists and antagonists induce or affect a number 
of animal locomotor and related overt behaviors including a state 
referred to as "alert non-mobile behavior" (ANMB; Karczmar ,· 1977) . 
Concerning the spontaneous locomotor activity in rats, ACh 
(Herman et al., 1972), arecoline (Costall et al., 1972), and physo-
stigmine (Adams, 1973) decrease spontaneous locomotor activity; 
this effect was reversed by atropine. Alternatively, atropine sul-
fate and scopolamine increase spontaneous locomotion; the corre-
spending quaternary compounds were ineffective(Adams, 1973). Thus, 
stimulation of central cholinergic muscarinic receptors attenuate 
while blocking those receptors enhances locomotion. 
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· The locomotor depression produced by cholinomimetics and anti-
cholinesterases appears to be primarily related to the relative activ-
ity of the dopaminergic and cholinergic systems in the nigrostriatal 
and extrapyramidal pathways; locomotion is mediated by cholinergic 
projections to the striatum which are behaviorally inhibitory; this 
system may be modulated via dopaminergic inhibition (Karczmar, 1977). 
However, locomotion may also depend upon a cholinergic inhibitory 
mechanism in the septa-hippocampal system. Atropine or scopolamine 
applied to dorsal or ventral hippocampal sites increased locomotor 
activity in the rat (Leaton and Rech, 1972) and mouse (Abeelen et al., 
1972). 
ANMB combines with what appears to be mental alertness; again, 
hippocampus may be the site involved as ANMB correlates with theta 
waves or hippocampal slow activity electroencephalographic (EEG) pat-
terns(Karczmar, 1977). However, hippocampal slow theta wave may not 
be always concomitant with immobility or ANMB. In rats, the presence 
of hippocampal theta wave activity was correlated with attentional or 
investigational responses occurring during exposure to a novel environ-
ment (exploratory activity; Komisaruk, 1970). In addition, intra-
hippocampal administrations of m2thylscopolamine increased exploratory 
activity, in two strains of mice; neostigmine was ineffective (Abeelen 
et al., 1972). Thus, exploration appears to be blocked by a cholin-
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ergic inhibitory mechanism residing probably in septal-hippocam?al 
pathways. 
1.2.5 Thermoregulation 
Meyers (1974) described a scheme for the role of the cholinergic 
system in thermoregulation of that cat and monkey. According to this 
scheme, the anterior hypothalamic preoptic area contains neurons which 
are thermosensitive as well as a comparator mechanism which contrasts 
the set point with local temperature; 5-HT and NE are released within 
this area to activate and inhibit, respectively, a cholinergic heat 
production system which then passes through the posterior hypothalamus. 
The posterior hypothalamus contains a set point mechanism which de-
d h +/++. b .... pen s upon t e Na Ca rat1o, an a errat1on of wh1ch w1ll act1vate an 
independent cholinergic heat dissipating system. 
Evidence from pharmacological studies support this scheme. 
First, intracerebral administrations of carbachol (Avery, 1970) or 
ACh (Rudy and Wolf, 1972) into anterior hypothalamic sites produced 
hyperthermia. Alternatively, pilocarpine or ACh produced hypothermia 
when administered into posterior hypothalamic sites; effects were re-
versed by atropine (Kirkpatrick and Lomax, 1970). Cholinomimetics and 
~,ticholinesterases administered systemically produce hypothermia in 
the rat (Lomax and Jenden, 1966; Kirkpatrick and Lomax, 1970; Meeter 
and Wolthius, 1968); however, whether sites and/or mechanisms other 
than the hypothalamic thermoregulatory center are involved is undeter-
mined at this time. 
1.3 Serotonergic System in Antinociception and Analgesia 
1.3.1 Central Serotonergic System 
Just as the central actions of drugs which affect the cholin-
ergic system must be considered in terms of the associated central 
cholinergic structures, so too must drugs which affect the central 
serotonergic system be viewed in terms of corresponding serotonin 
(5-HT) receptors, synapses, and pathways. 
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Unlike the cholinergic cell bodies which exist in a very diffuse 
pattern throughout the CNS, cell bodies of 5-HT neurons are mainly 
localized in midline raphe nuclei of the lower brainstem. Utilizing 
fluorescent histochemical techniques, Dahlstrom and Euxe (1964) 
identified nine distinct brainstem regions associated with 5-HT neu-
rons; these regions were consecutively labelled Bl through B9 from 
the caudal medulla to the rostral pons. 
Bl, B2, and B3, namely raphe nuclei pallidus, obscurus, and 
magnus (NRM), respectively, are located in the ventromedial medulla 
and send axons down the spinal cord via anterior and lateral funiculi 
to terminate with 5-HT containing terminals in the spinal dorsal, 
ventral grey matter, and sympathetic chain (Dahlstrom and Fuxe, 1965; 
Basbaum et al., 1978). These nuclei and associated projection path-
ways constitute the descending 5-HT system. 
5-HT neurons located in the central dorsomedial midbrain, namely 
raphe nuclei dorsalis (B7) and medianus (B8) project to the telenceph-
alan and diencephalon. The greatest number of ascending 5-HT fibers 
originate in the dorsal raphe (B7) ; striatal and hippocampal 5-HT 
projections arise chiefly in the dorsal and median raphe nuclei, 
respectively (Dahlstrom and Fuxe, 1964; Lorens and Guldberg, 1974). 
5-HT cells in the region of the formatio reticularis (B9) located 
just ventral to B7 and B8 in the midbrain also project rostrally to 
the diencephalon (Dahlstrom and Fuxe, 1964). 
51 
Two groups of 5-HT cells are found in the pons; the raphe nucleus 
po~tis (BS) lies at the level of the nucleus motorius and the B6 cell 
group is found on the midline just below the fourth ventricle; both 
BS and B6 send fibers to the hypothalamus (Dahlstrom and Fuxe, 1964; 
Fuxe and Jonsson, 1974). The final group of 5-HT cells is located 
in the vicinity of the area postrema in the medulla; projection sys-
'tems from this group remain to be identified (Dahlstrom and Fuxe,l964). 
Altogether, the B4 through B9 cell groups and projection systems com~ 
prise the ascending 5-HT system. 
The metabolic pathways involved in the synthesis and catabolism 
of brain 5-HT are outlined briefly as follows (Messing and Lytle,l977). 
First, the amino acid, tryptophan, is taken up into the neuron and 
5-hydroxylated by tryptophan hydroxylase (TH) to form the intermediate 
metabolite, l-5-hydroxytr1ptophan (5-HTP); the intracerebral hydroxyl-
ation of tryptophan is the primary factor and rate limiting reaction 
controlling cerebral 5-HT formation (Moir and Eccleston, 1968). 5-HTP 
is then decarboxylated by the enzyme aromatic l-amina acid decarboxyl-
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ase to form 5-hydroxytryptamine (5-HT; serotonin). Following release 
from the neuron, 5-HT is actively taken up by presynaptic nerve ter-
minals where it is deaminated and oxidized by the enzymes monoamine 
oxidase and aldehyde dehydrogenase, respectively, to form the major 
metabolite, 5-hydroxyindoleacetic acid (5-HIAA). 
1.3.2 Role of 5-HT in Antinociception and Analgesia 
Various experimental procedures have been utilized to investigate 
a possible role of 5-HT in the production of antinociception and anal-
gesia; included here are pharmacological studies, dietary manipula-
tions, and electrical lesions experiments; electrical stimulation 
studies will be discussed in section 1.3.4. 
Para-chlorophenylalanine (PCPA) decreases 5-HT and 5-HIAA levels 
by inhibiting TH, the rate limiting enzyme in 5-HT synthesis (Koe and 
Weissman, 1966). PCPA decreased jump response thresholds to electric 
shocks in rats; this effect was reversed by the administration of the 
metabolic precursor, 5-HTP (Tenen, 1967). 5-HTP produced antinoci-
ception when administered by itself to rats (Contreras and Tamayo, 
1967; Radouco-Thomas et al., 1967). However, administration of 5-HTP 
increases 5-HT formation within 5-HT neurons but also leads to the 
formation of 5-HT within dopamine neurons (Fuxe et al., 1971). In 
contrast, 1-tryptophan administrations increase 5-HT formation only 
in 5-HT neurons due to the relatively specific localization of the 
enzyme tryptophan hydroxylase (Moir and Eccleston, 1968). L-trypto-
phan administrations do not affect sensitivity to electric shocks in 
rats (Hole and Marsden, 1975). Fluoxetine hydrochloride (Lilly 
110140), a specific inhibitor of 5-HT uptake into synaptosome (Wong 
et al., 1974), increased jump response thresholds in rats (Messing 
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et al., 1975). Quipazine, which mimicks the effects of 5-HT on var-
ious smooth muscle preparations (Hong et al., 1969), also produced 
antinociception when administered to rats; effects were antagonized 
by methysergide (Samanin et al., 1976). The major factor which pre-
vents researchers from determining whether 5-HT participates in anti-
nociception and analgesia is the lack of a specific 5-HT receptor 
blocker. Five drugs (cinanserin, cyproheptadine, methysergide, 
methergoline, and methiothepin) have been suggested to block 5-HT 
receptors in the b~ain based on their ability to block the effects 
of 5-HT on smooth muscle and invertebrate neurons; unfortunately, 
their 5-HT antagonism is not entirely specific (Haigler and Aghajanian, 
1977). 
Rats fed a tryptophan deficient diet exhibited low tryptophan 
and 5-HT levels and decreased flinch-jump thresholds; PCPA augmented 
the hypernociceptive state; administrations of tryptophan or fluoxe-
tine restored flinch-jump thresholds to control levels (Lytle et al., 
1975; Messing et al., 1976). 
Electrolytic lesions in the median forebrain bundle, s~ptum, 
ventrolateral tegmentum, and dorsomedial tegmentum dec~eased telen-
cephalic 5-HT content and increased sensitivity to electric foot-shock 
in rats (Lints and Harvey, 1969; Harvey and Lints, 1971); these two 
effects were reversed by the administration of 5-HTP; administrations 
of 1-dopa were ineffective (Harvey et al., 1975). 
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While electrolytic lesions of specific CNS structures such as the 
median forebrain bundle decrease brain 5-HT content and produce hyper-
nociception, the electrolytic lesioning process itself probably de-
stroys non-serotonergic neurons as well. In addition, when 5-HT neu-
rons in the dorsal (B7) or median raphe (B8) are destroyed by electro-
lytic lesions no alteration in nociceptive responses in rats were 
observed (Harvey et al., 1974; Lorens and Yunger, 1974). 
In summary, while some evidence suggests that 5-HT participates 
in antinociception and analgesia, no conclusive evidence for the re-
lationship exists. 
l. 3. 3 Serotonin (5-HT) and !-lorphine-Induced Antinociception 
Many of the various pharmacological and physiological manipula-
tions which are known to affect the central serotonergic system and 
the nociceptive state also affect morphine-induced antinociception. 
Several compounds which affect the serotonergic system have been 
shown by a variety of testing procedures to potentiate narcotic-in-
duced antinociception; included here are 5-HTP (Contreras and Tamayo, 
1967; Radouco-Thomas et al., 1967), fluoxetine (Messing et al., 1975), 
as well as 5-HT itself administered intraventricularly (Ivt; Sewell 
and Spencer, 1974). Pretreatment with PCPA antagonized morphine-in-
duced antinociception; this effect was reversed by 5-HTP (Garlitz 
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and Frey, 1972). Methysergide, cinanserin, and cyproheptadine also 
antagonized morphine-induced antinociception (Garlitz and Frey, 1972; 
Yaksh et al., 1976a). 
Electrolytic lesion studies have produced varying effects on 
morphine-induced antinociception depending upon the lesion placement. 
Lesions that destroy specific ascending serotonergic fiber systems, 
as demonstrated by the resultant decrease in telencephalic 5-HT 
content, fail to alter the antinociceptive action of morphine in the 
rat: sites included here are (i) nucleus raphe medianus (B8; Lorens 
and Yunger, 1974; Hole and Marsden, 1975), nucleus raphe dorsalis 
(B7; Lorens and Yunger, 1974; Hole and Marsden, 1975), dorsal and ven-
tral tegmental nuclei of Gudden (Lorens et al., 1975), and median fore-
brain bundle (Harvey et al., 1975). 
On the other hand, electrolytic lesions of the nucleus raphe 
magnus (B3) antagonized morphine-induced antinociception in the rat 
(Proudfit and Anderson,l975). Since the nucleus raphe magnus (B3) is 
known to contain 5-HT neurons which descend to terminate on spinal 
cord structures known to respond to noxious stimuli (Proudfit and 
Anderson, 1975; Basbaum et al., 1978), the descending serotonergic sys-
tem may participate in the expression of morphine-induced antinoci-
ception. 
1.3.4 Serotonin(5-HT) and Stimulation Produced Analgesia (SPA) 
Drugs which affect the serotonergic system have been shown to 
alter stimulation produced analgesia (SPA) similarly to their effect 
on morphine-induced antinociception (see section 1.3.3). Thus, PCPA 
antagonized the antinocieptive state produced by morphine (Gorlitz 
and Frey, 1972) as well as by electrical stimulation (SPA) of the 
nucleus raphe dorsalis (B7) in the rat (Akil and Mayer, 1972). 
Similarly, electrical stimulation of the nucleus raphe magnus 
(B3) also produced antinociception in the rat (Proudfit and Anderson, 
1975) . Related studies have shown that selective lesions of the 
spinal cord dorsolateral funiculus (DLF) prevents the antinociceptive 
actions of SPA applied to periaqueductal grey ~ites (PAG) or of 
morphine (Basbaum et al., 1977). Similarly, DLF lesions prevent the 
inhibitory effect of nucleus raphe magnus (B3) on spinal cord neurons 
in laminae I, II, and v which are considered to be involved in pain 
modulation (Fields et al., 1976; see section 1.1.4.3). Recently, 
serotonin-containing fibers which descend from the nucleus raphe mag-
nus (B3) and terminate in lamina I, II, IV, and v have been shown to 
descend through the DLF (Basbaum et al., 1978). These particular 
studies along with those described in section 1.4.4 illustrate the 
importance of the descending serotonergic system underlying the anti-
nociceptive actions of SPA and morphine administrations. 
While the serotonergic system appears to participate, at least 
in part, in mediating SPA and morphine-induced antinociception, it 
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is also apparent that other neurotransmitter systems also mediate 
these effects. Pharmacological manipulations of catecholamine sys-
tems alter SPA; pimozide, a dopamine receptor blocker, decreased while 
apomorphine, a dopamine receptor stimulator increased SPA; disulfiram, 
which depletes NE by inhibiting the enzyme dopamine-beta-hydroxylase 
(DBH), increased SPA (Akil and Liebeskind, 1975). NE specifically 
reduced the firing rate of dorsal horn interneurons in response to 
noxious stimuli but did not alter the firing rate in cells excited by 
innocuous stimuli (Belcher et al., 1978). Recently, Yaksh (1979) 
reported that the antinociceptive action of morphine applied to PAG 
sites could be antagonized only by the combined intrathecal admin-
istrations of phentolamine, a NE receptor blocker, and methysergide; 
administrations of either antagonist alone significantly although 
incompletely antagonized this morphine effect. Clearly, non-seroton-
ergic systems exist which participate in the expression of SPA and 
morphine-induced antinociception. 
1.4 Endogenous Opioid System in Antinociception and Analgesia 
1.4.1 Endogenous Opioid System 
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One of the more interesting findings in neuroscience research has 
been the discovery of stereospecific opiate binding sites in the CNS 
(Goldstein et al., 1971) and subsequent isolation and identification 
of several endogenous opioid peptides (Hughes et al., 1975a; Guillemin 
et al., 1976; Li and Chung,l976). The endogenous opioid peptides sub-
sequently have demonstrated opiate-like activities, particularly the 
ability to produce antinociception, when administered to laboratory 
animals (see section 1.4.2). 
The first endogenous opioids found in the brain and sequenced by 
Hughes et al. (1975a) were the pentapeptides, methionine- and leucine-
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enkephalin, which differed from each other only in the terminal amino 
acid. Subsequently, other larger peptides found in the brain and pi-
tuitary exhibited similar opiate action; included here are beta (B)-
endorphin (Li and Chung, 1976) and alpha (a)- and gamma (y}-endorphin 
(Guillemin et al., 1976}. 
The endorphins each share a common amino acid sequence with the 
terminal residues of S-lipotropin (LPH), a 91 amino acid pituitary 
peptide discovered by Li et al. (1965}; residues 61 to 91, 61 to 76, 
and 61 to 77 of S-LPH are identical with s-, a-, andy-endorphin, 
respectively. Finally, the structure of methionine-enkephalin occu-
pies position 61 to 65 of B-LPH. 
Goldstein (1976) suggested that S-LPH might be enzymatically 
cleaved in the pituitary to form a-, B-, andy-endorphin and, in turn, 
methionine-enkephalin. However, it has recently been shown that 
hypophysectomy failed to alter the quantity and distribution of the 
endorphins (Cheung and Goldstein, 1976) or enkephalins (Kobayashi et 
al., 1978b) in the brain suggesting that the pituitary and brain 
constitute separate compartments with respect to these peptides. 
Presently, research aimed at identifying possible prohormones and/or 
precursors for the various opioid peptides is being conducted (Yang 
et al., 1979). 
The enkephalin content of various CNS structures has been shown 
to be unevenly distributed by a variety of assay procedures including 
bioassay (Hughes et al., 1977), radioimmunoassay (Yang et al., 1977; 
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Kobayashi et al., 1978b), and receptor binding studies (Simantov et 
al., 1976a). In general, the striatum, central grey region, nucleus 
accumbens, and hypothalamus contained the highest content of methi-
onine- and leucine-enkephalin; the thalamus, amygdala, pons, medulla, 
and caudate-putamen contained lesser amounts of the enkephalins; the 
midbrain, hippocampus, cerebellum, and cortex exhibited the lowest 
enkephalin content (Hughes et al., 1977; Yang et al., 1977; Kobayashi 
et al., 1978b; Simantov et al., 1976a). In every brain region stud-
ied, the methionine-enkephalin content was found to be 2 to 7 times 
greater than the corresponding leucine-enkephalin content (Kobayashi 
et al., 1978h). In addition, immunohistochemical studies have also 
demonstrated the presence of methionine- and leucine-enkephalin pos-
itive fibers in laminae I, II, III, V, and VII of the spinal cord 
(Watson et al., 1977; Simantov et al., 1977). 
On the other hand, S-endorphin-like immunoreactivity is seen 
predominantly in the h7pothalamus, septum, midbrain, and pons-medulla 
while no material attributable to B-endorphin could be found in the 
striatum, hippocampus, cortex, or cerebellum (Rossier et al., 1977b; 
Watson et al., 1978). Overall, the distribution of a B-endorphin 
reactive system and a methionine-enkephalin reactive system in the 
CNS appear to be quite different suggesting the existence of two 
separate opioid peptide systems. 
Opiate binding_sites and opioid peptide containing cell bodies 
and/or terminals have been found for the most part to be distributed 
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in close proximity to each other. For example, in accordance with the 
relative distributions of opioid peptides, the periaqueductal grey 
region, several hypothalamic nuclei, and spinal cord laminae I, II, 
and III exhibited high density of opiate binding sites; the cortex and 
cerebellum contained the least dense opiate binding sites (Kuhar et 
al., 1973b; Atweh and Kuhar, 1977a, b). On the other hand, the nu-
cleus raphe magnus (NRM) contains a high level of methionine-enkeph-
alin positive cells (Hokfelt et al., 1977) but exhibits a low level 
of opiate binding sites (Atweh and Kuhar, 1977a). 
Subcellular fractionation experiments demonstrated that enkeph-
alin-like-activity was predominantly localized to the synaptosomal 
fraction, the region known to contain several neurotransmitters 
(Simantov et al., 1976b). 
Finally, methionine- and leucine-enkephalin are released from 
synaptosomes and isolated striatal slices by potassium-induced neuron 
depolarization or veratridine (Henderson et al., 1978); 8-endorphin 
is released from pituitary as well as hypothalamic sites by potassium-
evoked cellular depolarization (Przewlocki et al., 1978; Osborne et 
al., 1979). 
Overall, the enkephalins and endorphins fulfill two criteria 
required for identity as a neurotransmitter substance. First, these 
peptides exhibit the differential distribution expected of a neuronal 
system in the CNS. Second, pharmacological antagonism establishes 
whether the neurotransmitter is released and characterizes the 
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receptor mediating the various responses (see sections 1.4.2 and 1.4.3), 
However, several other criteria such as physiologically-induced re-
lease, vesicular location, transmitter synthesizing system, and iden-
tity of action must be met before their role as neurotransmitter sub-
stances is established. 
1.4.2 Antinociception, Analgesia, Enkephalins, and Endorphins 
The enkephalins and 6-endorphin have been shown to produce a dose 
dependent, naloxone reversible, antinociceptive state following intra-
cerebroventricular (Icvt) administrations in the rat (Belluzzi et al., 
1976; Bloom et al., 1976), mouse (Buscher et al., 1976; Loh et al., 
1976), and cat (Meglio et al., 1977). 
Enkephalin-induced antinociception develops after a 2 to 3 
minute latency and lasts for 5 to 10 minutes (Buscher et al., 1976); 
antinociception produced by 6-endorphin lasts up to 90 minutes after 
administration (Loh et al., 1976). It appears that the short duration 
of enkephalin-induced antinociception and, in fact, the failure of 
some investigators to demonstrate any antinociceptive action (Bloom 
et al., 1976) is attributable to the fact that the enkephalins, unlike 
$-endorphin, are rapidly destroyed enzymatically in the brain (Dupont 
et al., 1977) . 2 Structurally altered enkephalins, most notably D-ala -
methionine-enkephalin, which are resistant to enzymatic degradation 
are active antinoci.:::eptive agents when administered systemically or 
orally (Roemer et al., 1977). 
The enkephalins and S-endorphin also produce antinociception in 
the rat when administered directly into the midbrain periaqueductal 
grey region (Chang and Fang, 1976; Malick and Goldstein, 1977) or 
intrathecally (Yaksh and Henry, 1978; Yaksh et al., 1978). 
62 
Finally, methionine-enkephalin reduced the firing rate of dorsal 
horn neurons activated by noxious stimuli but did not affect the fir-
ing rate of neurons activated by innocuous stimuli; inhibitory effects 
were reve~sed by naloxone (Randic and Miletic, 1978). 
1.4.3 Antinociception, Analgesia, ~,d Naloxone 
Jacob et al. (1974) first demonstrated that naloxone administered 
by itself produced hypernociceptive responses in rats; subsequently, 
some laboratories have confirmed this hypernociceptive action of nal-
oxone in rodents (Grevert and Goldstein, 1977; Carmody et al., 1979). 
Goldstein et al. (1976) failed to observe the hypernociceptive 
naloxone effect. Frederickson et. al. (1977) later reported 
that the hypernociceptive response produced by naloxone followed a 
diurnal rhythm. 
In humans, Grevert and Goldstein (1978) showed that naloxone 
failed to alter responses in experimentally-induced pain situations 
namely cold water imMersion and ischemia. Alternatively, Buschbaum 
et al., (1977) reported that naloxone produced hypoalgesia and hyper-
algesia in individuals determined to be pain sensitive and pain in-
sensitive, respectively. The diurnal variation in nociceptive respon-
siveness produced by naloxone in laboratory animals has also been 
demonstrated in humans (Davis et al., 1978). Finally, naloxone en-
hanced the post-operative pain arising from the removal of impacted 
molars (Levine et al., 1978). Naloxone also restored pain sensi-
tivity, measured as an increase in flexor reflex, in an individual 
who was congenitally insensitive to pain (Dehen et al., 1978). 
Overall, it appears that naloxone produces hypernociception 
and hyperalgesia only in special cases which may be associated with 
increased activity in the endogenous opioid system such as stress 
(Madden et al., 1977; Rossier et al., 1977a). 
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Several other pharmacologically- and physiologically-induced 
antinociceptive states can be antagonized by naloxone: included here 
are acupuncture (Mayer et al., 1976); transcutaneous electrical stim-
ulation (Chapman and Benedetti, 1977); stimulation produced analgesia 
(SPA; Akil et al., 1976; see section 1.4.4 for further discussion); 
stress induced by cold water (Bodnar et al., 1977), footshock(Chesher 
and Chan, 1977), and immobilization (Amir and Amit, 1978); phenoxy-
benzamine (Elliot et al., 1976); nitrous oxide (Berkowitz et al., 
1977); physostigmine and oxotremorine (Harris et al., 1969); acetyl-
choline (Pedigo et al., 1975); and diisopropyl phosphofluoridate 
(DFP; Koehn and Karczmar, 1978). It must be pointed out that naloxone 
antagonism of antinociception and analgesia is necessary but not suf-
ficient evidence to conclude the involvement of the endogenous opioid 
system as mediating these effects. Since non-specific actions of 
naloxone could contribute to its antagonism of antinociception and 
analgesia it is necessary to determine whether this antagonism is 
stereospecific. 
1.4.4 Stimulation Produced Analgesia (SPA) 
Reynolds (1969) first demonstrated that focal electrical stimu-
lation applied to the midbrain periaqueductal gray matter (PAG) rend-
ered rats sufficiently antinociceptive to permit abdominal surgery. 
Since then, numerous studies have demonstrated that focal electrical 
stimulation of discrete brain regions produced a profound, long last-
ing level of antinociception (SPA) in laboratory animals as well as 
in humans (see section 1.1.8.3). 
The most significant factor, however, concerning SPA is the fact 
that SPA and opioid-peptide-induced antinociception appear to share 
both common sites and mechanisms of action. A number of studies have 
mapped the b'rain for effective antinociceptive sites with SPA and 
opioid microinjections. 
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Electrical stimulation of the mesencephalic gray matter and peri-
aqueductal grey matter produced antinociception as measured by a va-
=ietv of noxious stimuli in the rat (Mayer and Liebeskind, 1974); loci 
in the central gray surrounding the aqueduct and caudal portions of 
the third ventricle were particularly effective (Rhodes and Liebeskind, 
1978). Similarly, the most sensitive sites to intracerebral applica-
tion of morphine in the rat lie in the ventrolateral sections of the 
caudal PAG region (Yaksh et al., l976b). 
Electrical stimulation of other brain areas such as the septum, 
medial thalamus, ventral tegmentum, and pretectal area produced test 
specific antinocicpetive states; ventrobasal thalamic and lateral 
hypothalamic sites were ineffective (Mayer and Liebeskind, 1974; 
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Rhodes and Liebeskind, 1978). On the other hand, morphine injected 
into the posterior, anterior, and ventromedial hypothalamus, medial 
thalamus, and caudate increased flinch-jump thresholds in rats (Jacquet 
and Lajtha, 1973). Inejcted into the septum, morphine was ineffective 
(Jacquet and Lajtha, 1973) . 
The nucleus raphe magnus (NRM) of the medulla yields a profo~md 
level of antinociception following electrical stimulation in the rat 
and cat (Proudfit and Anderson, 1975; Oliveras et al., 1978; see sec-
tion 1.3.4). Alternatively, the nucleus reticularis gigantocellularis 
of the medulla is extremely sensitive to local injections of morphine; 
applications into other medullary nuclei including NRM were ineffect-
ive (Takagi et al., 1977). 
In summary, the degree of overlap for common effective brain 
sites of SPA and morphine, while not perfect, is impressive as it 
concerns the medial portions of the brain stem extending from the ros-
tral medulla to the diencephalon. In fact, concurrent mapping studies 
performed in the same animal demonstrate that PAG sites are particu-
larly sensitive to both procedures (Yeung et al., 1977). 
The tail flick response in rats is considered to be a spinal 
reflex since both spinally intact animals as well as animals with 
spinal transections (T4-T5) respond to noxious heat stimulus applied 
to the rat's tail (Irwin et al., 1951). Since both morphine and SPA 
have been reported to block the tail flick response in rats (Mayer 
et al., 1975), the spinal cord appears to participate, at least in 
part, in mediating antinociception produced by these two methods. 
In addition, recent electrophysiological investigations demon-
strate that morphine injections as well as electrical stimulation of 
PAG sites specifically inhibited the responses of spinal cord wide 
dynamic range interneurons to noxious heat but not to innocuous me-
chanical stimuli. Neither the narcotics nor electrical stimulation 
affected neurons which responded exclusively to innocuous stimuli; 
thus, both procedures appear to specifically inhibit input at the 
spinal cord level (Bennett and Mayer, 1979). 
Cross tolerance studies were performed to identify common neural 
substrates activated by SPA and morphine. Tolerance to SPA develops 
upon repeated stimulation in both the rat (Mayer and Hayes, 1975) and 
human (Hosobuchi et al., 1977); this tolerance exhibits cross toler-
ance to the antinociceptive and analgesic actions of morphine; toler-
ance to morphine reduced the effectiveness of SPA in the rat (Mayer, 
and Hayes, 1975) whereas tolerance to SPA increased the dose of mor-
phine required to produce analgesia in humans (Hosobuchi et al., 
1977) . Tolerance to SPA and cross tolerance with morphine decreased 
after periods of nonstimulation in both species (Mayer and Hayes, 
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1975; Hosobuchi et al., 1977). 
As stated earlier (see section 1.4.3), Akil et al. (1976) 
demonstrated that the narcotic antagonist, naloxone, reduced by 
approximately 30% the antinociceptive state produced by SPA applied 
to the PAG region in the rat brain. Other investigators demonstrated 
only a minor antagonistic effect of naloxone 3 to 5 minutes post 
stimulation (Pert and Walter, 1976) while still others report no 
effect of naloxone at all (Yaksh et al., 1976b). On the other hand, 
naloxone completely reversed the analgesia produced by PAG stimul-
ation in 6 out of 7 patients studied (Adams, 1976; Hosobuchi et al., 
1977). 
Finally, analgesia arising from electrical stimulation of the 
PAG region was associated with increased amounts of enkephalin-like-
material (Akil et al., 1978) and immunoreactive-S-endorphin (Hoso-
buchi et al., 1979) in the ventricular cerebrospinal fluid (CSF); 
leucine-enkephalin levels were not altered (Hosobuchi et al., 1979). 
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Patients diagnosed as having organic pain exhibited significantly 
lower levels of methionine-enkephalin-like-material when compared with 
normal non painful volunteers or patients diagnosed as having psycho-
genic pain (Almay et al., 1978). In addition, patients with high 
levels (>0.9 pmol/ml) of methionine-enkephalin-like-material exhibit 
higher pain thresholds and pain tolerance levelz than did patients 
with low levels (<0.9 pmol/ml) of methionine-enkephalin-like-material 
(Von Knorring et al., 1978) . 
In summary, although the exact role of the endogenous opioid 
system in antinociception and analgesia remains to be established, 
the combined data reported above suggest that these naturally 
occurring peptides may be involved in the control of pain. 
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2 . RESEARCH OBJECTIVES 
All the known potent naturally occurring and various synthetic 
narcotic analgesics produce tolerance and physical dependence (Isbell, 
1977) . In spite of the fact that no nonaddicting potent analgesic 
exists, the research devoted to this particular problem has led to 
the development of other useful drugs such as methadone which is used 
for withdrawal procedures and to maintain persons addicted to the 
opioids (Isbell, 1977). Another benefit has been the stimulation of 
the basic sciences to pursue research programs directly and indirectly 
related to the management of the chronic pain state. These research 
efforts have led to a more complete understanding of the anatomical, 
neurochemical, neurophysiological, and psychological mechanisms in-
volved in the perception of pain. 
Compounds which produce antinociception when administered to 
laboratory animals do not necessarily produce analgesia when admin-
istered to humans; however, a correlation between the antinociceptive 
and analgesic properties of a drug does exist for many narcotics 
(Isbell, 1977), certain compounds which affect the cholinergic system 
(Herz, 1961; Harris et al., 1968; Sitaram et al., 1977; Sitaram, 1979, 
personal communication), ~d various derivatives of delta-9-tetra-
hydrocannabinol (Bhargava, 1978a; Jochimsen et al., 1978). Thus, 
investigating drug-induced antinociception as an index of effective-
ness of that drug to produce analgesia, while not applicable for all 
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drugs which produce antinociception is a valid procedure for specific 
drugs and/or classes of drugs. 
Previous studies indicate that ACh (Pedigo et al., 1975), 
various cholinomimetics (Chen, 1958; Herz, 1961; Harris et al., 1967, 
1968), and/or ~~ticholinesterases (Harris et al., 1968; Bhargava and 
Way, 1972; Koehn and Karczmar, 1978) produce antinociception as well 
as potentiate narcotic-induced antinociception when administered to 
rodents. In addition, anticholinesterases, long known to potentiate 
narcotic-induced analgesia in humans (Floodmark and Wrammer, 1945) 
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have recently been shown to produce analgesia when employed alone 
(Sitaram et al., 1977). Thus, present evidence suggests that com-
pounds which affect the cholinergic system may be useful agents to 
investigate concerning the management of pain. The purpose of this 
dissertation research is to examine the antinociceptive property of the 
anticholinesterase agent, diisopropyl phosphofluoridate, DFP, and 
its various aspects. 
The first objective of this research is to determine whether 
similarly to other anticholinesterases DFP will produce antinoci-
ception when administered to rats. 
Anticholinesterase agents produce a state of immobilization 
(Adams, 1973) and hypothermia (Meeter and Wolthius, 1968) when admin-
istered to rats. Since the methods employed to assess antinoci-
ception, the hot plate and tail flick tests, involve motor and temp-
erature dependent behavioral responses it will be important to 
separate the antinociceptive effects from the attenuated mobility 
and hypothermia produced by DFP; exploratory and motor activity 
levels and rectal temperatures will be measured for this purpose. 
The second objective of this research is to determine whether 
the antinociceptive action of DFP in the rat is related to the in-
volvement of· either the serotonergic or endogenous opioid systems 
in the CNS. Since increased activity of 5-HT neurons in the CNS 
is associated with the production of antinociception (see section 
1.3) and DFP markedly increases 5-HT levels and turnover rates 
(Barnes et al., 1975, 1978), it may be speculated that DFP-induced 
antinociception results from actions involving the serotonergic 
system (see section 1.2.2). 
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On the other hand, an endogenous opioid system may mediate DFP-
induced antinociception (see section 1.4). Several endogenous opioid 
peptides such as leucine- and methionine-enkephalin (Blasig and Herz, 
1976) and 8-endorphin (Szekely et al., 1977) produce antinociception 
when administered exogenously. Since antinociception produced by 
stress (Chesher and Chan, 1977 ; Bodnar et al., 1978), brain stimu-
lation (Ad~ms, 1976), acupuncture (Mayer et al., 1976), as well as a 
number of drugs (Elliot et al., 1976; Stewart et al., 1976; Harris 
et al., 1976; Berkowitz et al., 1977) is antagonized by naloxone, a 
narcotic antagonist, these various procedures may release endogenous 
opioids which then serve as endogenous antinociceptive agents. Nal-
axone also antagonizes the antinociceptive state produced by physo-
stigmine and oxotremorine (Harris, 1970) and ACh (Pedigo et al., 
1975). Thus, if the enkephalins or endorphins indeed function as 
endogenous antinociceptive agents, then the antinociceptive state 
produced by DFP may result from DFP-induced release of the endogenous 
opioids. 
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It is hoped that the study of the mechanisms involved in OFF-
induced antinociception may provide an explanation for certain con-
flicting findings and may also shed some light upon the mechanisms of 
antinociception in general. Finally, this investigation may, pos-
sibly, contribute to the management of pain by providing the rationale 
for implementing novel forms of drug therapy. 
3 • MATERIALS AND METHODS 
3.1 Animals 
Male Sprague-Dawley rats, 160-350 gm obtained from Locke-
Erickson and King Animal Distributors were used for behavioral 
studies as well as for brain serotonin (5-HT) and enkephalin level 
determinations. Male CFl mice, 25-40 gm obtained from Charles River 
Animal Distributors were used for vasa deferentia bioassay prepa-
rations. Animals were housed in a temperature-controlled (22 ± 2°C) 
room with lights on and off at 0700 and 1900 hours daily. In all 
cases, food and water were provided ad libitum. 
3.2 Drugs and Chemicals 
3.2.1 Source 
Diisopropyl phosphofluoridate (DFP) obtained from K & K Labora-
tories, Plainview, New York in propylene glycol vehicle was diluted 
as appropriate in peanut oil (Mallinckrodt Chemical Company) . 
Morphine sulfate (Merck Chemical Division); atropine sulfate 
(City Chemical Company); atropine methyl nitrate, para-chlorophenyl-
alanine methyl ester (PCPA) and pilocarpine HCl (Sigma Chemical 
Company); naloxone HCl (Endo Laboratories) ; MR 2266 and MR 2267 
(- and+ stereoisomers of 5,9 a-diethyl-2-(furylmethyl)-2'-hdyroxy-
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6,7-benzomorphan, Boehringer Ingelheim); GPA 1843 and GPA 1847 
(- and+ stereoisomers of 2-allyl-2'-hydroxy-9 B-methyl-5-phenyl-
6,7 benzomorphan, CIBA-Geigy Corporation); and d- and 1-cyclazocine 
(Sterling-Winthrop Research Institute) were dissolved in normal 
saline. 
Serotonin creatinine sulfate complex (Sigma Chemical Company) 
was dissolved in 0.1 N HCl (stock solution) and redissolved freshly 
each day in 0.1 N HCl for use in the fluorometric assay. Leucine-
and methionine-enkephalin (Beckman Biochemicals) were dissolved in 
distilled water (stock solution) and redissolved in Krebs solution 
for use in the bioassay. 
Distilled water, taken from the central storage tap, was de-
ionized (Barnstead Ultrapure Mixed Bead) and redistilled (Corning 
Water Distillation Apparatus) for use thro?ghout these experiments. 
3.2.2 Dosage and Schedules 
DFP (1.5, 1.0, 0.5, and 0.1 mg/kg) and morphine (3.0 mg/kg) 
were administered subcutaneously (s.c.) one hour prior to initiation 
of experiments. Atropine sulfate (4.0 mg/kg), atropine methyl 
nitrate (4.0 mg/kg), naloxone (5.0, 0.5 and 0.05 mg/kg) MR 2266 
and MR 2267 (1.0 rng/kg) ,GPA 1843 and GPA 1847 (5.0 rng/kg), and d-
and 1-cyclazocine (0.64 rng/kg) were administered intraperitoneally 
(i.p.) 30 minutes prior to experimentation. Pilocarpine (2.5 rng/kg) 
was administered subcutaneously 30 minutes prior to experimentation. 
PCPA was administered in doses of 100 (PCPA1) or 300 (PCPA2) 
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mg/kg i.p. on each of the two days preceeding testing; a third dose 
of 100 mg/kg i.p. was given two hours before the initiation of exper-
iments. 
In all cases, control animals were administered the drug vehicle, 
peanut oil or saline, in an identical manner. 
3.2.3 Development of Tolerance 
For the production of tolerance, animals were injected with mor-
phine 3 times per day (at 0800, 1600, and 2400 hours) at a total daily 
dose as follows: 30, 60, 90, 120, 150, 180, 300, 450, and 600 mg/kg 
i.p. on days 1 through 9, respectively. Control animals were admin-
istered the vehicle. Hot plate responses (see section 3.3.2) were 
measured on day 6 (Tolerance level A) and on day 9 (Tolerance level 
B) • 
3.3 Behavioral Studies 
3.3.1 Pretest Care of Animals 
Rats.were housed 3 or 4 per cage. Since handling produces stress 
in rats (Ader, 1968) and the handling involved in testing may affect 
the performance of rats not previously handled (Joffe and Levine, 
1973) , rats were handled for at least 5 minutes on each of the three 
days preceeding any testing situation to minimize stress effects. 
Preinjection (baseline) measurements of all responses except 
exploratory and motor activity level determinations (see sections 
4.2.1, 4.2.2, 4.6.1, 4.6.2, 4.7.2, and 4.7.3) were obtained at least 
one hour prior to the administration of any compound. 
Mice were housed 10 per cage until their use for bioassay prep-
arations. 
3.3.2 Hot Plate Test 
3.3.2.1 Apparatus 
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The following two apparatuses were utilized for hot plate studies. 
First, inverted blocks of a Tecam Driblock DB-3 Test Tube Heater 
served as the hot plate source. The heat blocks were surrounded by 
a wire cage (23 em long x 9.5 em wide x 9.5 em high) which restricted 
the animals' movement to the heat block surface. The temperature 
was maintained at 55 ± 0.5°C by a variable heat control. Rats weigh-
ing 160-220 gm were employed in experiments concerning (a) effect 
of atropine sulfate and atropine methyl nitrate on DFP-induced anti-
nociception (see section 4.1.3), (b) effect of PCPA on DFP-induced 
antinociception (see section 4.5.1), and (c) pharmacological compar-
ison of DFP- and morphine-induced antinociceptive states (see section 
4. 7 .1). 
Second, a standard hot plate (32 em square surface, property of 
the University of Iowa) was utilized. A plastic cylinder (22 em diam-
eter x 30 em high) restricted the animals' movements to the hot plate 
surface. The temperature was monitored and maintained at 55 ± 0.5°C 
by a series of built-in thermistors which provided the entire hot 
plate surface with a constant temperature. Rats weighing 200-350 gm 
were employed in experiments concerning: (a) DFP- and pilocarpine-
induced antinociception (see section 4.1.1), (b) Effect of naloxone 
on DFP-induced antinociception (see section 4.8.1), (c) Effect of 
stereoisomers of narcotic antagonists on DFP-induced antinociception 
(see section 4.9), and (d) Effect of tolerance to morphine on DFP-
and pilocarpine-induced antinociception (see section 4.10). 
·3.3.2.2 Testing Procedure 
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The hot plate test was carried out as follows. The rats were 
placed on the hot plate surface; the latency of onset of the following 
responses were recorded: ·(a) licking of the front paws, (b) licking 
or lifting/spinning movement of the hind paw, and (c) jumping off of 
the hot plate surface. All response times reported represent the 
latency of onset of the first response observed. A 30 second time 
limit was set to be the maximum nociceptive response time in all tests 
except those involving (a) DFP- and pilocarpine-induced antinocicep-
tion (see section 4.1.1) and (b) Effect of naloxone on DFP-induced 
antinociception (see section 4.8.1) where a EO second time limit was 
used. 
3.3.3 Tail Flick Test 
In the tail flick test, animals were placed in a plastic restrain-
ing cage which allowed the tail to extend outwards and to relax for 
3 minutes. The tail was then placed in a grooved slot of an asbestos 
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board; the beam of the light source, Blue M Infra Oven (375 watts), 
was focused one inch from the tip of the rats' tail. A 60 second time 
limit was set and the characteristic flicking movement of the tail was 
used as the endpoint. 
3.3.4 Activity Level Determinations 
3.3.4.1 Apparatus 
Exploratory and motor activity levels were assessed in a covered 
circular activity cage (Lehigh Valley Instruments Corporation) with a 
46 em high cylindrical wall. Six photoelectric cells, with opposing 
lights, were placed every 8.7 em along the cylindrical wall 2.5 em 
above the floor. Two counters, each responsive to 3 photoelectric 
cells, recorded the number of times each beam of light was broken. 
3.3.4.2 Exploratory and Motor Activity 
The number of photoelectric interruptions were recorded 15 and 
75 minutes after placing the rats individually in the activity cages. 
Activity levels reported represent the average of the two counters. 
Activity levels measured during the first 15 minutes and subsequent 
60 minutes of "the test are commonly referred to as the exploratory 
and motor activity periods, respectively (Karczmar and Scudder, 
1967) . 
Exploratory activity levels were also measured by placing the 
animals individually in the activity cages for 10 minute periods at 
at various times post drug administrations. Counters recorded the 
number of photoelectric interruptions during each 10 minute test 
session. 
3.4 Rectal Temperature 
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Rectal temperatures in rats were measured by means of a thermister 
probe (Yellow Springs Instrument Company) inserted into the rectum 
to a depth of 50 mm and retained in situ until a constant temperature 
reading was obtained (usually 30 seconds) . 
3.5 Brain Serotonin (5-HT) Assay 
Brain (5-HT) levels were determined according to modifications of 
methods originally described by Atack and Magnusson (1970) and Atack 
(1973) . This experimental procedure utilizes the processes of cation-
exchange chromatography to separate and spectrophotofluorometry to 
quantify 5-HT; it was employed with respect to 3 different brain re-
gions, and can be outlined as follows: 
3.5.1 Tissue Samples 
(a) Rats were sacrificed by decapitation (1000 to 1200 hours); 
brains were quickly removed from the cranial vault. 
(b) Meninges and cerebellum were discarded. 
(c) Brains were rapidly divided into three regions: 
(1) Medullary (medulla) 
(2) Meso-diencephalon (thalamus, hypothalamus, pons, and 
midbrain) 
(3) Telencephalon (cortex and caudate) 
(d) Brain regions ~ere frozen in liquid nitrogen and stored at 
-2ooc until analyzed. 
3. 5. 2 Reagents 
(a) Water (see section 3.2.1) 
(b) 2N NaOH + l% EDTA (Dissolve 40 gm NaOH and 5 gm EDTA in 
500 ml water) 
(c) lON, 2N, and lN HCl (Made appropriately from concentrated 
12 N HCl) 
(d) ETOH/HCl (Combine equivalent volumes of redistilled 95% 
ETOH and 2N HCl) 
(e) O.lN Sodium Phosphate Buffer (Dissolve 8.83 gm NaH 2Po4 , 
12.88 gm Na2HP04 '12H2o, and 1 gm EDTA in 1,000 ml water) 
(f) Homogenizing Solution (Dissolve 0.125 gm Na2s2o5 and 0.5 gm 
EDTA in water. Add 8.55 ml 70% HCl04 and bring to a final volume of 
250 ml with water) 
(g) 5N K2co 3 (Dissolve 69.0 gm K2co 3 in 200 ml water) 
(h) BromPhenol Blue Solution (B.P.B.; dissolve 1-6 -mg 3'3"5'5"-
tetrabromophenolsulphonephthalein Na in 100 ml of redistilled 95% 
ETOH) 
(i) Ortho-phthaldehyde (OPT, stock solution; dissolve 29.65 mg 
of OPT in 50 ml of lON HCl) 
OPT (experimental solution; take 8.72 ml of OPT stock so-
l uti on up to 100 ml final volume with lON HCl) . 
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(j) Serotonin (5-HT, stock solution; dissolve 42.95 mg of 
serotonin creatinine sulfate complex in 250 ml of O.lN HCl) 
5-HT (Experimental solution; take 1.0 ml of 5-HT stock 
solution up to 50 ml final volume with O.lN HCl) 
3.5.3 Column Preparation 
3.5.3.1 Cycling and Regeneration of Resin 
Ion-exchange chromatography resin should be given at least one 
complete change of form to remove other ions and impurities (Mikes, 
1970). Utilizing a magnetic stirring apparatus, 250 gm of DOWEX AG 
SOW X4 200-400 mesh H+ from ion-echange resin was cycled and regen-
erated ten times with the following solutions: 
(a) 300 ml 2N NaOH + l% EDTA 
(b) 300 ml ETOH/HCl 
(c) 300 ml 2N HCl 
(d) 300 ml water 
The regenerated resin was stored in water at S°C. 
3.5.3.2 Packing of Columns 
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The columns to be packed with ion-exchange resin have been 
adapted from 1.0 ml disposable syringes (4.2 mm internal diameter x 
7.0 em high; Fig. 1). A piece of tygon tubing, which serves to attach 
the column assembly to the glass syringe apparatus was affixed to the 
upper end of the syringe barrel (Fig. 1). Since air bubbles disrupt 
the uniform packing of t~e resin, the actual packing was performed 
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FIGURE 1 
Diagram of column assembly and glass syringe apparatus 
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with the columns submerged in water. First, a small piece of glass 
wool which serves to trap the resin in the column, was inserted into 
the column and forced to the tip with a stirring rod (Fig. 1). A 2 ml 
pipet filled with resin was inserted into the top of the column and 
the resin was allowed to flow into the column. When the resin bed 
had reached a height of 50 mm, another piece of glass wool was insert-
ed into the top of the column, thus trapping the resin between the 
two pieces of glass wool (Fig. 1). The freshly packed column was 
mounted onto one of the glass syringes in the glass syringe apparatus 
(Fig. 1). The glass syringe apparatus consisted of the following. 
Two 20 ml glass syringe barrels were connected to each other through 
a series of three-way stopcocks (Fig. 1). One syringe barrel served 
as a reservoir through which the extract and other reagents could be 
added to the column (Fig. 1). The other glass syringe barrel served 
as the site of attachment for the column (Fig. 1). The glass syringe 
apparatus was suspended vertically through holes in a wooden board 
(Fig. 1). 
3.5.3.3 Preparing Columns for Samples 
It is oftennecessary to ion exchange resin for elution ion-
exchange chromatography to adjust the pH to optimal for separation 
(Mikes, 1970). Here, the resin was prepared for the addition of tissue 
extracts by cycling the resin into the form of the buffer cation (Na+) 
and then washing with buffer (Atack, 1973). This was accomplished by 
passing the following solutions through the column: (a) 20 ml 2N 
NaOH + 1% EDTA, (b) 50 ml water, (c) 20 ml 2N HCl, (d) 50 ml water, 
(e) 20 ml O.lN sodium phosphate buffer (pH=6.5), and (f) 5 ml 
water. The pH of the effluent is taken as a control measurement to 
check that the inflowing solution and effluent have the same compo-
sition; thus, a pH of 6.5 indicated that the column was ready for 
the addition of the tissue extracts. 
3.5.4 Extraction Process 
(a) Weighed brain regions were chilled and homogenized in 8.0 ml 
of homogenizing solution (see section 3.5.2). 
(b) Homogenate was centrifuged at 4000 RPM for 15 minutes. 
(c) Supernatant was poured into 15 ml graduated tubes. 
(d) Pellet was reextracted with 3.0 ml of homogenizing solution; 
centrifuged at 4500 RPM for 10 minutes; supernatants were combined. 
(e) pH was adjusted to 6.5 with 5N K2co3 (using 2 drops of B.P.B. 
as pH indicator) . 
(f) Supernatant was set for 10 minutes on ice. 
(g) Centrifuged at 5000 RPM for 15 minutes. 
(h) Tissue extracts filtered (Watman No.1) onto ion-exchange 
column; passed through column (flow rate <0.5 ml/min) mol. 
(i) Columns rinsed by passing the following solutions: 
(1) 15 ml water 
(2) 15 ml O.lN sodium phosphate buffer 
(3) 15 ml water 
(j) 5-HT was eluted with the following sulutions: 
(1) 10.5 ml lN HCl (discard) 
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(2) 4.7 ml ETOH/HCl (discard) 
(3) 6.0 ml ETOH/HCl (collect = 5-HT fraction) 
Internal standards were prepared by substituting 1400, 700, and 
350 ng of 5-HT as well as 0.5 ml of ETOH and H2o in place of a brain 
sample. Per cent recovery of 5-HT and column reagent blanks fluores-
cent values were determined from these five internal standards. 
3.5.5 Conversion of Serotonin (5-HT) to Fluorophore 
Serotonin (5-HT) content in biological tissues can be determined 
by fluorescent methods directly (Maicker and Miller, 1966). However, 
reacting 5-HT with o-phthaldehyde (OPT) yields a substituted indole 
compound which is 20 times more fluorescent than 5-HT itself (sensi-
tive to 1.0 ng 5-HT; Maicker and Miller, 1966). Therefore, 5-HT was 
reacted with OPT according to the methods described by Maicker and 
Miller (1966). The process is outlined as follows: (a) Add 2 drops 
of OPT and 0.5 ml of sample eluate to 1.0 ml lON HCl (b) Boil for 
15 minutes (c) Allow to cool to room temperature. 
External standards and reagent blanks were prepared as follows. 
To 1.0 ml of lON HCl the following amounts of standard 5-HT and re-
agents were added: 
(a) 700 ng 5-HT [0.500 ml 5-HT (Experimental solution) + 0.000 ml 
O.lN HCl] 
(b) 350 ng 5-HT [0.250 ml 5-HT (Experimental solution) + 0.250 ml 
O.lN HCl] 
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(c) 175 ng 5-HT [0.125 ml 5-HT (Experimental solution) + 
0.375 ml O.lN HCL] 
(d) ETOH Blank (0.500 ml ETOH) 
All samples and standards were read in an Aminco-Bowman Spectra-
photofluorometer at uncorrected wavelengths of 360 m~ (activation) 
and 470 m~ (emission). The water reagent blank was set at 0.05 
fluorescent units and the samples were read accordingly. 
3.5.6 Calculations 
The formula for calculating ng 5-HT/gm brain tissue is as 
follows: 
A X (B - C) 
ng 5-HT/gm brain tissue (D - E) X F X G 
where, 
A= 12 (6.0 ml/0.5 ml; total volume of 5-HT eluate fraction collected, 
see section 3.5.4 
Volume of 5-HT eluate fraction converted to fluorophore, see 
section 3.5.5) 
B = Fluorescent units of sample (tissue extract) 
C = Fluorescent units of column reagent blank (determined from intern-
al standards passed through the column, see section 3.5.4). 
D Fluorescent units of external standard 
E Fluorescent units of external reagent blanks 
F = Per cent recovery (determined from internal standards passed 
through the column, see section 3.5.4) 
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G = Brain region weight 
Average recoveries for 5-HT were found to vary between 65 and 
80 per cent. Brain sample concentrations (ng/gm) were always correct-
ed for 100 per cent recovery based on the internal standard recovery 
percentage for each experiment. 
3.6 Brain Enkephalin-like-material Level Assay 
Brain enkephalin-like-material levels were determined according 
to methods originally described by Hughes et al. (1975b; 1977) and 
modified at present. Experimental procedures involved are (1) mole-
cular seive chromatography to separate and {2) vas deferens bioassay 
preparation to quantify enkephalin-like-material; procedures are out-
lined as follows. 
3.6.1 Tissue Samples 
(a) Rats were sacrificed by decapitation (0800 to 1000 hours); 
brains were quickly removed on ice. 
(b) Meninges and cerebellum were discarded. 
(c) Weighed brains were placed in 10 ml of 0.1 N HCl for the 
extraction of enkephalin-like-material (see section 3.6.4). 
3.6.2 Reagents 
(a) Water (see section 3.2.1) 
(b) O.lN HCl (Made appropriately from concentrated 12N HCl) 
(c) Dichloromethane (As obtained commercially) 
(d) Methanol (MeOH) (Degassed under vacuum in heavy walled 
filtering flask) 
(e) Kreb's Solution (Dissolve 13.72 gm NaCl, 0.70 gm KCl, 
0.734 gm cac1 2 ·2H2 0, 0.332 gm NaH2Po4 ·H2o, 3.96 gm d-glucose, and 
4.20 gm NaHC0 3 in 2000 ml water) 
(f) Leucine/Methionine-Enkephalin (Stock solution; dissolve 
1.0 mg leucine/methionine-enkephalin in 1.0 ml water) 
(g) Leucine/Methionine-Enkephalin (Experimental solution; 
take 10 ~1 of leucine/methionine-enkephalin stock solution up to a 
final volume of 10 rnl in Kreb's solution) 
3.6.3 Column Preparation 
3.6.3.1 Resin Cleaning Procedure 
Chromatography resin was cleaned prior to its use to remove 
any impurities. Utilizing a magnetic stirring apparatus, 250 gm of 
Arnberlite XAD2, neutral polystyrene bead resin was washed with t~e 
following solutions ten times: 
(a) 300 rnl Dichloromethane 
(b) 300 rnl Isopropyl alcohol 
(c) 300 rnl water 
The cleaned resin was stored in water at room temperature. 
3.6.3.2 Packing of Columns 
Cylindrical columns (25 ern high, Kontes Martin Company) were 
used in this procedure. The lower portion of the column (14 ern, 8.0 
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8.0 mm internal diameter) held the chromatography resin; the upper 
portion (11 em, 32 mm internal diameter; 125 ml capacity) served as 
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a reservoir for the application of brain extracts and various solu-
tions. A rotating plastic stopcock located at the base of the column 
adjusted the flow rate. The columns were suspended vertically through 
holes in a wooden board. A small piece of glass wool was inserted 
into the column to trap the resin at the lower end. The column was 
filled with resin to a height of 80 mm. To remove air bubbles which 
interfere with the uniform packing of the resin and flow of solutions 
through the columns, a small glass stirring rod was used periodically 
during the times at which the columns were filled with resin as well 
as during the subsequent extraction process. 
3.6.4 Extraction Process 
(a) Chilled homogenization of weighed brains in 10.0 ml of 
O.lN HCl 
(b) Centrifugation of homogenate in a total volume of 20-30 ml 
of O.lN HCl at 19,000 RPM for 30 minutes 
(c) Pouring of supernatant onto prewashed(300 ml H20) column 
and pass through resin (flow rate < 1 ml/minute) 
(d) Rinsing of columns by passing the following solutions: 
(1) 40 ml QlN HCl 
(2) 50-200 ml H2o 
(e) Eluting enkephalin-like-material with 40 ml MeOH (~egassed) 
(f) Vaporizing and withdrawing ~eOH down to approximately 2 ml 
under vacuum at 40°C (Buchi Rotorvapor-R Apparatus) 
(g) Transfer of remaining eluate to 25 ml round bottom flask 
and desication to complete dryness under vaccum at 50°C (Buchi Roto-
vapor-R-apparatus) 
(h) Freezing (-20°C) dried sample until used in bioassay 
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Internal standards were prepared by substituting 400 mg of leu-
cine-enkephalin in place of two brain samples; per cent recovery of 
enkephalin for each experiment was determined from these two internal 
standards. 
3.6.5 Bioassay 
3.6.5.1 Preparation of Vasa Deferentia 
(a) Mice were sacrificed by cervical dislocation. 
(b) Vasa deferentia were quickly removed and placed in Kreb's 
solution. 
(c) Cotton threads were attached to one end of each vas defer-
ens. 
(d) Tissues were mounted vertically in a 1.7 ml organ bath 
(Kontes Martin Corporation, as by design) containing oxygenated (95% 
o2 ; 5% co2); Krebs solution at 37°C. 
(e) The upper end of each tissue was attached by a thread to an 
isometric or isotonic transducer (Harvard Apparatus). 
(f) The tissue was placed initially under 200-500 mg tension. 
3.6.5.2 Electrical Stimulation 
(a) Two platinum wires (10 mm long) located at each vertical 
92 
extremity served as stimulating electrodes. 
(b) Tissues were submaximally stimulated with square pulses of 
0.5 to 0.8 msec duration from a Grass 548 Stimulator. 
(c) Frequencies of 0.07 to 0.10 Hz were used. 
3.6.5.3 Measurement of Enkephalin-like-material 
Enkephalins inhibit the electrically evoked contractions of the 
longitudinal muscle of the mouse vas deferens by depressing evoked 
norepinephrine output; this effect is mediated through the opiate re-
ceptor (Hughes et al., 1975b). The depression of evoked contraction 
is represented as a depression of the twitch height and is related to 
the amount of enkephalin added to the bath in a dose dependent manner 
(Fig. 2). Utilizing a bracket assay, the amount of enkephalin-like-
material in a sample may be determined as follows. First, constant 
responses (±5%) to repeated applications of known amounts of standard 
leucine-enkephalin were obtained to insure reliability of tissue re-
sponses (Fig.2). Second, various amounts of unknown sample are applied 
until an amount which depresses the twitch height by approximately 
50% is determined. ·Third, the unknown sample is bracketed between 
predetermined low and high doses of standard leucine-enkephalin; the 
low dose of standard should depress the twitch height less than the 
brain sample; the high dose of standard should depress the twitch 
height more than the brain sample. Finally, complete antagonism, that 
is 100% reversibility, by the narcotic antagonist, naloxone (900 nM) 
of the twitch height depression due to the administration of the brain 
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FIGURE 2 
Inhibition of electrically evoked contractions of 
the longitudinal muscle of the mouse vas deferens 
by leucine-enkephalin (Leu-Enk). W =washout time. 
Application of naloxone (Nal. 900 nM, bath concen-
tration) prior to washout is used to demonstrate 
that the depressant action of Leu-Enk is mediated 
through the opiate receptor. 
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sample identified the depressant action of the brain sample as being 
mediated through the opiate receptor. A 6 minute dose cycle was used 
throughout. 
3.6.6 Calculations 
The amount of enkephalin-like material expressed as ng leucine-
enkephalin-equivalents/gm brain tissue was calculated using the fol-
lowing formula: 
A x B 
= ng leucine-enkephalin-equivalents/gm brain tissue 
C X D X E 
where, 
A = ng leucine-enkephalin equivalent in organ bath (determined 
from the standard curve drawn from the low and high doses of stand-
ard leucine-enkephalin used in the bracket assay) 
B = Total volume of Krebs solution used to redissolve sample 
C Volume of sample injected into the organ bath 
D Per cent recovery (determined from internal standards, see 
section 3. 6 .4) 
E = Brain weight 
Average per cent recovery for internal standards of leucine-
enkephalin (400 ng) varied between 20 and 90%. Calculations were 
always corrected for 100% recovery based on the internal standard 
recovery percentage for each experiment (see section 3.6.4). 
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3.7 Statistical Analysis 
Hot plate responses (see sections 4.1.1, 4.1.3, 4.5.1, 4.7.1, 
4.8.1, 4.9, and 4.10), tail flick responses (see sections 4.1.2, and 
4.5.2), and rectal temperature measurements (see section 4.3 and 
4.8.3) were compared to preinjection, baseline, values for each animal 
(paired student t test, two tailed). 
Exploratory activity levels (see sections 4.2.2, 4.6.1, 4.7.2, 
and 4.8.2), motor activity levels (see sections 4.2.1, 4.6.2, and 
4.7.3), brain region 5-HT levels (see section 4.4.1, 4.4.2, and 4.4.3) 
and whole brain enkephalin-like-material levels (see section 4.11) 
were compared to responses and values obtained from animals adminis-
tered the appropriate vehicle/s (analysis of variance, Newman-Keuls 
test) . Other tests for statistical significance are as stated in 
Chapters 4 and 5. 
3.8 Definitions 
The statistical analysis employed in this dissertation require 
more restrictive definitions of some commonly· used terms as follows. 
"Antinociception" is defined as statistically significant (p<0.05) 
increase in hot plate or tail flick response times (latencies) in rats 
administered a compound when compared to preinjection, baseline resp-
onses (paired student t test) . 
When the preinjection, baseline, and postinjection hot plate or 
tail flick response latencies (times) in rats administered known anti-
nociceptive doses of DFP or morphine did not differ (p>O.OS; paired 
student t test) due to the administration/s of an additional com-
pound, this effect was referred to as "antagonism of the antinocicep-
tive state". 
Rarely, the administration of a compound reversed the effect of 
known antinociceptive doses of DFP or morphine; that is, DFP or mor-
phine in the presence of an additional compound produced a statistic-
ally significant (p<O.OS) decrease in the latency of the hot plate or 
tail flick responses in rats when compared to preinjection, baseline 
responses (paired student t test) . This effect is referred to as 
"reversal of the antinociceptive state". 
Some compounds, administered alone, significantly decrease 
(p<0.05) the animals' hot plate or tail flick response latencies when 
compared to preinjection, baseline responses (paired student t test). 
This effect is referred to as the production of a "hypernociceptive 
state". 
All other comparative terms such as increased, decreased, atten-
uated, etc. reflect statistically significant (p<0.05) differences as 
described by the appropriate statistical analysis. 
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4. RESULTS 
4.1 DFP- and Pilocarpine-Induced Antinociception in Rats 
4.1.1 Hot Plate Test 
The effect of a single s.c. administration of DFP (0.1, 0.5, 
1.0, and 1.5 mg/kg) or pilocarpine (2.5 mg/kg) on the hot plate re-
sponse times of rats was measured 1, 2, 4, 6, 8, 24, and 48 hours 
after the DFP and 30 minutes after the pilocarpine injection, respec-
tively. DFP produced antinociception 1 hour post injection at all 
doses tested; pilocarpine (2.5 mg/kg) also produced a significant 
antinociceptive state 30 minutes after its administration; the vehi-
cle was ineffective (Table 1). Response times of animals administered 
the vehicle were not significantly different when compared to response 
times of control, non-injected, animals in the hot plate test or in 
any other test or measurement described in this dissertation (analysis 
of variance, Newman-Keuls test; Table 1). 
The antinociceptive state produced by DFP followed a dose depend-
ent relationship in terms of potency and duration of effect. Thus, 
the response latency was increased by 77 to 94% by doses of 1.0 and 
1.5 mg/kg of DFP, and by some 28% by the dose of 0.1 mg/kg. Antinoci-
ception produced by DFP (1.0 and 1.5 mg/kg) was maintained for 6 hours 
with maximum effects at 2 and 4 hours, respectively; DFP (0.1 and 0.5 
mgjkg) produced antinociception that lasted for l hour after admin-
istration (Fig. 3). Finally, it should be noted that animals admin-
98 
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TABLE 1 
Hot plate response times (seconds ± S.E.M.) of rats 
subsequent to the single s.c. administration of the 
vehicle, DFP (0.1, 0.5, 1.0 and 1.5 mgjkg), or pilo-
carpine (2.5 mg/kg). n = number of animals employed 
in each group. Postinjection responses were compared 
to preinjection responses for each animal (paired 
Student's t Test). *p<0.05 and **p<O.Ol. 
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TABLE l 
EFFECT OF DFP AND PILOCARPINE ON HOT PLATE RESPONSE 
TIMES OF RATS 
Hot Plate 
Res,Eonse Times (Sec) ± S.E.M. 
Group (n) Preinjection Postinjection 
Control (non-injected) 3 9.6 ± 0.7 9.5 ± 0.8 
Peanut oil 8 8.9 ± 0.6 9.2 ± 0.6 
DFP (0 .1 mg/kg) 8 9.9 ± 0.9 12.8 ± 1.6* 
DFP (0.5 mg/kg) 8 11.0 ± 0.9 15.2 ± 1.3* 
DFP (1.0 mg/kg) 8 9.7 ± 0.9 18.8 ± 3.2** 
DFP (1.5 mg/kg) 8 9.4 ± 0.8 16.6 ± 2.0** 
Pilocarpine (2. 5 mg/kg) 8 9.2 ± 1.3 16.0 ± 1.4** 
*p<0.05 and **p<O.Ol 
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FIGURE 3 
Hot plate response times (seconds ± S.E.M.) of rats 
subsequent to the administration of vehicles (closed 
circles) or DFP (0.1 mg/kg, closed squares; 0.5 mg/kg, 
closed triangles; 1.0 mg/kg, op~n circles; and 1.5 mg/kg, 
open squares). Each point represents the mean± S.E.M. 
of eight animals. Hot plate response times were comp-
ared to preinjection (P on abscissa) response values 
(paired Student's t Test). Statistical analysis for 
significance is as stated in the text (see section 4.1.1). 
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istered the vehicle or DFP (0.1 mg/kg) exhibited attenuated hot plate 
responses 6 and 8 hours postinjection (Fig. 3). 
4.1.2 Tail Flick Test 
The effect of DFP (0.1, 0.5, 1.0, and 1.5 mg/kg) on the tail 
flick response times of rats was measured 1 hour after the DFP admin-
istration. DFP in doses of 1.5 and 1.0 mg/kg produced antinocicep-
tion; at doses of 0.1 and 0.5 mg/kg, DFP was ineffective; animals ad-
ministered the vehicle did not exhibit antinociception (Table 2) . 
4.1.3 Effect of Atropine Sulfate and Atropine Methyl Nitrate 
To determine whether DFP-induced antinociception arises from 
stimulation of central cholinergic receptors (see section 1.2.2), 
the effect of atropine sulfate and atropine methyl nitrate on DFP-
i~duced antinociception was studied utilizing the hot plate test. Ad-
ministered 30 minutes after the administration of DFP (1.5 mg/kg), 
atropine sulfate (4.0 mg/kg) antagonized whereas atropine methyl ni-
trate (4.0 mg/kg) did not affect the antinociceptive state produced by 
DFP (Table 3). Atropine sulfate (4.0 mg/kg) or the vehicles did not 
affect the hot plate response when administered alone (Table 3) . 
Altogether, it is obvious that, similarly to other drugs which 
affect the central cholinergic system, DFP and pilocarpine produce 
antinociception. 
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TABLE 2 
Tail flick response times (seconds ± S.E.M.) of rats 
subsequent to the single s.c. administration of the 
vehicle or DFP in doses of 0.1, 0.5, 1.0 and 1.5 mgjkg. 
n = number of animals employed in each group. Post-
injection responses were compared to preinjection 
responses for each animal (paired Student's t Test). 
*p<.O .05. 
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TABLE 2 
EFFECT OF DFP ON TAIL FLICK RESPONSE TIMES OF RATS 
Tail Flick 
ResEonse Times (sec) ± S.E.M. 
Group (n) Preinjection Postinjection 
Control (non-injected) 8 17.9 ± 2.0 16.9 ± 1.5 
Peanut oil 9 18.1 ± 1.9 18.1 ± 1.7 
DFP (0 .1 mg/kg) 8 17.7 ± 1.6 18.9 ± 2.4 
DFP (0.5 mg/kg) 6 18.1 ± 2.1 18.3 ± 2.7 
DFP (1.0 mg/kg) 6 18.0 ± 1.8 22.8 ± 2.6* 
DFP (1.5 mg/kg) 8 17.2 ± 1.9 23.6 ± 1.8* 
*p <0.05 
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TABLE 3 
Hot plate response times (seconds ± S.E.M.) of rats 
subsequent to the administrations of vehicles, DFP 
(1.5 mg/kg)-saline, DFP (1.5 mg/kg)-atropine sulfate 
(4.0 mg/kg), DFP (1.5 mg/kg)-atropine methyl nitrate 
(4.0 mg/kg), and peanut oil-atropine sulfate (4.0 mg/kg). 
n = number of animals employed in each group. Post-
injection responses were compared to preinjection 
responses for each animal (paired Student's t Test). 
**p < 0.01 and ***p<O.OOl. 
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TABLE 3 
EFFECT OF DFP ON HOT PLATE RESPONSE TIMES OF RATS 
Hot Plate 
Res;eonse Times (Sec) ± S.E.M. 
Group (n) Pre injection Postinjection 
Control (non-injected) 12 8.2 ± 0.3 7.8 ± 0.7 
Peanut oil-saline 10 8.7 ± 0.5 9.1 ± 0.8 
DFP (1.5 mg/kg)-saline 10 8.2 ± 0.3 16.9 ± 0.8*** 
DFP (1.5 mg/k~-atropine 8 8.4 ± 0.4 9.0 ± 0.5 
sulfate (4 .0 mg/kg) 
DFP (1. 5 mg/kg)-atropine 8 8.6 ± 0.4 14.9 ± 0.5** 
methyl nitrate (4 .0 mg/kg) 
Peanut oil-atropine 6 7.9 ± 0.4 9.5 ± 0.4 
sulfate (4 .0 mg/kg) 
**p<O.Ol and ***p<O.OOl 
4.2 OFF-induced Immobilization in Rats 
An established effect of DFP is reduction of the animal's motor 
activity (Karczmar, 1977). Since the effects of DFP on rat motor 
activity and environmental response may interfere with the hot plate 
assessment of antinociception, motor and exploratory activity levels 
were studied. 
4.2.1 Exploratory Activity 
The animal's exploratory activity, that is, its response to a 
novel environment may be a particularly pertinent correlate of anti-
nociception as measured by the hot plate test. 
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The effect of DFP administered in doses of 0.1, 0.5 and 1.5 mg/kg 
on exploratory activity was studied one hour after the administration 
of DFP. DFP (1.5 mg/kg) decreased by 45% exploratory activity; in 
doses of 0.1 and 0.5 mg/kg, DFP was ineffective; administration of the 
vehicle did not affect exploration (Table 4) . 
To further investigate the effect of DFP on exploration, explor-
atory activity levels were measured 1 to 48 hours after the adminis-
tration of DFP (0.1, 0.5, 1.0, and 1.5 mg/kg) at the same time inter-
vals at which hot plate responses were measured (see section 4.1.1). 
DFP (1.5 mg/kg) reduced exploratory activity in rats 1, 2, and 48 
hours after the DFP administration. DFP in doses of 0.1, 0.5, and 1.0 
mg/kg reduced exploratory activity 2 hours after the DFP injection; 
the diminution in exploration at 2 hours followed a dose dependent 
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TABLE 4 
Exploratory and motor activity levels (activity cage 
counts± S.E.M.) of rats subsequent to the administration 
of vehicle or DFP in doses of 0.1, 0.5 and 1.5 mg/kg. 
n = number of animals employed in each group. Exploratory 
and motor activity levels were compared to levels obtained 
from animals administered the vehicle (analysis of variance, 
Newman-Keuls test). *p<0.05 and **p<O.Ol. 
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TABLE 4 
EFFECT OF DFP ON EXPLORATORY AND MOTOR ACTIVITY LEVELS 
OF RATS 
Activit;[ Cage Counts± S.E.M. 
Group (n) Explorato;y Motor Activit;[ 
Control (non-injected) 12 462 ± 27 511 ± 19 
Peanut oil 9 448 ± 12 512 ± 12 
DFP (0 .1 rng/kg) 7 410 ± 33 404 ± 29** 
DFP (0 .5 rng/kg) 8 336 ± 28 239 ± 24** 
DFP (1.5 rng/kg) 7 252 ± 19** 164 ± 13** 
*p<0.05 and **p<O.Ol 
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relationship for all doses of DFP tested (Fig. 4). Exploratory activ-
ity levels were compared to levels obtained from animals administered 
the vehicle (analysis of variance, Newman-Keuls test; Fig. 4). 
4.2.2 Motor Activity 
The effect of DFP administered in doses of 0.1, 0.5 and 1.5 mg/kg 
reduced motor activity levels (Table 4). The diminution in motor ac~ 
tivity produced by DFP(O.l to 1.5 mg/kg) followed a dose dependent re-
lationship. Administration of the vehicle did not affect motor activ-
ity (Table 4) . 
4.3 Effect of DFP on Rectal Temperature of Rats 
Mild hypothermia (a 2 to 3°C decrease in rectal temperature below 
normal) produced hypernociception in the cat (Liu and Fang, 1972). 
Since the systemic adrninist=ation of DFP produces hypothermia in the 
rat (Meeter and Wolthius, 1968), this effect of DFP may interfere with 
the correct evaluation of antinociception as measured by temperature 
sensitive tests such as the hot plate and tail flick tests. The ef-
fect of DFP on rectal temperatures of rats was measured l to 48 hours 
after the administration of DFP at the same time intervals at which 
hot plate responses were measured (see section 4.1.1). DFP (1.0 mg/ 
kg) produced hypothermia (a 2.4oc decrease in rectal temperature) 2 
hours postinjection at 4 hrs the effect was not significant any more. 
The vehicle was ineffective (Fig. 5). 
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FIGURE 4 
Exploratory activity levels of rats expressed as the 
percent of preinjection activity cage counts ± S.E.M. 
subsequent to the administration of vehicle (closed 
circles) and DFP (0.1 mg/kg, closed squares; 0.5 mg/kg, 
closed triangles; 1.0 mg/kg, open squares; and 1.5 mg/kg, 
open circles). Each point represents the mean of five 
animals. Exploratory activity levels were compared to 
levels obtained from animals administered the vehicle 
(analysis of variance, Newman-Keuls test). Statistical 
analysis for significance is as stated in the text (see 
section 4.2.2). 
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FIGURE 5 
Rectal temperature measurements (Oc) of rats subsequent 
to the administration of vehicle (closed circles) and 
DFP (1.0 mg/kg; open circles). Each point represents 
the mean± S.E.M. of eight animals. Rectal temperature 
measurements were compared to preinjection (P on abscissa) 
values for each animal (paired Student's t Test) . 
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4.4 Brain Region Serotonin (5-HT) Levels of Rats 
4.4.1 Effect of DFP 
Increased levels and turnover of acetylcholine (ACh; see section 
1.2.3) and/or serotonin (5-HT; see section 1.3.2) in the central 
nervous system (CNS) have been associated with antinociception and 
analgesia. Since DFP markedly increased brain 5-HT levels when admin-
istered to rabbits (Barnes et al., 1975), it was important to ascer-
tain whether-DFP exerted a similar effect in the rat. 
The effect of DFP on 5-HT levels in three rat brain regions was 
investigated one hour after the administration of DFP. As shown in 
Table 5, DFP (1.·5 mg/kg) increased 5-HT levels in the medulla, meso-
diencephalon, and telencephalon when compared to 5-HT levels of 
animals administered t~e vehicle, peanut oil (analysis of variance, 
Newman-Keuls test; Table 5). These increases amounted to 217, 132, 
and 131 per cent in the medullary, meso-diencephalic, and telenceph-
alic brain regions respectively, with respect to animals administered 
the vehicle (Table 5). 5-HT levels of animals administered peanut 
oil, saline, or saline and peanut oil did not differ from values ob-
tained in control, non-injected animals in any case (analysis of var-
iance, Newman-Keuls test; Table 5). 
4.4.2 Effect of PCPA 
To ascertain the significance of the rise in 5-HT with respect to 
the antinociception produced by DFP, PCPA, a tryptophan hydroxylase 
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TABLE 5 
Serotonin (5-HT)levels expressed as ng 5-HT/gm tissue 
± S.D. in three rat brain regions (medulla, meso-
diencephalon and telencephalon) subsequent to the 
administration of DFP (1.5 mg/kg), PCPA1 , or PCPA2 (see 
section 3.2.2), PCPA1-DFP (1.5 mg/kg), PCPA2-DFP 
(1.5 mg/kg) as well as vehicles. n =number of brain 
regions measured. In all cases, 5-HT levels in animals 
administered the various drug/s were compared to 5-HT 
levels obtained in animals administered the appropriate 
vehicle/s (analysis of variance, Newman-Keuls test). 
**p<O .01. 
TABLE 5 
EFFECT OF DFP, PCPA, AND PC?A-DFP ON RAT BRAIN REGION SEROTONIN (5-HT) LEVELS 
BRAIN REGION 5-HT LEVELS (ng 5-HT/gm TISSUE) ± S.D. 
Group (n) t-tedulla (n) Meso~iencephalon (n) 
Control (non-injected) 12 270 ± 21 ll 548 ± 26 ll 
DFP (1.5 mg/kg) 7 589 ± 26** 7 724 ± 43** 8 
Peanut oil 6 272 ± ll 8 518 ± 24 8 
PCPAl 6 202 ± 20** 5 196 ± 17** 6 
PCPA2 8 143 ± ll** 8 159 ± 25** 8 
Saline 6 259 ± 23 8 517 ± 44 8 
PCPA1-DFP (1.5 mg/kg) 6 213 ± 19** 7 234 ± 26** 9 
PCPA 2-DFP (l. 5 mg/kg) 6 173 ± 10** 6 187 ± 16** 6 
Saline-peanut oil 7 279 ± 19 8 526 ± 30 8 
**p<O.Ol 
Telencephalon 
339 ± 26 
444 ± 30** 
350 ± 21 
237 ± 13** 
196 ± 13** 
379 ± 19 
282 ± 29 
227 ± 18** 
348 ± 33 
..... 
..... 
00 
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inhibitor, was employed and its action on the DFP mediated changes in 
5-HT levels, antinociception, and exploration and locomotion were 
evaluated. 
First~ the effect of PCPA on brain region 5-HT levels was stud-
ied; two dose regimens, PCPA1 and PCPA2 , were employed (see section 
3.2.2); in either case, PCPA reduced 5-HT levels in all three brain 
regions; particularly PCPA2 reduced 5-HT levels by 52, 70, and 48 per 
cent in the medullary, meso-diencephalic, and telencephalic brain 
regions, respectively, when compared to saline injected animals 
(analysis of variance, Newrnan-Keuls test; Table 5). 
4.4.3 Effect of PCPA-DFP 
The effect of PCPA pretreatment regimens, PCPA1 and PCPA2 , on the 
DFP-induced increase in 5-HT levels was studied. Administered to 
1 2 PCPA and PCPA pretreated animals, DFP (1.5 mg/kg) did not affect the 
dimunition in 5-HT levels produced by either PCPA1 or PCPA2 in any 
brain region studied (analysis of variance, Newrnan-Keuls test; Table 
5). Brain 5-HT levels in PCPA1-DFP (1.5 mg/kg) and PCPA2-DFP (1.5 
mg/kg) treated animals were still significantly reduced when compared 
to animals administered saline and peanut oil except for the effect of 
PCPA1-DFP (1.5 mg/kg) on the telencephalic 5-HT levels (analysis of 
variance, Newrnan-Keuls test; Table 5). 
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4.5 Effect of PCPA on OFF-induced Antinociception in Rats 
4.5.1 Hot Plate Test 
Since pretreatment with PCPA antagonized the OFF-induced in-
crease in brain region 5-HT levels in rats, it was important to deter-
mine whether PCPA pretreatments would affect the antinociceptive state 
produced by OFP; the hot plate and tail flick tests were employed for 
this purpose. 
mens 
Table 6 demonstrates the effect of two PCPA pretreatment regi-
(PCPA1 and PCPA2 ; see section 3.2.2) on the OFF-induced anti-
nociceptive state of rats as measured by the hot plate test. Employed 
1 2 
alone, PCPA and PCPA , produced hypernociception (Table 6). However, 
PCPA pretreatments did not antagonize the antinociceptive state prod-
uced by OFP (1.5 mg/kg; Table 6). Administration of the vehicles was 
ineffective (Table 6) . 
4.5.2 Tail Flick Test 
PCPA2 (see section 3.2.2) produced a bypernociceptive state when 
administered alone to rats as measured by the tail flick test (Table 
7). However, PCPA2 pretreatment did not affect the antinociceptive 
state produced by OFP (1.5 mg/kg; Table 7). Vehicles were ineffective 
in the tail flick test (Table 7) . 
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TABLE 6 
Hot plate response times (seconds ± S.E.M.) of rats 
subsequent to the administration of vehicles, DFP 
l 2 (1.5 mg/kg), PCPA or PCPA (see section 3.2.2), as 
well as the combination PCPA~or PCPA2-DFP (1.5 mg/kg). 
n = number of animals employed in each group. Post-
injection responses were compared to preinjection 
responses for each animal (paired Student's t Test). 
*p<0.05, **p<O.Ol, and ***p<O.OOl. 
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TABLE 6 
EFFECT OF PCPA ON DFP-INDUCED ANTINOCICEPTION: 
HOT PLATE TEST 
Hot Plate 
Res:eonse Times (Sec) ± S.E.M. 
Grou:e (n) Preinjection Postinjection 
Control (non-injected) 10 8.1 ± 0.4 8.3 ± 0.4 
Saline-peanut oil 10 6.9 ± 0.6 7.3 ± 0.4 
DFP (1.5 mg/kg) 7 8.6 ± 0.9 15.3 ± 1.0** 
PCPAl 12 7.1 ± 0.4 5.3 ± 0.4* 
PCPA2 8 9.2 ± 1.1 5.4 ± 0.4** 
PCPA1-DFP (1.5 mg/kg) 7 7.2 ± 0.7 21.2 ± 1.3*** 
PCPA2-DFP (1. 5 mg/kg) 7 7.5 ± 0.5 21.4 ± 2.1*** 
*p<0.05, **p<0.01 and ***p<O.OOl 
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TABLE 7 
Tail flick response times (seconds ± S.E.M.) of rats 
subsequent to the administration of vehicles, DFP 
(1.5 mg/kg), PCPA2 (see section 3.2.2), and PCPA2-
DFP (1.5 mg/kg). n = number of animals employed 
in each group. Postinjection responses were compared 
to preinjection responses for each animal (paired 
Student's t Test). ***p<O.OOl. 
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TABLE 7 
EFFECT OF PCPA ON DFP-INDUCED ANTINOCICEPTION: 
. TAIL FLICK TEST 
Tail Flick 
Res12onse Times (Sec) ± S.E.M. 
Group (n) Preinjection Postinjection 
Control (non-injected) 8 17.5 ± 0.5 18.1 ± 0.6 
Saline-peanut oil 9 17.3 ± 0.5 16.9 ± 0.5 
DFP (1. 5 mg/kg) 8 17.2 ± 0.5 23.6 ± 0.6*** 
PCPA2 9 17.0 ± 0.5 10.7 ± 0.5*** 
PCPA2-DFP (1. 5 mg/kg) 8 17.6 ± 0.7 25.8 ± 0.5*** 
***p<O.OOl 
125 
4.6 Effect of PCPA on DFP-induced Immobilization in Rats 
4.6.1 Exploratory Activity 
The effects of PCPA and PCPA-DFP combinations on exploratory 
and motor activity were evaluated to test whether or not the lack of 
effect of PCPA on DFP-induced antinociception was related to a PCPA 
action on the mobility of the rats. As shown previously (see section 
4.2.1), DFP (1.5 mg/kg) decreased exploratory activity (Table 8). 
Administered alone, PCPA2 , did not affect exploratory activity (Table 
8). In addition, pretreatment with PCPA2 did not affect the diminu-
tion in exploration produced by DFP(l.5 mg/kg; Table 8). Administra-
tion of the vehicles was ineffective (Table 8). 
4.6.2 Motor Activity 
As demonstrated earlier (see section 4.2.2), DFP (1.5 mg/kg) de-
creased motor activity; the diminution amounted to 61% when compared 
to animals administered the vehicle (Table 8). PCPA, administered by 
itself, si9nificantly increased motor activity; yet, pretreatment with 
PCPA2 did not affect the diminution in locomotion produced by DFP 
(1.5 mg/kg; Table 8). The vehicles did not affect motor activity 
(Table 8) . 
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'!'ABLE 8 
Exploratory and motor activity levels (activity 
cage counts ± S.E.M.) of rats subsequent to the 
administration of vehicles, DFP (1.5 mg/kg), PCPA2 
(see section 3.2.2), and PCPA2-DFP (1.5 mg/kg). 
n = number of animals employed in each group. 
Exploratory and motor activity levels were compared 
to levels obtained from animals administered the 
vehicles (analysis of variance, Newman-Keuls test). 
**p<O .01. 
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TABLE 8 
EFFECT OF PCPA ON THE ATTENUATED EXPLORATORY AND 
MOTOR ACTIVITY LEVELS OF RATS PRODUCED BY DFP 
Activity Cage Counts ± S.E.M. 
Group (n) Exploratory Motor 
---
Control (non-injected) 8 473 ± 18 521 ± 28 
Saline-peanut oil 9 493 ± 24 543 ± 30 
DFP (1.5 mg/kg) 8 257 ± 13** 211 ± 12** 
PCPA2 9 372 ± 40 820 ± 21** 
PCPA2-DFP (1.5 mg/kg) 8 177 ± 17** 183 ± 10** 
**p<O.Ol 
4.7 Pharmacological Comparison of DFP- and Morphine-induced 
Behavioral Effects in Rats 
4.7.1 Antinociception 
In an attempt to ascertain whether DFP-induced antinociception 
is related to a narcotic sensitive and/or endogenous opioid system, 
the following experiments were performed. 
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The antinociceptive actions of DFP and morphine were evaluated 
pharmacologically; the hot plate test was employed for this analysis 
(Table 9). DFP (1.5 mg/kg) and morphine (3.0 mg/kg)produced equiva-
lent levels of antinociception(Table 9). Atropine sulfate (4.0 mg/kg) 
antagonized the antinociceptive action of DFP but did not affect mor-
phine-induced antinociception (Table 9). However, naloxone (5.0 mg/ 
kg) antagonized both morphine- and DFP-induced antinociceptive states 
(Table 9). Atropine sulfate (4.0 mg/kg) and naloxone (5.0 mg/kg) 
were ineffective when administered alone. The vehicles were ineffec-
tive (Table 9) . 
4.7.2 Exploratory Activity 
The effect of DFP and morphine on exploration and locomotion was 
investigated pharmacologically to determine whether the antinocicep-
tive state produced by these two compounds could be attributed to a 
drug effect on animal mobilization. 
DFP (1.5 mg/kg) and morphine (3.0 mg/kg) reduced exploratory 
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TABLE 9 
Hot plate response times (seconds ± S.E.M.) of rats 
subsequent to the administrations of vehicles, DFP 
(1.5 mgjkg) and morphine (3.0 mgjkg) as well as DFP 
(1.5 mgjkg) or morphine (3.0 mg/kg) in combination 
with either atropine sulfate (4.0 mg/kg) or naloxone 
(5.0 mgjkg). n =the number of animals employed in 
each group. Postinjection responses were compared 
to preinjection responses for each animal (paired 
Student's t Test). *p<0.05 and ***p<O.OOl. 
TABLE 9 
PHARMACOLOGICAL COMPARISON OF DFP- AND MORPHINE-INDUCED ANTINOCICEPTIVE STATES: HOT PLATE TEST 
Hot Plate 
Res;eonse Times (Sec) ± S.E.M. 
Group (n) Preinjection Postinjection 
Control (non-injected) 12 8.2 ± 0.3 8.3 ± 0.4 
Peanut oil-saline 10 8.6 ± 0.4 8.8 ± 0.4 
DFP (1.5 mg/kg) 10 8.2 ± 0.3 16.9 ± 0.8*** 
DFP (1.5 mg/kg)-atropine sulfate (4.0 mg/kg) 8 8.4 ± 0.4 8.9 ± 0.5 
DFP (1.5 mg/kg)-naloxone (5.0 mg/kg) 8 7.8 ± 0.4 8.5 ± 0.5 
Morphine (3.0 mg/kg) 10 9.1 ± 0.3 17.3 ± 0.5*** 
Morphine (3.0 mg/kg)-atropine sulfate (4. 0 mg/kg) 9 8.6 ± 0.5 •19.4 ± o. 7*** 
Morphine (3.0 mg/kg)-naloxone (5 .0 mg/kg) 8 8.9 ± 0.6 7.0 ± 0.4* 
*p<0.05 and ***p<O.OOl 
~ 
w 
0 
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activity levels (Table 10). The reduction in exploration by morphine 
or DFP was not affected by atropine sulfate (4.0 mg/kg) or naloxone 
(5.0 mg/kg), nor was the affect of DFP (1.5 mg/kg) affected by atro-
pine methyl nitrate(4.0 mg/kg; Table 10). Administered alone, atro-
pine sulfate(4.0 mg/kg) decreased exploratory activity; the vehicles 
were ineffective (Table 10) . Exploratory activity levels were comp-
ared to levels obtained from animals administered the vehicles (anal-
ysis of variance, Newman-Keuls test; Table 10). 
4.7.3 Motor Activity 
Employed at equi-antinociceptive doses, DFP (1.5 mg/kg) decreas-
ed, whereas morphine (3.0 mg/kg) increased motor activity (Table 10). 
Atropine sulfate (4.0 mg/kg) ,atropine methyl nitrate (4.0 mg/kg) ,and 
naloxone (5.0 mg/kg) did not affect the attenuated motor activity 
produced by DFP (1.5 mgjkg; Table 10). However, atropine sulfate 
(4.0 mg/kg) did antagonize the increase in motor activity produced by 
morphine (3.0 mg/kg); naloxone (5.0 mg/kg) not only antagonized but 
reversed the motor response induced by morphine (3.0 mg/kg; analysis 
of variance, Newman-Keuls test; Table 10). Administered alone, atro-
pine sulfate (4.0 mg/kg) reduced motor activity; the vehicles were in-
effective (Table 10) . Motor activity levels were compared to levels 
-obtained from animals which received the vehicles (analysis of var-
iance, Newman-Keuls test; Table 10). 
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TABLE 10 
Exploratory and motor activity levels (activity cage 
counts± S.E.M.) of rats subsequent to the administration 
of vehicles, atropine sulfate (4.0 mg/kg), DFP (1.5 mg/kg), 
and morphine (3.0 mg/kg) as well as DFP (1.5 mg/kg), 
or morphine (3.0 mg/kg) in combination with either 
atropine sulfate (4.0 mg/kg) or naloxone (5.0 mg/kg). 
n = number of animals employed in each group. Explor-
atory and motor activity levels were compared to levels 
obtained from animals administered the vehicle (analysis 
of variance, Newman-Keuls test). **p<O.Ol. 
TABLE 10 
PHARMACOLOGICAL COMPARISON OF THE EFFECTS OF DFP AND MORPHINE ON EXPLORATORY AND MOTOR ACTIVITY 
LEVELS OF RATS 
Activity Cage Counts ± S.E.M. 
Group (n) Exp1orat()!"Y Motor Act:.i_vity 
Control (non-injected) 12 483 ± 17 524 ± 12 
Peanut oil-saline 10 501 ± 21 511 ± 15 
DFP (1.5 mgjkg) 10 248 ± 18** 236 ± 10** 
DFP (1.5 mg/kg)-atropine sulfate (4.0 mg/kg) 8 311 ± 13** 249 ± 15** 
DFP (1.5 mg/kg)-atropine methyl nitrate (4. 0 mg/kg) 8 232 ± 19** 248 ± 18** 
DFP (1.5 mg/kg)-naloxone (5 .0 mgjkg) 8 198 ± 10** 196 ± 11** 
Morphine (3.0 mg/kg) 10 324 ± 10** 791 ± 21** 
Horphine (3.0 mg/kg)-atropine sulfate (4.0 mg/kg) 9 297 ± 15** 557 ± 32 
Morphine (3.0 mg/kg)-naloxone (5.0 mg/kg) 8 293 ± 12** 158 ± 23** 
Atropine sulfate (4 .0 mg/kg) 6 325 ± 27** 390 ± 19** 
**p<O.Ol I-' w 
w 
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4.8 Effect of Naloxone on DFP-induced Responses in Rats 
4.8.1 Antinociception 
It was particularly noteworthy that naloxone, a pure narcotic 
antagonist, antagonized DFP-induced antinociception (see section 
4.7.1). To further study this effect, the effect of naloxone (0.05, 
0.5, and 5.0 mg/kg) on DFP-induced antinociception in rats was stud-
ied 1 to 48 hours after the single administration of DFP (1.0 mg/kg) 
utilizing the hot plate test. At the dose of 0.05 mg/kg, naloxone 
did not affect DFP-induced antinociception; it was effective 1 hour 
after the administration of DFP in antagonizing the DFP-induced anti-
nociceptive state at doses of 0.5 and 5.0 mg/kg (Fig. 6). In fact, 
administered in a dose of 5.0 mg/kg, naloxone produced hyper-
nocicpetion 1 hour after the DFP administration (Fig. 6). Vehi-
cles were ineffective (Fig. 6). 
4.8.2 Exploratory Activity 
As demonstrated earlier (see section 4.7.2), DFP (1.5 mg/kg) de-
creased exploration 1, 2, and 48 hours after the administration of 
DFP (Fig. 4). Naloxone in doses of 0.05, 0.5,and 5.0 mg/kg did not 
affect the attenuated exploratory activity produced by DFP (1.5 mg/kg). 
Figure 7A demonstrates exploratory activity levels 1, 2, and 4 hours 
after the DFP injection for animals administered the vehicles, DFP 
(1.5 mg/kg), and the combination DFP (1.5 mg/kg) with naloxone (5.0 
mg/kg). 
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FIGURE 6 
Hot plate response times (seconds ± S.E.M.) of rats 
subsequent to the administrations of vehicles (closed 
circles) ;DFP (1.0 mg/kg) with naloxone (0.05 mg/kg-
closed triangles; 0.5 mg/kg-open circles; 5.0 mg/kg-
closed squares); and DFP (1.0 mg/kg with saline-closed 
hexagons). Each point represents the mean ± S.E.M. 
of eight animals. Hot plate responses were compared 
to preinjection (P on abscissa) responses for each 
animal (paired Student's t Test) .. p<0.05, •. p<O.Ol, 
and .•• p<O.OOl. 
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FIGURE 7A 
Exploratory activity levels of rats expressed as percent 
prein,jection a_cti vi ty cage counts ± S .E .M. subsequent to 
the administration of vehicles (circles), DFP (1.5 mg/kg) 
with saline (squares), and DFP (1.5 mg/kg)-naloxone 
(5.0 mg/kg) combination (triangles). Each point represents 
the mean± S.E.M. of five animals. Exploratory activity 
levels were compared to activity levels obtained from 
animals administered the vehicles (analysis of variance, 
Newman-Keuls test) .•• p<O.Ol. 
7B 
Rectal temperature measurements (°C) of rats subsequent to 
the administration of vehicles (circles), DFP (1.0 mg(kg) 
with saline (squares), and DFP (1.0 mg(kg)-naloxone (5.0 
mg/kg) combination (triangles) . Each point represents 
the mean± S.E.M. of eight animals. Rectal temperature 
measurements were compared to preinjection (P on abscissa) 
measurements for each animal (paired Student's t Test) . 
. . p<O .01. 
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4.8.3 Hypothermia 
As demonstrated earlier (see section 4.3), DFP (1.0 mg/kg) 
produced hypothermia 2 hours after its administration (Fig. 7B). 
Naloxone (5.0 mg/kg) did not affect the hypothermic state produced 
by DFP (1.0 mg/kg) 2 hours after DFP (Fig. 7B). Administered alone, 
naloxone (5.0 mg/kg) did not affect rectal temperatures; the vehi-
cles were ineffective (Fig. 7B). 
Thus, naloxone reduced the antinociceptive state produced by DFP 
(see section 4.8.1) but did not affect the attenuated exploration 
(see section 4.8.2) or hypothermia (see section 4.8.3) produced by 
DFP. 
4.9 Effect of Stereoisomers of Narcotic Antagonists on 
DFP-induced Antinociception in Rats 
Since non-specific actions of naloxone could contribute to its 
inhibition of DFP-induced antinociception, it was important to deter-
mine if the antagonism was stereospecific. 
MR 2266, MR 2267, GPA 1843, GPA 1847, d-cyclazocine, and 1-cyclaz-
ocine were administered individually 30 minutes after the adminis-
tration of DFP (1.0 mg/kg) or morphine (3.0 mg/kg). MR 2266 (1.0 mg/ 
kg) and GPA 1843 (5.0 mg/kg), the (-) isomers and active narcotic ant-
agonists, reduced both morphine and DFP-induced antinociceptive states 
(Table 11). MR 2267 (1.0 mg/kg) and GPA 1847 (5.0 mg/kg), the corre-
spending (+) isomers, did not affect the antinociceptive s~ates pro~uced 
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~ABLE 11 
Hot plate response times (seconds± S.E.M.) of rats 
subsequent to the administrations of DFP (1.0 mg/kg) 
or morphine (3.0 mg/kg) followed 30 minutes later by 
either the vehicle, MR 2266 {1.0 mg/kg), MR 2267 
(1.0 mg/kg), GPA 1843 (5.0 mg/kg), GPA 1847 (5.0 mg/kg), 
d-cyclazocine (0.64 mg/kg), or 1-cyclazocine (0,64 mg/kg). 
n = number of animals employed in each group. Post-
injection responses were compared to preinjection 
responses for each animal (paired Student's t Test). 
*p<0.05 and **p<O.Ol. 
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TABLE 11 
EFFECT OF STEREOISOMERS OF NARCOTIC ANTAGONISTS ON 
MORPHINE AND DFP-INDUCED ANTINOCICEPTIVE STATES: HOT PLATE TEST 
Hot Plate 
Res12onse Times (Sec) ± S.E.M. 
Group (n) Preinjection Postinjection 
Morphine-saline 17 9.3 ± 1.2 18.6 ± 2.4** 
Morphine-MR 2266 (-) 12 9.1 ± 0.9 9.8 ± 1.6 
Morphine-MR 2267 (+) 12 9.0 ± 0.9 18.3 ± 2.9** 
Morphine-GPA 1843 (-) 12 9.7 ± 0.7 12.2 ± 1.1 
Morphine-GPA 1847 ( +) 12 9.4 ± 0.8 16.5 ± 2.2** 
Morphine-l,cyclazocine (-) 5 11.4 ± 1.0 13.6 ± 0.7 
Morphine-d,cyclazocine (+) 5 11.1 ± 3.2 18.2 ± 3.2* 
uFP-saline 13 8.8 ± 1.2 18.3 ± 2.7** 
DFP-MR 2266 (-) 8 6.7 ± 0.7 7.4 ± 1.2 
DFP-MR 2267 ( +) 8 8.7 ± 1.4 12.2 ± 2.8* 
DFP-GPA 1843 (-) 8 10.8 ± 1.9 12.2 ± 1.5 
DFP-GPA 1847 (+) 8 8.8 ± 1.9 15.4 ± 3.1* 
DFP-l,cyclazocine (-) 5 9.7 ± 0.7 16.7 ± 1. 7* 
DFP-d,cyclazocine (+) 5 11.2 ± 1.3 10.6 ± 1.4 
duced by either morphine or DFP (Table 11). The vehicle was inef-
fective (Table 11). 
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On the other hand, the relationship between the antagonist action 
against DFP- and morphine-induced antinociception and the stereoiso-
mers of cyclazocine, a partial narcotic agonist, was reversed; d-
cylcazocine (0.64 mg/kg) antagonized the antinociceptive action of 
DFP but did not affect morphine-induced antinociception; l-cyclazo-
cine(0.64 mg/kg) reduced morphine-induced antinociception but was in-
effective against DFP-induced antinociception (Table 11) . 
4.10 Effect of Tolerance to Morphine on DFP- and 
Pilocarpine-induced Antinociception in Rats 
Cross tolerance studies were performed to discern a possible 
common neural mechanism mediating antinociception produced by mor-
phine, pilocarpine, and DFP. As demonstrated earlier (see sections 
4.1.1 and 4.7.1) DFP (1.0 mg/kg), pilocarpine (2.5 mg/kg), and mor-
phine (3.0 mg/kg) produced antinociception as measured by the hot 
plate test in rats (Pretolerance; Table 12). Morphine-induced anti-
nociception was completely attenuated in animals rendered tolerant to 
morphine as measured on day 6 (tolerance level A; Table 12). However, 
DFP-and pilocarpine-induced antinociception was maintained in animals 
rendered tolerant to morphine on day 6 (tolerance level A) ; in addi-
tion, DFP-induced antinociception was maintained on day 9 (tolerance 
level B; Table 12). Thus, the antinociceptive actions of DFP and 
pilocarpine did not exhibit cross tolerance to the antinociceptive 
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TABLE 12 
Hot plate response times (seconds± S.E.M.) of rats 
subsequent to administrations of DFP (1.0 mg(kg)) pilo-
carpine ( 2 . 5 mg/kg ), or morphine ( 3. 0 mg(kg) . Hot 
plate measurements were made both prior to the develop-
ment of tolerance (Pretolerance) as well as after the 
development of tolerance to morphine at different 
levels (TOlerance levels A and B; see section 3.2.3). 
n = number of animals employed in each group. All 
responses were compared to Preinjection, baseline, 
responses for each animal (paired Student's t Test). 
*p<O.OS and **p<O.Ol. 
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TABLE 12 
EFFECT OF TOLERANCE TO MORPHINE ON DFP- AND PILOCARPINE-INDUCED 
ANTINOCICEPTION: HOT PLATE TEST 
Hot Plate 
Res12onse Times (sec) ± S.E.M. 
Administration Morphine DFP Pilocarpine 
(n-8) (n=8) (n=8) 
Preinjection 11.0 ± 0.6 11.0 ± 1.1 7.0 ± 0.7 
Pretolerance 22.7 ± 1.1** 21.2 ± 1.4** 12.3 ± 2.2* 
Tolerance Level A 11.4 ± 1.0 17.6 ± 1. 7* 13.3 ± 2.6* 
Tolerance Level B 17.3 ± 2.0* 
M5 
actions of morphine. Tolerant animals exhibited no altered responses 
when administered the vehicle alone. Non-tolerant animals demonstrated 
antinociceptive responses to morphine (3.0 mg/kg) and DFP (1.0 mg/kg) 
on days 1,6, and 9; responses to pilocarpine (2.5 mg/kg) were not 
measured on these days. 
4.11 Effect of DFP on Rat Brain Enkephalin-like Material Levels 
The stereospecificity of the narcotic antagonist action on the 
antinociceptive state produced by DFP (see section 4.9) suggests that 
DFP-induced antinociception is mediated via opiate receptors, possibly 
by the release of endogenous opioids. Therefore, the effects of DFP 
on whole brain enkephalin-like-material levels in the rat were stud-
ied l hour after the administration of DFP. 
Sixty-eight rat brains were assayed for enkephalin-like-material 
content utilizing the mouse vas deferens bioassay technique as describ-
ed in section 3.6. Unfortunately, only 7 rat brain samples were found 
to be acceptable according to the criteria of the bioassay procedure 
(see section 3.6.5.3). Enkephalin-like-material content of whole rat 
brains, expressed as ng leucine-enkephalin equivalents/gm brain tissue, 
was determined to be 229 ng leucine-enkephalin equivalents/gm brain 
tissue in animals which received DFP (1.0 mg/kg; n=2), and 252 ng 
leucine-enkephalin equivalents/gm brain tissue in animals which re-
ceived peanut oil (n=5). These levels were not significantly differ-
ent (analysis of variance, Newman-Keuls test). 
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The following reasons explain why, for the most part, the re-
maining brain samples (n=61) failed to meet acceptable bioassay cri-
teria and therefore could not be included in the results:(i) per cent 
recovery of the internal standards (see section 3.6.4) often was less 
than 90% and occasionally even as low as 20% in some experiments, (ii) 
the rat brain sample increased t~1e resting tone of the longitudinal 
muscle of the mouse vas deferens making it impossible to accurately 
measure the depression of the electrically-evoked twitch height (Fig. 
SA), (iii) the rat brain sample inconsistently depressed the electric-
ally-evoked twitch height of the longitudinal muscle of the mouse vas 
deferens, that is, the depressed twitch height returned to normal 
prior to washout time; this suggests that substances other than en.-
kephalin-like-material were responsible for the twitch height depres-
sion (Fig.SB), and (iv) the depression of the electrically-evoked 
twitch height of the longitudinal muscle of the mouse vas deferens 
produced by the rat brain sample could not be completely (that is by 
100%) reversed by the addition of naloxone (900 nM bath concentration); 
this indicates that additional not enkephalin-like-materials may be 
responsible for the twitch height depression (Fig. 8C). 
Overall, the experiments designed to determine the effect of DFP 
on rat brain enkephalin-like-material levels were incomplete and in-
conclusive due to the lack of reliable, extraction and bioassay tech-
niques. 
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FIGURE SA 
Inhibition of the electrically-evoked contraction of the longitud-
inal muscle of the mouse vas deferens by a rat brain sample extract 
{S) . Notice the increased resting tone of the vas deferens produced 
by S when compared to the normal resting tone following the adminis-
tration of standard leucine-enkephalin (see Figure 2). W =washout 
time. 
8B 
Inhibition of the electrically-evoked contractions of the longitudinal 
muscle of the mouse vas deferens by a rat brain sample extract {S) . 
Notice the non-constant depression of twitch height produced by S 
when compared to the constant twitch height depression produced by 
standard leucine enkephalin (see Figure 2). W =washout time. 
sc 
Inhibition of the electrically-evoked contractions of the longitudinal 
muscle of the mouse vas deferens by a rat brain sample extract (S) 
and subsequent reversal by the addition of naloxone (N; 900 nM bath 
concentration) prior to washout (W). Notice the incomplete, less 
than 100%, reversibility by N of the depressed twitch height produced 
by S when compared to the complete reversal of the twitch height 
depression produced by standard leucine-enkephalin (see Figure 2). 
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5. DISCUSSION 
5.1 General 
5.1.1 DFP, Mechanism of Action 
Anticholinesterase (anti-ChE) agents constitute one of the few 
classes of drugs for which a mechanism of action has been defined in 
terms of inhibition of a specific enzyme. Until World War II, the 
enzyme cholinesterase (ChE) was of pure academic interest; however, 
during the war, intense research programs arose in the field of 
organophosphorus anti-ChE's because their toxicities suggested their 
use as potential chemical warfare agents. Investigations in England 
produced a series of organophosphorus anti-ChE's, one of which was 
diisopropyl phosphofluoridate (DFP; Holmstedt, 1959; Karczmar, 1970). 
Cholinesterases (ChE's) contain at least one anionic and one 
esteratic site in their active centers; the most likely carrier of 
the negative charge in the anionic site is glutamic acid while serine 
and histidine are the basic groups of the esteratic site (Karczmar, 
1970). 
True cholinesterase (AChE) which hydrolyzes acetylcholine at a 
higher rate than butyrylcholine is the enzyme present in the brain, 
spinal cord, striated muscles, smooth muscles of the bronc:':-.ioles, 
urinary bladder, salivary glands, and erythrocytes of several but not 
all vertebrates (Koelle, 1951). Pseudocholinesterase (BuChE) which 
hydrolyzes butyrylcholine at a higher rate than acetylcholine is found 
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in the serum of most vertebrates, carotid body, hepatic cells, and 
muscularis mucosa of intestinal cells (Koelle, 1951). DFP produces 
a 50% inhibition of BuChE at low concentrations (10-8M) while AChE 
-6 is 50% inhibited by higher concentrations of DFP (10 M); thus, DFP 
preferentially inhibits BuChE (Aldridge, 1953). The doses of DFP 
used in this dissertation, 0.1 to 1.5 mg(kg may be extrapolated in 
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terms of equidistribution in the tissues as corresponding to 5.4 x 
10-7 to 8.2 x 10-6M. Thus, it would be expected that DFP in doses of 
0.5, 1.0, and 1.5 mg/kg inhibit at least 50% of AChE; less than 50% 
inhibition of AChE would be expected from the administration of 0.1 
mg/kg DFP. Actually, as an extremely lipid soluble compound (Usdin, 
1970) , DFP may be expected to be distributed preferentially in the 
nerve tissue. 
Anti-ChE's may be classified as reversible or irreversible based 
upon the ease with which the inhibitory action can be reversed. Re-
versible inhibition has been divided into three groups: (i) competitive 
(ii) noncompetitive and (iii) uncompetitive. Competitive inhibition 
occurs with anti-ChE's which are structurally similar to the normal 
substrate; with these compounds, Km increases and Vmax is unaltered. 
Noncompetitive inhibitors bind with some site on the ChE molecule 
distinct from the active site; in this case, Vmax decreases and Km 
remains unaltered. Uncompetitive inhibition occurs when the inhibi-
tion binds to the enzyme substance complex; in this case, Km and vmax 
both decrease. Oximes, inorganic compounds, and bis and mono quater-
nary compounds are examples of reversible inhibitors (Karczmar, 1970). 
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The inhibitory action of irreversible inhibitors is not easily 
reversed and the amount of inhibition increases as the amount of in-
hibitor present increases. Irreversible inhibition occurs in a two 
step process (i) a reversible formation of enzyme-inhibitor complex 
and (ii) an irreversible phosphorylation (carbamylation) of the 
enzyme; the degree of inhibition depends upon the rate constant of 
inhibition and is directly proportional to the amount of inhibitor 
present. Organophosphorus compounds such as DFP, carbamates, and 
organosulfonates are irreversible inhibitors (Usdin, 1970). 
DFP contains an electron deficient phosphorus atom by virtue of 
the attached highly electronegative fluorine atom. This phosphorus 
atom makes an electrophilic attack on the electron rich oxygen atom 
of the serine residue yielding diisopropylphosphoserine, a fluorine 
atom, and a proton. Thus, DFP enters the active site of serine con-
taining enzymes including ChE's, phosphorylates the serine residue, 
and inactivates the enzyme (Jansz et al., 1959; Koshland, 1963). 
The major mechanism of action of DFP, as well as the other ChE 
inhibitors, is actually due to the accumulation of ACh within the body 
as a result o= continued release from nerve terminals and failure to 
be subsequently hydrolyzed by active ChE (Usdin, 1970). Thus, the 
pharmacological effects of DFP are for the most part predictable based 
upon a knowledge of thosP sites where ACh is released by and the cor-
responding effector organs of the c~emical ~ediator. 
Single incremental subcutaneous (s.c.) administrations of DFP 
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in rats produced (i) skeletal muscle twitches; (ii) increased saliva-
tion, retching, diarrhea, and micturition; and (iii) general flacid-
ity; death when it occurred was attributed to respiratory failure, 
caused in part by the neuromuscular paralysis, central depression, 
and increased bronchiole secretions. Lethal dose-SO (LD-50) established 
in our laboratories and elsewhere amounted 3.0 mg/kg (Horton et al., 
1946); it depends on the source and the batch of DFP. 
In humans, the systemic administration of DFP produced the fol-
lowing: (i) twitching and generalized weakness of skeletal muscles; 
(ii) bronchoconstriction and increased secretions; (iii) increased 
sweating, salivation, lacrimation, and micturition; (iv) gastrointes-
tinal disorders; and(v) slight bradycardia (Grab, 1963). Central nerv-
ous system (CNS) manifestations included giddiness, tension excessive 
dreaming, insomnia, nightmares, headache, electroencephalographic 
(EEG) alterations, drowsiness, confusion, and generalized depression 
of respiratory and circulatory centers (Grab, 1963). 
Finally, a delayed, demyelinating neuropathy characterized by an 
onset of sensory symptoms and motor weakness has been reported 8 to 
14 days after exposure to DFP and other organophosphorus compounds; 
the mechanism responsible for this effect remains to be determined 
(Grab, 1963). 
5.1.2 DFP, Investigational Compound 
DFP was chosen as the investigational compound for these studies 
for several reasons. Fi=st, cholinergic-induced antinociception 
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arises from stimulation of central cholinergic receptors (see section 
1.2.3). Drugs administered systemically must therefore be able to 
cross the blood brain barrier (BBB) to produce antinociception. DFP, 
being highly lipophilic readily penetrates the BBB. 
Second, the irreversible inhibition of ChE produced by DFP allows 
the various biochemical and behavioral experimental procedures to be 
performed at times distant from injection or one another, reducing the 
injection frequency and handling stress effects (see section 3.3.1). 
Third, both the serotonergic (see section 1.3) and cholinergic 
(see section 1.2) systems have been implicated in antinociception. 
That the serotonergic system is coupled with the cholinergic system 
is suggested by the fact that pilocarpine, arecoline, oxotremorine, 
DFP, and physostigmine increase serotonin (5-HT) and 5-hydroxyindole-
acetic acid (5-HIAA) levels in rats indicating an increased 5-HT turn-
over (Reid, 1970; Haubrich and Reid, 1972; Barnes et al., 1978). In 
addition, DFP increased 5-HT levels to a greater extent than did the 
other compounds. This research was initiated to separate the cholin-
ergic from the serotonergic effects with respect to cholinergic·-in-
duced antinociception. DFP, which produced the greatest effect on 
5-HT levels, appeared to be best suited for this purpose. 
Finally, the ability to produce antinociception when administered 
to laboratory animals had not yet been demonstrated for DFP. In fact, 
DFP failed to produce antinociception in previous studies; however, 
experimental procedures involved differed from those employed pres-
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ently (Saxena, 1958; Cox and Tha, 1972). Saxena (1958) utilized 
noxious pressure applied to the rats tail; the hot plate and tail 
flick tests were used here. Cox and Tha (1972) used mice; rats were 
studied in this laboratory. 
5.1.3 Methods of Evalu~ting Antinociception 
Antinociception can be measured by a variety of laboratory test-
ing procedures in several laboratory animals. For instance, electric-
al st~rnulation of the tooth pulp in the dog, cat, and rabbit has been 
useful in determining antinociceptive activity since the tooth pulp 
contains nociceptors (see section 1.1.4.1). 
Pressure or noxious mechanical stimulation applied to the tail 
of the rat or mouse has been used as a means of evaluating antinoci-
ceptive activity .. This method, originally described by Haffner (1929), 
utilized an artery clip applied to the base of the tail; the latency 
of biting at the clip was quantitated. 
The intraperitoneal (i.p.) administration of a number of corn-
pounds such as ACh, acetic acid, and phenylquinone produce a character-
istic response in mice called writhing. The ability of compounds to 
inhibit this response has also been used to assess antinociceptive 
activity. 
The classical method of experimentation employs noxious heat 
stimuli to evaluate the antinociceptive activity of drugs. The orig-
inal method of D'Amour and Smith (1941) involved focusing a beam of 
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of light through a prism onto a rats tail; the latency of the 
characteristic tail flick was quantitated. 
The reaction of a mouse or rat placed on a hot plate, noxious 
heat source, has also been used extensively to evaluate antinocicep-
tive activity. The original paper of Woolfe and MacDonald (1944) 
described the responses observed when mice were placed on a hot plate; 
included here were sitting up, blowing on the front paws so as to 
cool them, licking of the hind paws, and eventually jumping off of the 
hot plate surface. 
Overall, the simplest and yet effective method is the use of the 
hot plate. By placing the animal, which has received the test drugs, 
on the hot plate surface and recording the time to response it is 
possible to determine the relative potency, onset, intensity, and 
duration of antinociceptive activity. Thus, the hot plate test was 
used in these experiments. 
The application of heat to the rats tail is another method which 
may prove useful in the evaluation of antinociception since the char-
acteristic tail flick response represents a spinally mediated reflex 
which appears to be independent of motor behavior; thus, this test 
also was used here. 
The choice of animals and procedures was dependent also on the 
following considerations; (i) the hot plate and tail flick tests are 
easily performed requiring no additional surgical procedures as in the 
tooth pulp stimulation experiments and no additional injections as in 
the writhing tests, (ii) the choice of antinociception testing proce-
dures limited the choice of laboratory animals to be used to the rat 
or mouse. The decisive factor was the ability to extract sufficient 
quantities of 5-HT and enkephalin-like-material for quantitative 
analysis of the brain. 
5.2 DFP-Induced Antinociception 
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DFP produced antinociception when administered to rats whether 
measured by the hot plate or tail flick test (Tables 1 and 2) . The 
antinociceptive state produced by DFP followed a dose dependent re-
lationship as determined by the hot plate procedure (Table 1) . 
Antinociception produced by DFP was long lasting, up to 6 hours dur-
ation in the hot plate test, which is consistent with the irreversible 
effect of DFP on ChE (Fig. 3). 
When one considers that besides being bound to ChE's, DFP is also 
bound irreversibly to non-ChE proteins and proteolipids and as it is 
readily hydrolyzed enzymatically (Mazur, 1946), DFP is a particularly 
potent antinociceptive agent, as at the dose of 1.5 mg/kg it increased 
by 214 and 132% the animals response times in the hot plate and tail 
flick tests, respectively (Tables 1 and 2). 
It is noteworthy that even at low doses (0.1 mg/kg), DFP produced 
a significant antinociceptive response (Table 1). While DFP is con-
sidered as acting primarily via the inhibition of ChE with resultant 
ACh accumulation, it appears that anti-ChE's may have actions inde-
pendent of ChE inhibition (Van Meter et al., 1978). Therefore, DFP may 
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produce antinociception by actions independent of ChE inhibition such 
as affecting ionic conductances or rendering the cholinergic receptor 
more reactive to ACh (Van Meter et al., 1978). 
Cholinergic-induced antinociception and analgesia result from 
actions involving central cholinoceptive sites of the muscarinic type 
(see section 1.2.3). Similarly, DFP-induced antinociception appears 
to result from central actions involving muscarinic receptors since 
atropine sulfate antagonized while atropine methyl nitrate was in-
effective in blocking this response (Table 2). 
Specific central sites involved in mediating the antinociceptive 
effects of DFP cannot be determined from these studies. However, 
additional experiments which would provide evidence for specific sites 
of action could be performed as follows. 
First, spinal and supraspinal structures may be associated with 
DFP-induced antinociception. Assessment of tail flick response in 
animals in which the spinal cord has been transected (T6-T8) may pro-
vide evidence for a principal spinal or supraspinal site of action. 
Second, previous investigations suggest that certain structures such 
as the septum, mesencephalic reticular formation, and medial thalamic 
nuclei may be involved in mediating cholinergic-induced antinocicep-
tion(see section 1.2.3). Localized injections of DFP with the concom-
itant assessment of nociceptive responses may therefore provide addi-
tional evidence for an anatomical substrate for the particular DFP 
effect. 
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Third, cholinergic-induced antinociception may be indirectly medi-
ated through the involvement of other neurotransmitter systems in the 
CNS as suggested earlier (see section 1.2.4). Various pharmacological 
manipulations can be used to ascertain which neurotransmitter system 
or systems as well as which tracts or areas are involved. In fact, 
this principle was utilized to determine the involvement of the sero-
tonergic system in DFP-induced antinociception (see section 5.5). 
Similar studies could be designed to determine the involvement of 
other neurotransmitter systems such as the noradrenergic and dopamin-
ergic systems. 
Another problem is concerned with the clinical application of 
the data. Although DFP is too toxic to be employed in clinical stud-
ies, other anti-ChE's such as physostigmine can be utilized to gain 
information concerning a possible site of action and mechanism of 
cholinergic-induced antinociception. The assessment of pain in a clin-
ical setting may provide evidence to suggest which component of the 
pain experience, sensory-discriminative, ~otivational-affective, or 
cognitive-evaluative, is affected by the drug. Since specific brain 
mechanisms are thought to be related to specific anatomical structures 
data obtained in the clinics may provide evidence for not only which 
brain process but also which anatomical loci are involved in cholin-
ergic-induced antinociception (Melzack and Casey, 1968; Melzack,l975). 
Recently, Sitaram et al. (1977) have demonstrated that physostig-
mine produced analgesia in normal human volunteers as measured by 
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(i) the subjects verbal response and (ii) specific cortical average 
evoked electroencephalographiG responses (AER). Sitaram et al. (1977) 
suggest that physostigmine affects the motivational-affective and cog-
nitive-evaluative psychological components of the pain experience via 
its cortical arousal effect. This dissertation provides the basis for con-
tinued clinical investigations concerned with the involvement of the 
cholinergic system in the pain phenomenon. In particular, the effect 
of physostigmine on narcotic-induced analgesia will be studied (appen-
dix 1). See section 5.6.3 and appendix 1 for a complete discussion of 
the appended clinical investigation protocol. 
Finally, one problem concerning the present data should be empha-
sized. Hot plate responses of animals administered either 0.1 mg/kg 
or 0.5 mg/kg of DFP or the drug vehicle were attenuated 6 to 8 hours 
post injection (Fig. 3). Two explanations concerning this effect may 
be presented as follows. The attenuation of hot plate responses could 
be attributed to a learning/conditioning effect; repeated exposure to 
a task involving a negative consequence (hot plate surface) de-
creases the time associated in the task. Alternatively, the animals 
were exhibiting a diurnal variation in responsiveness to noxious input. 
Significant diurnal variations have been demonstrated for hot plate 
response times in mice (Frederickson et al., 1977). Thus, the animals 
administered the vehicle or DFP in low doses (0.1 and 0.5 mg/kg) may 
have been exhibiting a normal diurnal variation in responsiveness; 
employed in doses of 1.0 and 1.5 mg/kg DFP was so potent as not to 
allow this expression of a diurnal rhythm (Fig. 3). 
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5.3 DFP-Induced Immobilization 
The first question which arises is whether the antinociceptive 
state produced by DFP is due to or dependent on, the attenuation of 
spontaneous locomotor activity; tnis is particularly pertinent in the 
case of the hot plate test since the behavioral responses which are 
measured in this test involve locomotor movements (see section 3.3.2). 
The animals exploratory activity level, that is its response to 
a novel environment, may be a pertinent correlate of antinociception 
as measured by the hot plate test since both measurements were made 
immediately after placing the animal in this novel environment. 
DFP reduced exploratory activity levels; neither atropine sulfate 
nor atropine methyl nitrate affected the attenuation of exploration 
produced by DFP (Tables 4 and 10). In fact, atropine sulfate also 
reduced exploration when administered alone; this may account for its 
inability to restore exploratory activity attenuated by DFP (Table 
10). Yet, DFP-induced antinociception was antagonized by atropine 
sulfate; atropine sulfate, alone, failed to alter hot plate responses 
(Table 3). Thus, the antinociceptive state produced by DFP is not 
related to the attenuated exploration produced by DFP. 
An apparent discrepancy arises concerning the effect of anti-
cholinergic agents on exploration (see section 1.2.4), as many inves--
tigators reported that atropine augments exploratory and/or motor 
activity. However, this discrepancy can be explained by examining 
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the operational definitions employed in each case. Kornisaruk (1970) 
defined exploratory activity in terms of sniffing behaviors; Abeelen 
et al. (1972) regarded rearing, leaning, and sniffing as exploratory 
acts; presently, exploration was defined in terms of gross locomotor 
movements during early phase of exposure to novel surroundings (see 
section 3.3.4.2). Clearly, while all studies measured behaviors in 
a novel environment, exploration, these studies do not measure iden-
tical behaviors. 
Additional evidence that the antinociception and attenuation of 
exploration produced by DFP are independent phenomena is as follows: 
(i) peak attenuation of exploration did not coincide with peak anti-
nociceptive responses at any time tested 1 to 48 hours after the ad-
ministration of any dose of DFP, (ii) at 0.1 mg/kg, DFP produced anti-
nociception but did not affect exploratory activity, and (iii) nalox-
one antagonized DFP-induced antinociception but did not affect DFP-
induced attenuation of exploration (Tables 9 and 10) . A complete dis-
cussion of the effect of naloxone on DFP-induced behavioral responses 
is provided in section 5.6. 
Motor activity levels which represent the animals ability to make 
spontaneous locomotor movements also were studied as a potential 
correlate to antinociception. It should be pointed out that motor 
activity was measured 15 minutes after the animals had been placed in 
the activity cages while hot plate responses were measured immediately 
after placing the animal on the hot plate surface(see section 3.3.4.2). 
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DFP reduced in a dose dependent manner motor activity in rats; 
the diminution in motor activity produced by DFP was not affected by 
atropine sulfate, atropine methyl nitrate, or naloxone (Tables 4 and 
10). However, employed by itself, atropine sulfate reduced motor 
activity; this may account for its inability to restore motor activ-
ity attenuated by DFP (Table 10). On the other hand, DFP-induced 
antinociception was antagonized by atropine sulfate and naloxone; 
atropine methyl nitrate was ineffective (Table 9). Thus, DFP-induced 
antinociception was sensitive to the actions of both atropine sulfate 
and naloxone whilst DFP-induced attenuation of motor activity was not 
affected by either atropine sulfate or naloxone. Therefore, the anti-
nociception and attenuation of motor activity produced by DFP do not 
appear to be related. 
Finally, it must be emphasized that DFP produced antinociception 
in the tail flick test as well; this test appears to be less dependent 
on changes in motor behavior than the hot plate test. Since antinoci-
ception and the attenuation of locomotion appear to be independent, 
further experiments to separate these two phenomena need not be pro-
posed. 
5.4 DFP-Induced Hypothermia 
Since the hot plate and tail flick tests involve temperature 
sensitive measurements and as the systemic administration of DFP is 
known to produce hypothermia (Meeter and Wolthius, 1968), the hypo-
thermic state produced by DFP may interfere with the evaluation of 
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DFP-induced antinociception. 
In agreement with the earlier data of Meeter and Wolthius (1968) , 
DFP produced a pronounced hypothermia (Fig. 5). Here, DFP-induced 
antinociception and hypothermia were seemingly independent effects: 
(i) DFP (1.0 mg/kg) produced antinociception which lasted up to 6 
hours post administration (Fig. 3) while hypothermia was obtained only 
at 2 hours post injection (Fig. 5) and, (ii) naloxone antagonized the 
DFP-induced antinociceptive state (Table 8) but did not affect hypo-
thermia produced by DFP (Fig. 7). A complete description of the 
effect of naloxone on DFP-induced behavioral responses is given in 
section 5.6. 
Liu and Fong (1972) demonstrated that hypothermia produced an 
alteration in the antinociceptive response to intra-arterial injec-
tions of ACh in cats; mild hypothermia, a 2 to 3° decrease in rectal 
temperature below normal, produced a hypernociceptive state; a further 
reduction in rectal temperature, 5 to 6° below normal rectal tem-
perature, produced antinociception. Based upon the study of Liu and 
Fong (1972) , the hypothermia produced by DFP in the present experi-
ments, a 2.4° decrease in rectal temperature, would be expected to 
produce hypernociception and thus antagonize the antinociceptive state 
produced by DFP. In fact, DFP produced both a pronounced level of 
antinociception and hypothermia in the rat and thus it appears that 
DFP-induced antinociception and hypothermia are unrelated. 
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5.5 DFP-Induced antinociception and the Serotonergic System 
5.5.1 Neurochemistry 
The next question which arises concerns the neurochemical mech-
anisms involved in DFP-induced antinociception. The antinociceptive 
state and ACh levels and/or turnover rates may be correlated for some 
but not all centrally acting cholinomimetics, anticholinesterases, 
narcotic agonists and antagonists, and various CNS depressants (see 
section 1.2.3). Thus, the antinociceptive state produced by those 
compounds may not be directly attributable to actions via the central 
cholinergic system. The multitransmitter character of the CNS as well 
as the effects which cholinergic agents produce on systems other than 
the cholinergic system suggest the possibility that DFP-induced anti-
nociception may be attributed to a DFP action mediated by non-cholin-
ergic systems (Karczmar, 1975). 
First, the interplay between the ~holinergic and serotonergic 
systems may be involved. For a long time now the serotonergic system 
has been implicated in antinociception; increased activity of brain 
and spinal cord serotonin neurons such as that produced by electrical 
stimulation, precursor loading, uptake inhibitors, and receptor ago-
nists is associated with antinociception and enhanced antinociceptive 
potency of drugs such as morphine; decreased activity in those neurons 
induced by electrical and chemical lesioning as well as precursor 
restricted diets is associated with hypernociception and diminished 
antinociceptive drug potency (see section 1.3). 
That the serotonergic system may be coupled with the cholinergic 
system is suggested by the fact that oxotremorine and physostigmine 
(Reid, 1970) , pilocarpine and arecoline (Haubrich and Reid, 1972), 
and DFP (Barnes et al., 1974, 1975) increase 5-HT and 5-HIAA levels; 
these data indicate that DFP increased 5-HT turnover, and indeed 
appropriate measurements showed that this is so (Barnes et al., un-
published) . 
It was therefore important to determine if DFP had a similar 
effect in rats. As shown in Table 5, 5-HT levels were markedly in-
creased in the rat medulla, meso-diencephalon, and telencephalon fol-
lowing a single administration of DFP. DFP increase in 5-HT levels 
and turnover as well as the antinociceptive state produced by DFP are 
mediated through activation of central muscarinic receptors since 
atropine sulfate antagonized whereas atropine methyl nitrate did not 
affect these two effects of DFP (Barnes et al., 1978; Koehn and 
Karczmar, 1978). 
It may be speculated that the resultant accumulation of ACh due 
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to DFP inhibition of ChE depolarizes serotonergic neurons thus in-
creasing 5-HT levels and turnover. On the other hand, the increase in 
5-HT levels and turnover elicited by DFP might be due to a direct 
stimulatory action of DFP upon 5-HT release. The present experiments 
do not demonstrate which explanation is correct. Finally, DFP may 
increase 5-HIAA brain levels by affecting transport systems responsible 
for 5-HIAA elimination. 
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Since the rise in 5-HT levels and turnover produced by DFP could 
underlie DFP-induced antinociception, it was important to separate 
these two phenomena produced by DFP. One method by which this could 
be accomplished is by manipulating the serotonergic system followed by 
DFP administration,measurements of nociception and of 5-HT levels. 
Para-chlorophenylalanine (PCPA) which inhibits the synthesis of 5-HT 
by inhibiting tryptophan hydroxylation was employed for this purpose. 
The use of PCPA as an inhibitor of 5-HT biosynthesis was first 
reported by Koe and Weissman (1966). The mechanism of action of PCPA 
on the 5-HT biosynthetic process appears to involve three separate 
parts. These various mechanisms must be considered in experiments in 
which PCPA is used to evaluate biochemical mechanism underlying behav-
ioral and pharmacological phenomenon. 
First, a reversible inhibition of tryptophan hydroxylase (TH) 
activity lasting 4 hours with peak effect at 1 to 2 hours post injec-
tion was observed following the systemic administration of PCPA; this 
inhibition of enzyme activity was attributed to 1) competition of PCPA 
with substrate for entry into the nerve ending as well as 2) the co~ 
petitive inhibition of the enzyme for the substrate (Knapp and Mandell, 
1972). A second, irreversible inhibition of TH was observed 2 days 
after the PCPA injection; this inhibition has been attributed to in-
corporation of PCPA into TH during new protein synthesis in the nerve 
cell body (Gal et al., 1970). Thus, pretreatment of the animal two 
days as well as 2 hours prior to experimentation yields a model 
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system in which the three mechanisms involved in the inhibition of 
5-HT synthesis by TH are maximally inhibited. In fact, this was the 
1 2 basis of the injection schedules employed presently (PCPA and PCPA ; 
see section 3.2.2). 
Finally, the doses of PCPA utilized in these experiments were 
selected because these doses specifically inhibited TH activity with-
out affecting the activity of other enzymes such as tyrosine hydrox-
ylase, aromatic amino acid decarboxylase, or monoamine oxidase all 
of which affect dopaminergic or noradrenergic neurotransmitter systems 
(Koe and Weissman,l966). 
Serotonin (5-HT) levels were measured in rat medulla, meso~dien-
cephalon, and telencephalon subsequent to the administration of PCPA1 
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or PCPA (see section 3.2.2) to monitor the inhibitory action of PCPA 
on 5-HT biosynthesis. As shown in Table 5, PCPA decreased 5-HT levels 
in all three rat brain regions, particularly following the two daily 
300 mg/kg doses followed on the third day by a 100 mg/kg dose (PCPA2). 
It should be pointed out that the depletion of rat brain 5-HT was not 
as great as that originally described by Koe and Weissman (1966). 
However, the experimental procedures in these two studies differed in 
the following ways. First, Koe and Weissman (1966) sacrificed the 
rats by an intravenous (i.v.) administration of pentobarbital; decap-
itation was used in the present studies (see section 3.5.1). Second, 
spectrophotofluorometric methods for quantitation of 5-HT differed; 
Koe and Weissman (1966) measured 5-HT directly whereas, here, 5-HT 
was converted to a substituted indole compound which is more fluo-
rescent than 5-HT itself (see section 3.5.5). 
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Subsequently, the effect of DFP on rat brain region 5-HT levels 
in animals pretreated with either PCPA1 or PCPA2 was determined (see 
section 3.2.2). DFP did not affect attenuation of 5-HT levels by 
PCPA pretreatment dosage regimens in any of the three rat brain reg-
ions studied; that is, PCPA pretreatment prevented the DFP-induced 
augmentation of 5-HT levels (Table 5). Thus, DFP-induced increase in 
rat brain 5-HT levels depends upon a functionally intact 5-HT bio-
synthetic system. 
5.5.2 Antinociception 
Since the DFP augmentation of 5-HT levels in rat brain depends 
upon a functionally intact 5-HT biosynthetic system, it was important 
to determine whether the antinociceptive state produced by DFP also 
depends upon this system. 
PCPA produced hypernociceptive responses in rats as measured by 
the hot plate test (Table 6). This effect of PCPA is consistent with 
earlier findings of Tenen (1967) and Messing et al. (1975) who demon-
strated an increased sensitivity to electric footshock in rats as 
measured by the flinch-jump test. 
The tail flick test was also employed to assess the nociceptive 
responses of rats following PCPA treatment. Here, the tail flick 
apparatus was adjusted so that the response latency of control animals 
169 
was long enough (15 seconds; see section 4.5.2) to allow monitoring 
of possible hypernociceptive responses. As a result, it would be 
shown that PCPA produced hypernociception in rats also as measured by 
the tail flick test (Table 7). Thus, just as in the case of previous 
reports (see section 1.3), decreased serotonergic neurotransmission 
such as that produced by PCPA correlates with the hypernociceptive 
state in rats. 
As demonstrated earlier (see sections 4.1.1 and 4.1.2), DFP pro-
duced antinociception in rats as measured by the hot plate (Table 6) 
and tail flick tests (Table 7). If DFP-induced antinociception were 
dependent upon a functionally intact 5-HT system, the pretreatment 
with PCPA would be expected to antagonize the antinociceptive action 
of DFP. Alternatively, if DFP-induced antinociception were independ-
ent of the 5-HT system, PCPA pretreatment would not be expected to 
affect the DFP-induced antinociceptive state. Tables 6 and 7 demon-
strate the effect of PCPA pretreatment on the DFP-induced antinoci-
ceptive state as measured by the hot plate and tail flick tests, re-
spectively. The interesting finding was that PCPA pretreatment 
did not antagonize DFP-induced antinociception as evaluated by either 
test (Tables 6 and 7). Thus, DFP-induced antinociception and the 
increase in brain 5-HT levels produced by DFP appear to be independent 
effects. The augmentation of rat brain 5-HT levels is dependent 
whereas antinociception produced by DFP is independent of a function-
ally intact 5-HT biosynthetic system. 
Generally, the antinociceptive effects of physostigmine were 
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affected by manipulation of the serotonergic system (see section 1. 
2.3.3). This discrepancy concerning the effect of PCPA pretreatment 
on cholinergic-induced antinociception (see section 1.2.3.3) may be 
due to differences in the mechanism of the cholinergic effects of oxo-
tremorine, DFP and physostigmine. Thus, it should not be surprising 
that the antinociceptive states produced by these compounds may arise 
through different mechanisms. In fact, in the case of oxotremorine· 
and physostigmine this was found to be so; oxotremorine-induced anti-
nociception is potentiated by procedures which decrease brain cate-
cholamine systems but is unaffected by procedures which change the brain 
5-HT system; physostigmine-induced antinociception is affected by pro-
cedures which alter catecholamine and 5-HT systems (Pleuvry and Tobias, 
1971). It should also be noted that with the exception of the present 
study, none of the other investigations measured 5-HT levels and/or 
turnover and thus were unable to correlate behavioral and neurochem-
ical data. Finally, differences in technique and dosages must also be 
considered in this context. 
5.5.3 Immobilization 
It has long been known that PCPA affects spontaneous locomotor 
activity in the rat (Tenen, 1967). Since the hot plate test involves 
locomotor sensitive measurements, the effects of PCPA and PCPA-DFP 
combinations were evaluated to determine whether the lack of effect of 
PCPA on DFP-induced antinociception was related to a PCPA action on 
the mobility of the rat. 
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Previous investigations have demonstrated that PCPA decreased 
exploration in rats (Marsden and Curzon, 1976), contrary to the pres-
ent findings. However, it should be noted that Marsden and Curzon 
(1976) defined exploration in terms of open field activities such as 
the number of squares entered, number of rearings, number of 1800 
turns, grooming time, and number of fecal pellets; thus, their oper-
ational definition of exploration was different from the locomotor 
activity levels measured as exploration in the present experiments 
(see section 3.3.4.2). 
As demonstrated earlier (see section 4.2.1), DFP reduced explo-
ratory activity levels of rats(Table 8). PCPA, administered by itself, 
did not affect exploration nor was it capable of affecting the dimi-
nution of exploratory activity produced by DFP (Table 8). It would 
be expected that via reducing exploratory activity in rats PCPA could 
interfere with the assessment of the nociceptive response. However, 
since PCPA did not affect exploration nor did pretreatment with PCPA 
affect the diminution of exploration produced by DFP, the lack of 
effect of PCPA on DFP-induced antinociception was not related to an 
alteration of exploration produced by PCPA. 
As demonstrated earlier (see section 4.2.2), DFP reduced motor 
activity levels of rats (Table 8). PCPA, administered by itself, in-
creased motor activity (Table 8); this effect of PCPA on motor activ-
ity is consistent with the original findings of Tenen (1967). How-
ever, PCPA was unable to affect the DFP-induced decrease in motor ac-
tivity(Table 8). If PCPA affected the antinociceptive state produced 
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by OFF by altering the animals motor activity levels, it would be ex-
pected that the PCPA-induced increase in motor activity would antag-
onize OFF-induced antinociception. However, PCPA pretreatment did not 
antagonize the antinociception produced by OFF (Table 8). Thus, the 
PCPA affect on motor activity was not related to the PCPA lack of 
effect on OFF-induced antinociception. 
5.6 OFP-induced Antinociception and the Endogenous Opioid System 
5.6.1 Antinociception, Pharmacological Analysis 
It has long been known that anti-ChE's such as prostigmine 
(Slaughter and Munsell, 1940), physostigmine (Floodmark and Wrammer, 
1940), and OFP (Bhargava and Way, 1972); cholinomimetic compounds such 
as pilocarpine (Saxena and Gupta, 1957); as well as ACh (Pedigo et 
al., 1975) itself, potentiate narcotic-induced antinociception and/or 
analgesia. Recent discoveries of the stereospecific opiate receptor 
(Goldstein et al., 1971) and several endogenous opioid-like peptides, 
enkephalins (Hughes et al., l975a) and endorphins (Li and Chung, 1976; 
Guillemin et al., 1976) have advanced our working knowledge of pain 
mechanisms. Therefore, any hypothesized role for a neurotransmitter 
such as ACh in pain modulation must take into account possible inter-
actions with endogenous opioid system. A pharmacological analysis of 
the antinociceptive actions of OFP and morphine was performed to in-
vestigate possible relationships between the cholinergic and endog-
enous opioid systems in the pain phenomenon. 
As described earlier (see section 4.1.1), DFP produced anti-
nociception in the rat as measured by the hot plate test (Table 9). 
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As expected, morphine also produced antinociception in rats as measur-
ed by the hot plate test; this effect was antagonized by the narcotic 
antagonist, naloxone; atropine sulfate was ineffective (Table 9). The 
interesting finding of this study was the fact that naloxone antagcn-
ized DFP-induced antinociception (Table 9) . 
Naloxone has been reported to block the antinociceptive effects 
of other compounds which affect the cholinergic system such as physo-
stigmine and oxotremorine (Harris et al., 1969) and ACh (Pedigo et 
al., 1975) as well as other pharmacologically- and physiologically-
induced antinociceptive states such as those produced by acupuncture 
(Mayer et al., 1976), stimulation produced analgesia (SPA; Akil et 
al., 1976), and stress (Bodnar et al., 1977; Chesher and Chan, 1977). 
The fact that naloxone antagonized the antinociception arising from 
these various procedures suggests that antinociception may result from 
actions mediated through the opiate receptor, possibly via the release 
of endogenous opioids. 
However, it must be pointed out that naloxone antagonism of anti-
nociception is necessary but not sufficient evidence to implicate the 
involvement of the endogenous opioid system. Nonspecific actions of 
naloxone could interfere with the assessment of nociceptive responses. 
First, naloxone may act as a gamma amino butyric acid (GABA) antago-
nist. The iontophoretic application of naloxone antagonized GABA-
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induced inhibition of firing in 21 out of 27 spontaneously active, 
olfactory tubercle neurons in the rat (Dingledine et al., 1978). 
Furthermore, applied iontophoretically, naloxone antagonized ACh, 
nicotine and morphine-induced excitation but did not affect morphine-
induced inhibition of Renshaw cells in cats (Duggan et al., 1975). 
Thus, naloxone also may act as a cholinergic-nicotinic receptor an-
tagonist. Alternative explanations describing the naloxone effect 
are also plausible. Finally, naloxone itself, has been shown in some 
cases to produce analgesia. Lasagna (1965) demonstrated a bidirec-
tional effect of naloxone; low doses of naloxone, 1 to 2 mg, produced 
analgesia whereas higher doses, 5 to 8 mg, produced ~yperalgesia as 
measured by verbal reports in patients with postoperative pain. Re-
cently, naloxone has been shown to produce analgesia measured as chan-
ges in cortical evoked potentials following electrical stimulation, in 
pain-sensitive individuals; the same dose of naloxone produced hyper-
algesia in pain-sensitive individuals (Buschsbaum et al., 1977). 
Experiments which would help define the role of the endogenous 
opioids include the following. First, stereoisomers of narcotic an-
tagonists other than naloxone may be used to determine the stereospeci-
ficity of the narcotic antagonism. Experiments with MR 1452/3 and 
MR 2266/7, the~ methyl and~ ethyl N furylmethyl analogues of ~-5,9-
dialkyl-2'-hydroxy-6,7-benzomorphan, respectively and GPA 1843/7, the 
N-allyl analogue of S-9-methyl-5-phenyl-2'-hydroxy-6,7-benzomorphan, 
have confirmed the stereospecific effects of naloxone on the electric-
ally evoked release of ACh from guinea pig ileum (Waterfield and 
Kosterlitz, 1975). Jacob and Ramabadran (1978) also have confirmed 
stereospecific effects of MR 2266/7 on the morphine-induced antinoci-
ceptive state in mice utilizing the hot plate test. The effect of 
stereoisomers of narcotic antagonists on DFP-induced antinociception 
is discussed in section 5.6.2 below. 
Next, the existence of cross tolerance with the antinociceptive 
action of morphine may be used to demonstrate the involvement of a 
common neural substrate. Both exogenous S-endorphin (Szekely et al., 
1977) and methionine-enkephalin (Blasig and Herz, 1976) pro-
duce cross tolerance with morphine. In addition, tolerance to mer-
phine reduced the effective level of antinociception produced by elec-
trical stimulation (SPA) of periaqueductal gray areas (PAG; Mayer and 
Hayes, 1975) and stress in rats (Spiaggia et al., 1979); reciprocal 
tolerance was incomplete in each case (Mayer and Hayes, 1975; Spiaggia 
et al., 1979). Cross tolerance studies between DFP- and morphine-
induced antinociception are described in section 5.6.3). 
Direct release of endogenous opioid peptides by an appropriate 
stimulus constitutes further evidence for the involvement of the endog-
enous opioid system. Electrical stimulation (SPA) of the periaque-
ductal gray region (PAG) , which produced analgesia in patients suffer-
ing from chronic intractable pain, was associated with increased cere-
brospinal fluid (CSF) levels of enkephalin-like-material (Akil et al., 
1978) and immunoreactive-S-endorphin (Hosobuchi et al., 1979). Elec-
tro-acupuncture increased endorphin activity CSF levels in chronic 
l76 
pain patients (Sjolund et al., 1977). The effect of DFP on the endog-
enous opioid system is discussed below in section 5.6.4. 
Additional experiments that would clarify the mechanisms involv-
ed in DFP-induced antinociception may be suggested. Pomeranz et al. 
(1977) demonstrated that electro-acupuncture-induced antinociception 
could be blocked by hypophysectomy in mice. Li and Chung (1976) and 
Guillemin et al. (1976) have reported that morphine-like-pituitary-
peptides, endorphins, are concentrated in the pituitary. If OFF-
induced antinociception was mediated via the release of endorphins 
from pituitary sites, then hypophysectomy would be expected to block 
the antinociceptive action of DFP. Carboxypeptidase A and leucine 
aminopeptidase are known to enzymatically degrade enkephalins (Hughes 
et al., 1975a). In addition, the enkephalins are rapidly degraded by 
enzymes found in rat cerebral tissues (Dupont et al., 1977). If OFF-
induced antinociception were mediated by the release of enkephalins, 
agents which inhibit the degradative enzymes should potentiate this 
response. For example, bacitracin is known to inhibit the enzymatic 
breakdown of enkephalins in rat brain tissue extracts (Simantov et 
al., 1976c). However, the specificity and potential side effects as-
sociated with any enzyme inhibitor which would otherwise interfere with 
nociception measurements, must be considered. 
5.6.2 Stereospecificity 
Since non-specific actions of naloxone could contribute to its 
inhibition of DFP-induced antinociception (see section 5.6.1), it was 
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important to determine whether the antagonism was stereospecific; 
synthetic antagonists of the benzomorphan series were employed for 
this purpose. MR 2266, MR 2267 and GPA 1847 possess relatively low 
agonists activity while GPA 1843 possesses no agonist activity as 
measured by their abilities to depress the electrically evoked 
contraction of the guinea-pig ileum (Waterfield and Kosterlitz, 19751. 
The (-) isomers of two narcotic antagonists, MR 2266 and GPA 1843, 
antagonized both morphine and DFP-induced antinociceptive responses 
whereas the corresponding (+) isomers, MR 2267 and GPA 1847, did not 
reduce either morphine or DFP-induced antinociceptive responses 
(Table 11). This stereospecificity of narcotic antagonist action 
suggests that DFP-induced antinociception is indeed mediated via 
opiate receptors. Jacob and Ramabadran (1978) have demonstrated 
similar effects of MR 2266 and MR 2267 on antinociception p~oduced 
by arecoline and physostigmine. 
Although Pert and Snyder (1973) could not find affinity of ACh, 
atropine, or carbamylcholine for stereospecific opiate receptors, 
the possibility remains that DFP may itself act directly on the 
opiate receptor; appropriate binding studies are required. 
Stereoisomers of cyclazocine, a partial narcotic agonist, had a 
differential effect on the antinociceptive states produced by OFP 
and morphine; (-) cyclazocine antagonized whereas (+) cyclazocine 
did not affect morphine-induced antinociception; alternatively (+) 
cyclazocine antagonized DFP-induced antinociception while (-) cycla-
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zocine was ineffective (Table 11). This effect has been reported 
previously employing stereoisomers of cyclazocine and pentazocine 
(Pedigo et al., 1975). The discrepancy between the action of narcotic 
antagonists and partial narcotic.agonists on cholinergic-induced 
antinociception is particularly puzzling. The type of test employed 
or drug specificity does not explain this effect as different tests 
for measuring nociceptive responses and different compounds which 
affect the cholinergic system have produced similar results (Pedigo 
et al., 1975; Table 11). No plausible interpretation of this ef-
fect can be presented at present. 
Finally, inconsistencies in the actions of the (+) isomers (MR 
2267, GPA 1847, and d-cyclazocine, Table 11) suggest that different 
opiate receptors may mediate the antinociceptive actions of DFP and 
morphine. Additional investigations such as pA2 studies are required 
to clarify these effects. 
5.6.3 Cross Tolerance Studies 
Cross tolerance exists.between the antinociceptive responses to 
morphine and exogenous opioid peptides (Blasig and Herz, 1976; 
Szekely et al., 1977). It would be expected that if DFP- and mor-
phine-induced antinociception were mediated via a common neuronal 
substrate, cross tolerance to morphine and DFP would be observed 
(see section 5.6.1). However, cross tolerance did not develop 
between morphine-induced antinociception and the antinocieptive 
state produced by DFP (Table 12) . Cross tolerance studies between 
morphine and pilocarpine were performed to determine whether 
the lack of cross tolerance between morphine and DFP was specific 
for DFP or representative of cholinergic-induced antinociception. 
Pilocarpine was selected since it enhances cholinergic neuro-
transmission by different mechanisms than does DFP {see section 
5.1.1); pilocarpine mimicks directly the action of ACh on cholin-
ergic-muscarinic receptors. Again, cross tolerance failed to 
develop between the antinociceptive actions of morphine and pilo-
carpine (Table 12). A similar lack of cross tolerance between 
morphine and oxotremorine (Howes et al., 1969) and physostigmine 
(Pleuvry and Tobias, 1971) has been reported. Thus, it appears 
that morphine- and cholinergic-induced antinociception is not 
cross tolerant. 
The possibility that the level of morphine tolerance was in-
adequate to demonstrate cross tolerance with DFP appears unlikely 
since DFP maintained an antinociceptive action even at increased 
levels of morphine tolerance (tolerance level B, Table 12). 
Alternatively, the lack of cross tolerance suggests that 
multiple neural substrates may act via opiate receptors to produce 
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antinociception. The chronic administration of morphine while 
producing tolerance to exogenous opioid peptides (Blasig and Herz, 
1976; Szekely et al., 1977) may not induce tolerance at those 
site? in the CNS at which a DFP- and pilocarpine-endogenous 
opioid interactions occur. 
Distinct opiate receptor populations which exhibit selective 
high affinity binding for (D-ala, D-leu)-enkephalin and morphine 
have been identified in the rat CNS (Chang and Cuatrecasas, 1979). 
It has not been established whether morphine, exogenous opioid 
peptides, or endogenous opioid peptides normally interact with 
one or both opiate receptors. However, it may be that cholinergic 
compounds release endogenous enkephalins which then interact with 
one type of opiate receptor while morphine interacts with another 
opiate receptor. Whether cross tolerance occurs between these 
two opiate receptor populations remains to be established. 
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The basis for implementing the appended clinical investigation 
protocol (see appendix 1) may be reviewed in light of these present 
findings as to the lack of cross toler~nce between morphine and DFP. 
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Anti-ChE's administered by themselves, are known to produce antinoci-
ception (Harris et al., 1968; Koehn and Karczmar, 1978) and analgesia 
(Sitaram et al., 1977); in addition, anti-ChE's potentiate narcotic-
induced antinociception (Bhargava and Way, 1972; Ireson, 1970) and 
analgesia (Floodmark and Wrammer, 1940). The antinociceptive actions 
of anti-ChE's do not exhibit cross tolerance with the antinociceptive 
action of morphine (Pleuvry and Tobias, 1971; Koehn et al., 1979). 
The appended clinical investigation protocol (see appendix 1) was de-
signed to determine whether the anti-ChE's agent, physostigmine, would 
produce analgesia in narcotic tolerant patients. It is hoped that 
this study will provide evidence for the existence of a cholinergic 
sensitive system which may be manipulated pharmacologically for the 
treatment of pain. 
5.6.4 Effect of DFP on the Endogenous Opioid System 
The release of endogenous opioid peptides by an appropriate stim-
ulus is required to establish the involvement of the endogenous opioid 
system in antinociception. If OFF-induced antinociception arises via 
actions involving the endogenous opioid system, DFP should release 
endogenous opioids. Potassium~induced depolarizations have been shown 
to release methionine- and leucine-enkephalin from isolated stria~al 
slices (Henderson et al., 1978) as well asS-endorphin from pituitary 
and hypothalamic sites (Przewlocki et al., 1978; Osborne et al., 1978). 
The present experiments were designed to study the effect of DFP on 
enkephalin-like material release from rat brain. Experimental proce-
dures for extraction (Hughes et al., 1977) and quantitation (Hughes et 
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al.,l975b) of enkephalin-like-material were chosen for this purpose 
(see section 3.6). In fact, the studies of the effects of DFP on 
enkephalin-like-material did not yield adequate data due to the lack 
of reliable extraction and bioassay techniques (see section 4.11). 
Methodological requirements for release studies include the 
following. First, the extraction process should eliminate any cont-
aminants which would otherwise interfere with the quantitation proce-
dure. This, in fact, was the primary failure in the present experi-
ments(see section 4.11). Second, the assay technique must be appro-
priately sensitive to measure experimentally-induced changes; here, 
sensitivities of 0.5 ng leucine-enkephalin equivalents are required, 
and this sensitivity did not obtain in our experiments. Enkephalin-
like-material levels in rats were studied with and without a DFP in-
jection in an attempt to establish proper methodology required for re-
lease studies as well as to demonstrate an effect of DFP on enkeph-
alin-like-material content (see section 4.11). While only 7 out of 
68 rat brain samples studied fulfilled acceptable criteria for bio-
assay (see section 3.6.5.3), no significant differences in enkephalin-
like-material levels were observed between animals administered DFP 
or the drug vehicle. The failure of the remaining brain samples to 
meet acceptable criteria was due to the presence of a non-enkephalin-
like-material contaminant (see section 4.11). 
Several changes implemented to eliminate any impurities or con-
taminants can be outlined as follows: (i) the chromatography resin 
was recycled an additional 10 times with isopropyl alcohol and water 
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(see section 3.6.3.1), (ii) brain homogenates were centrifuged at 
between 5 and 120,000 G for between 10 to 60 minutes (see section 
3.6.4), (iii) height of the resin bed was changed to 40, 80 and 120 mm 
(see section 3.6.3.2), (iv) eluate was put through columns to reelute 
enkephalin-like-material (see section 3.6.4), (v) eluate was taken to 
complete dryness by freeze evaporation techniques under vaccurn with 
phosphorus pentoxide as drying agent whenever samples would not go 
to complete dryness in Rotorvapor Apparatus (see section 3.6.4), (vi) 
freeze dried samples were heated (see section 3.6.4), and (vii) brain 
samples were passed through Arnberlite IRA-400 anion exchange resin 
prior to introduction onto Arnberlite XAD-2 columns (see section 3.6.4). 
Invariably, these changes failed to improve the extraction process. 
Although the experimental procedures utilized in these experi-
ments failed to produce results, alternative methods are available. 
Radioimmunoassay techniques have been used to determine the enkephalin 
content of several rat brain regions (Yang et al., 1977; Kobayashi et 
al., 1978b). The sensitivity and specificity of the antisera employed 
in the radioimmunoassay must be taken into account for quantitative 
analysis of this type. 
5.6.5 Exploratory and Motor Activity 
An established effect of DFP treatment is reduction of the ani-
mal's locomotion (see section 1.2.4). Since the effects of DFP and 
morphine on rat mobility and environmental response may interfere with 
the hot plate assessment of antinociception, exploratory and motor 
activity effects of these drugs with and without their antagonists 
were studied. 
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As described earlier (see section 5.3), DFP reduced exploratory 
activity levels in rats; neither atropine sulfate, atropine methyl 
nitrate, nor naloxone affected the DFP reduction of exploration (Table 
10). Morphine also reduced exploration in rats; naloxone and atropine 
sulfate did not alter this morphine effect (Table 10). However, the 
antinociceptive states produced by DFP and morphine do not depend upon 
the reduction of exploration produced by either compound since nalox-
one antagonized the antinociceptive state but failed to alter the 
attenuated exploration produced by these two compounds. 
It must be pointed out that atropine sulfate, alone, reduced 
exploration; this may account for its lack of effect in reversing th~ 
DFP-induced reduction in exploratory activity. A similar effect of 
naloxone, alone, could account for its failure to reverse the reduc~ 
tion in exploration produced by morphine. Since the effect of naloxone 
on exploration was not studied in the present experiments, further in-
vestigations are required to clarify this point. 
As described earlier (see section 5.3), DFP reduced motor activ-
ity levels of rats; atropine sulfate, atropine methyl nitrate, and 
naloxone did not affect the diminution in locomotion produced by DFP 
(Table 10). On the other hand, morphine increased locomotion; atro-
pine sulfate prevented while naloxone reversed the morphine-induced 
increase in motor activity (Table 10). 
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Section 5.3 describes the effect of DFP on locomotion, indica-
ting that DFP-induced antinociception and DFP-induced attenuation of 
locomotion are not related. In addition, the endogenous opioid system 
does not appear to participate in the DFP-induced depression of loco-
motion since naloxone failed to alter this DFP effect. 
It is well recognized that morphine affects spontaneous locomotor 
activity in rats. Low doses of morphine (1.0 to 5.0 mg/kg) increase 
locomotion while higher doses of morphine (10 to 40 mg/kg) produced 
biphasic changes, initial depression followed by stimulation of loco-
motion (Domino et al., 1976). In the present experiments, morphine 
(3.0 mg/kg) increased locomotion (Table 10). The locomotor effect of 
morphine appears to be mediated via opiate receptors since naloxone 
antagonized this effect (Table 10) . Naloxone not only antagonized but 
actually reversed the effect of morphine on locomotion (Table 10). 
However, since the effect of naloxone, alone, was not studied it is 
impossible to determine whether the action of naloxone on morphine de-
pression of locomotion was due to the effect of the former on motor 
behavior or involved the endogenous opioid system. Other investiga-
tors failed to demonstrate an effect of naloxone on motor activity 
(Bhargava, 1978b; Amir et al., 1979). 
It is interesting to note that atropine sulfate antagonized the 
increased locomotion produced by morphine thus implicating the cholin-
ergic system in this particular morphine effect (Table 10) . Recent 
studies have s~own that the effect of morphine on locomotion and ACh 
synthesis in rats correlates for some but not all doses of morphine; 
thus, the depressant and/or stimulant action of morphine on loco-
motion may involve neurotransmitter systems other than the cholin-
ergic system (Vasko and Domino, 1978). 
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Finally, the antinociceptive effects of morphine and DFP do not 
appear to be related to the effect of these drugs on motor activity 
since (i) employed at equiactive antinociceptive doses, morphine 
increased while DFP decreased locomotion, (ii) atropine sulfate and 
naloxone antagonized DFP-induced antinociception but failed to alter 
the attenuation of locomotion produced by DFP, (iii) atropine sulfate 
antagonized the augmented motor activity produced by morphine but 
failed to alter morphine-induced antinociception (Table 10). 
5.6.6 Effect of Naloxone on DFP-induced Responses 
The effect of naloxone on antinociception, attenuated mobility, 
and hypothermia produced by DFP was studied 1 to 48 hours after the 
DFP injection to determine if the naloxone antagonism of DFP-induced 
antinociception was related to a naloxone effect on animal mobility 
or temperature. 
As discussed earlier (see section 4.7.1), naloxone antagonized 
DFP-induced antinociception in a dose dependent manner (Fig. 6). 
Naloxone (5.0 mg/kg) not only antagonized DFP-induced antinociception 
but also produced hypernociception following the DFP administration 
(Fig. 6). Naloxone has been shown to produce hypernociception 
only under certain circumstances such as stress (Madden et al., 
1977; Rossier et al., 1977a). Thus, the reversal of DFP-
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induced antinociception may be attributed in part to a naloxone effect 
in a stressed animal. It should also be pointed out that naloxone 
(5.0 mg/kg) produced different effects on DFP-induced antinociception 
in different studies; naloxone (5.0 mg/kg) antagonized DFP-induced 
antinociception in earlier studies (see section 5.6.1). 
That the duration of action of DFP was greater than that of nal-
oxone correlates well with the irreversible nature of this anti-ChE 
agent (Fig. 6). In adnition, the antinociceptive response induced 
by morphine similarity outlasts the antagonistic action of naloxone 
(Smits, 1976). 
As described earlier (see section 4.8.2), naloxone failed to 
alter DFP-induced decrease in exploration 1 to 48 hours post DFP in-
jection (Fig. 7A). Naloxone also failed to affect DFP-induced atten-
uation of motor activity (Table 10). Thus, the naloxone antagonism 
of DFP-induced antinociception is not related to a naloxone effect 
on DFP-induced immobilization. 
As discussed earlier (see section 4.3), DFP produced hypothermia 
in rats. Naloxone did not affect the hypothermia produced by DFP nor 
did it alter rectal temperatures in naive animals (Fig. 7B). Since 
naloxone antagonized DFP-induced antinociception (Table 9) but failed 
to affect the hypothermia produced by DFP (Fig. 7B), the naloxone ant-
agonism of DFP-induced antinociception is independent of a naloxone 
temperature effect. 
5.7 Concluding Comments 
Pain, by itself, is an extremely complex, ill-defined pheno-
menon (see section 1) . All research investigations concerning 
the various aspects of the pain phenomenon entail experimental 
procedures which may produce complicating factors, thus, the 
scientific study of pain can be additionally complex. 
The basic scientist attempts to correlate the antinociceptive 
and analgesic properties of a drug so that preliminary research 
on pain can be conducted in the laboratory. Here, behavioral 
responses to a variety of noxious stimuli in several laboratory 
animals are measured (see section 5.1.3). While this procedure 
does not appear to be valid for all drugs which produce antinoci-
ception, a correlation does exist between the antinociceptive and 
analgesic properties of a particular drug or group of drugs such 
as drugs which affect the cholinergic system (see section 2) . The 
antinociceptive action of the anticholinesterase agent, diisopropyl 
phosphofluoridate (DFP), was studied in this dissertation. 
Certain factors, which can interfere with the correct assessment 
of antinocicpetion, are inherent in every testing procedure. For 
instance, here, DFP is kn~Nn to depress locomotor activity and 
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produce hypothermia (see section 2) . While these two effects of 
DFP were controlled during the present studies, either effect 
could have interfered with the correct evaluation of antinoci-
ception (see sections 5;3 and 5.4). 
It also should be pointed out that DFP may produce antinoci-
ception by stimulating Renshaw Cells. Here, the apparent anti-
nociception would be attributable to a decreased alpha motor neuron 
excitability, thus, a decreased ability to respond. This mechanism, 
however, seems unlikely since cholinergic-induced antinociception 
is known to arise from stimulation of supraspinal cholinergic 
receptors (see section 1.2.3.2). 
The ultimate test, however, is to determine whether the drug 
in question produces a clinically significant level of analgesia 
when administered to humans. The clinical value must take into 
account potential deleterious side effects as well as the effective 
level of analgesia produced by the drug. Thus, pain studies can 
be conducted only in the clinical setting. 
While DFP is too toxic for use in clinical studies, another 
anticholinesterase agent, physostigmine, is available and approved 
for clinical use. A study to determine the effect of physostigmine 
on the pain state in narcotic-tolerant individuals is described in 
the appendix (see appendix 1) . 
189 
6. SUMMARY 
Oiisopropyl phosphofluoridate (DFP; 0.1 to 1.5 mg/kg s.c.) pro-
duced antinociception in rats as measured by the hot plate test. The 
duration and intensity of the antinociceptive response incr~ased as 
the dose of OFP was increased. Administered 30 minutes after the ad-
ministration of DFP (1.5 mg/kg s.c.), atropine sulfate (4.0 mg/kg i.p.) 
antagonized while atropine methyl nitrate (4.0 mg/kg i.p.) did not 
affect the OFF-induced antinociceptive response. Administered in. 
doses of 1.0 and 1.5 mg/kg s.c., OFF produced antinociception in rats 
as measured by the tail flick test. OFF (0.1 to 1.5 mg/kg s.c.) de-
creased exploratory and motor activity levels in rats. Administered 
in a dose of 1.0 mg/kg s.c., DFF decreased rectal temperatures in 
rats. Atropine sulfate (4.0 mg/kg i.p.) failed to alter the diminu-
tion in exploration or motor activity produced by OFP. These results 
indicate that OFF-induced antinociception in rats arises via actions 
involving central cholinergic system; antinociception produced by OFF 
was independent of the locomotor depression and hypothermia produced 
by DFF. 
OFF (1.5 mg/kg s.c.) increased serotonin (5-HT) levels in rat 
medulla, meso-diencephalon, and telencephalon. As the serotonergic 
and cholinergic systems have been implicated in antinociception, OFF-
induced antinociception could be attributed to either system; para-
chlorophenylalanine (FCFA) was employed to clarify this point. Ad-
ministered alone, FCPA (i) decreased 5-HT levels in all three rat 
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brain regions studied, (ii) produced hypernociception as measured by 
the hot plate and tail flick tests, and (iii) increased motor activity 
levels; PCPA, alone, did not affect exploratory activity. Pretreat-
ment with PCPA prevented the augmentation of 5-HT levels produced by 
OFF (1.5 mg/kg s.c.) but did not affect the antinociceptive state or 
attenuation of exploratory or motor activity levels produced by OFF. 
Thus, OFF-induced antinociception is independent of the serotonergic 
system. 
Administered 30 minutes after the administration of OFF (1.0 mg/ 
kg s.c.), naloxone (0.5 to 5.0 mg/kg i.p.) antagonized OFF-induced 
antinociception. MR 2266 (-5,9 a-diethyl-2-(3-furylmethyl)-2'-hy-
droxy-6,7-benzomorphan, 1.0 mg/kg i.p.) and GPA 1843 (-2-allyl-2'-
hydroxy-9 S-methyl-5-phenyl-6,7-benzomorphan, 5.0 mg/kg i.p.), the 
active (-) isomers of narcotic antagonists, reduced morphine- and 
OFF-induced antinociception; MR 2267 and GPA 1847, the inactive (+) 
isomers of the corresponding narcotic antagonists, did not affect 
morphine- or OFF-induced antinociception. MR 2266, MR 2267, GPA 1843, 
and GPA 1847 did not produce antinociception in naive animals. An-
imals rendered tolerant t9 the antinociceptive action of morphine 
(3.0 mg/kg s.c.) by repeated daily injections of morphine failed to 
exhibit cross tolerance to an equiactive antinociceptive dose of DFP 
(1.0 mg/kg s.c.) or pilocarpine (2.5 mg/kg s.c.). These results sug-
gest that OFF-induced antinociception is mediated via stereospecific 
opiate receptors, possibly by the release of endogenous opioid pep-
tides. This latter phenomenon could not be demonstrated at this time. 
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CLINICAL INVESTIGATION PROTOCOL 
1. Introduction 
Acetylcholine, various cholinomimetics, and several anticholin-
esterase agents exhibit an antinociceptive action and the ability to 
potentiate narcotic-induced antinociception in experimental animals 
(Chen, 1958; Harris et al., 1968; Pedigo et al., 1975). Several in-
vestigations have demonstrated that the anticholinesterase agent, 
physostigmine has similar actions in humans (Slaughter, 1950; Karczmar, 
1977) . Recent animal studies in these laboratories are particularly 
pertinent (Koehn and Karczmar, 1978). First, we confirmed the anti-
nociceptive potency of anticholinesterase compounds described by 
others; in fact, some of those compounds appeared, in animals, to be 
several times more potent than morphine. Second, we have showed that 
this antinociceptive effect can be obtained in full in animals ren-
dered tolerant to morphine. Presently, intractable pain is treated by 
the chronic administrations of narcotic analgesic compounds. Side 
effects associated with this treatment include nausea, drowsiness, 
constipation, hypotension, and increased intracranial pressure, as 
well as addiction liability. What is most important, there is develop-
ment of tolerance to the analgetic action of the narcotic compound; 
thus, to achieve pain control larger and larger doses of narcotic is 
needed. Ultimately, the patients become refractory, as there is no 
dose of the narcotic that will produce analgesia short of causing re-
spiratory depression and death. 
This study is designed to test the analgetic property of physo-
stigmine, when used in combination with narcotic analgesics. It is 
hoped that the results will demonstrate that it is possible to in-
crease the pain threshold beyond that obtained with any dose of the 
narcotic used alone, thus, allowing the dose of narcotic analgesic to 
be reduced; smaller dose of the narcotic may be sufficient to produce 
pain control in the presence of physostigmine. Altogether, it is hoped 
to establish new therapeutic regimen for treating intractable as well 
as other associated pain states. 
The feasibility and safety of the proposed study can be readily 
substantiated. In the past, neostigmine was used in man to produce 
analgesia and to potentiate analgesia produced by codeine (for refer-
ences cf. Karczmar, 1977); as is well known, neostigmine is used safe-
ly fo~many years in myasthenic patients. Physostigmine was tested 
as an analgesic in normal volunteers (Sitaram et al., 1977); further-
more, it was employed in man in a number of other conditions. For 
instance, it is used to antagonize toxicity due to scopolamine and 
atropine, phenothiazines and tricyclic antidepressants; in fact, it is 
the treatment of choice in this latter condition (Snyder et al., 1974). 
It was used also in facilitating recovery from general anesthesia 
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(Bidwai et al., 1976; Brebner and Hadley, 1976). Furthermore, it is 
used currently in man to control mania, Huntington's chorea, and tar-
dive dyskinesia, and to improve memory (for references, cf. Karczmar, 
1976; 1977; Karczmar and Dun, 1978). In these various conditions, 
physostigmine was used in intravenous (IV) , intramuscular (IM) , and 
oral (PO) doses of up to 2-4 mg total dose; there is no report of se-
rious side actions and none of toxicities. In some patients, nausea 
and abdominal cramps were noticed. More rarely, sweating and saliva-
tion were observed. However, pretreatment with a synthetic anti-
cholinergic agent Robinul (0.15 mg IM) 30 minutes prior to the admin-
istration of physostigmine (0.5 mg IV) prevents these peripheral side 
effects. No further side actions or toxicities will be expected from 
the dose used. There are special considerations pertinent in the con-
text of the safety of study in question. First, physostigmine is a 
so-called reversible inhibitor of cholinesterase, the inhibition being 
short-lived and not extending, in both animal and human studies, be-
yond l to 2 hours. Second, physostigmine acts via temporary accumu-
lation of acetylcholine;as the latter is hydrolyzed upon the termin-
ation (reversal) of anticholinesterase action of physostigmine, no 
potentially deleterious delayed effects and no pathology result from 
the action of physostigmine. Third, there are specific, fast acting 
and safe antagonists of physostigmine; the quaternary anticholinergics 
such as methanthaline and propanthaline can be used to control the 
peripheral effects of physostigmine, such as gastrointestinal hyper-
motility, while atropine and scopolamine may be used to prevent both 
central and peripheral actions of physostigmine. Finally, physostig-
mine (Antilirium) is obtainable in a preparation designed for human 
use. 
2. Specific Aims 
This investigation is designed to establish the following: 
(A) Physostigmine potentiation of narcotic-induced analgesia in terms 
of: 
(1} Latency to onset of analgesia after drug administration 
(2) Duration of analgesic effect 
(3) Peak analgetic action 
(B) Therapeutic evaluation of combined narcotic-physostigmine drug 
treatment on the subjective pain experience. 
(l) Sensory qualities in terms of temporal, spatial, pressure et 
al. 
(2) Affective qualities in terms of tension, fear, and autonomic 
properties • 
(3) Evaluative qualities that describe the subjective overall 
intensity of the total pain experience. 
3. Experimental Protocol 
All patients and controls used in this study will be obtained by 
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their consent from the service of Dr. K. Badrinath, Chief, Oncology 
Section, Loyola University Medical Center. Patients who are presently 
being administered narcotic analgesics on a chronic basis for relief 
of intractable pain will be selected for this study. Patients shall 
have no known history or evidence indicating the presence of cardiac 
arrythmias, demonstrable intracranial lesions or any other physical 
or psychological abnormalities which would by the discretion of the 
attending physician place them at any particular risk. The age range 
of the patients will vary; primarily adults (i.e. greater than 21 years 
of age) will be used. No financial compensation is planned as part of 
this study. No additional laboratory or diagnostic procedures will be 
employed in or solely for the purpose of this study. 
4. Clinical Protocol 
Patients who receive narcotic analgesics on a regular basis will 
be utilized in this study. All patients participating in this study 
will be required to complete an informed consent (see pp.203). Having 
obtained the patients consent, the research investigator along with 
the patient will complete the McGill Pain Assessment Questionnaire 
which is used to gather a medical history as well as to initially 
evaluate the patients' pain status (Melzack, 1975). This requires 
approximately 30 minutes of the patients time. 
On the test day (day 1, Table 1) a patient will receive his/her 
regularly scheduled pre-determined dose of narcotic analgesic. Robinul 
(0.15 mg IM) will be administered 30 minutes before the subsequent 
drug administration for the relief of pain. At that time, the nar-
cotic analgesic physostigmine or narcotic-analqesic placebo comination 
will be employed in place of the regularly scheduled dose of narcotic 
analgesic. The correct evaluation of any drug effect requires that a 
double blind study be utilized. The choice of the combination for the 
particular patients will be randomized according to the methods de~ 
scribed by Sakal and Rohlf (1973). Furthermore, neither the patients 
nor the physician administering the drugs will know whether he/she is 
given the narcotic analgesic-placebo or the narcotic analgesic-physo-
stigmine combination. The patients will be asked to evaluate and com-
pare his/her conditions for the time periods corresponding to the two 
drug administrations mentioned previously; all evaluations will be 
made by completing the McGill-Melzack Pain Questionnaire 20 minutes 
after the administration of the regularly scheduled dose of the nar-
cotic analgesic and subsequent narcotic analgesic-physostigmine/placebo 
combination (Melzack, 1975). This procedure will be repeated (day 3, 
Table 1). Those patients who received the narcotic-analgesic physo-
stigmine drug combination on day 1 will now, day 3 receive the nar-
cotic analgesic-placebo drug combination and vice versa. The McGill-
Melzack Pain Questionnaire will be administered as before. Double 
blind study technique will be employed. In accordance with the I.R.B. 
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guidelines, patient confidentiality will be secured. Patients will be 
identified by a coded patient identification number on all forms. 
5. Interpretation of Data 
This investigation will be evaluated by tabulating the patients 
responses from the McGill-Melzack Pain Questionnaire (Melzack, 1975). 
The original McGill-Melzack Pain Questionnaire was specifically de-
signed to provide quantitative measures of clinical pain that can be 
treated statistically. The 3 major measures are: (1) the pain rating 
index, based on two types of numerical values that can be assigned to 
each word descriptor, (2) the number of words chosen, and (3) the 
present pain intensity based on a 1 to 5 intensity scale. Modifica-
tion of the original questionnaire (i.e. the addition of part 5) was 
instituted to gather additional pertinent information for this study 
(Melzack, 1975). 
Statistical analysis to determine the effecti,~ness of this pro-
cedure can be performed by comparing the patients responses in the 
various categories for the regularly scheduled dose of the narcotic 
analgesic and the narcotic analgesic-physostigmine/placebo combination 
testing sessions. If a patient's responses for the drug combination 
are greater than for the regularly scheduled dose of narcotic, it is 
rated+; if less,-; if no change, '0'. Then, a simple sign test for 
significance can be carried out. Similarly, the t test can be used 
in which the mean net changes are calculated and the differences from 
the mean are calculated for each testing session to determine whether 
a statistically significant difference has occurred. Both types of 
tests will be employed in this study. It is anticipated that this 
study will employ 20 to 40 patients. However, a pilot study utilizing 
5 patients will be performed in an unblinded manner which will allow 
the investigators to determine the degree of significance, thus allow-
ing for a better estimate of the number of patients (n) required. 'n' 
will be set on the basis of fewest patients which would be likely to 
show a statistically significant difference (p<0.05). 
6. Risks and Potential Benefits 
Risks to the patient include the potential side effects of Robinul 
and physostigmine treatments; dry mouth, nausea, bradycardia, and hypo-
tension. Gastric symptoms and heart signs if they appear will be 
treated with clozapine and atropine respectively. Any complaints of 
pain at any time during the study will be recorded and a narcotic an-
algesic given immediately. The only actual discomfort associated with 
this experiment is due to the intramuscular (IM) and intravenous (IV) 
administrations of Robinul and physostigmine/placebo respectively. 
The potential benefits of this experiment are as follows: physo-
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stigrnine is expected to potentiate narcotic-induced analgesia by pro-
ducing a greater level of analgesia; thus,(l) the refractory patient 
would be responsive to the analgetic effect of the combined drug 
treatment and (2) the dose of the narcotic analgesic could be reduced, 
thus reducing the severity of associated side effects. If the results 
are positive this would lend evidence and support for establishing a 
new more effective treatment plan for the control of pain. This could 
also lend further evidence for the use of anticholinesterase agents 
as analgesic substances (new use). 
7. Table 1 
Informed consent form for each patient utilized in this study must 
be completed (see pp. 203). 
McGill Pain Assessment Questionairre completed before test day 
(Melzack, 1975). 
Test Day Drug Administrations 
Regularly scheduled, predetermined dose of narcotic anal-
gesics administered throughout study (Narc.). 
Narc. 
*McGill-Melzack Pain Questionnaire 20 min. post drug 
administration. 
Robinul (0.15 mg IM) 30 minutes prior to Narc. + Physo-
stigmine/Placebo 
1 Narc. + Physostigmine (0.5 mg IV)/Placebo 
*McGill-Melzack Pain Questionnaire 20 min. post drug 
administration 
Narc. 
Narc. 
2 Narc. 
Narc. 
Narc. 
*McGill-Melzack Pain Questionnaire 20 min. post drug 
administration 
Robinul (0.15 mg IM) 30 minutes prior to Narc. + Physo-
stigmine/Placebo 
3 Narc. + Physostigmine (0.5 mg IV)/Placebo 
*McGill-Melzack Pain Questionnaire 20 min. post drug 
administration 
Narc. 
*McGill-Melzack Pain Questionnaire (Melzack, 1975). 
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8. Informed Consent IRB Number 
--------
Loyola University Medical Center 
Maywood, Illinois 
Department of Medicine 
Section of Oncology and Pharmacology 
Patient's Name 
Project Title: 
Date: 
--------------
-------------------------------------------------------------
8.1 Patient Information 
8.1.1 Description and Explanation of Procedure 
Your illness requires frequent and repeated administration of 
narcotic analgesic drugs to prevent the pain which you experience. As 
you become tolerant to the analgetic action of the narcotics the dose 
must be increased to remain effective. Associated with the chronic 
administration of narcotics are several side effects; most notably 
nausea, drowsiness, constipation, and respiratory depression. Some-
times your pain cannot be controlled satisfactorily even as we in-
crease the dose. The purpose of this investigation is to study the 
usefulness of the drug physostigmine, used in a combination therapy 
program with the narcotic analgesic to potentiate the effective level 
of analgesia. This would allow the dose of the narcotic to be re-
duced lessening the severity of side effects attributable to narcotic 
administration, and may improve pain control and your well-being. 
The correct pharmacological analysis requires that this study 
be done according to double-blind technique. To correctly evaluate 
the usefulness of physostigmine each patient will receive the narcotic 
analgesic-physostigmine combination and the narcotic analgesic-placebo 
(inactive compound) combination on test days l and 3 or vice versa. 
Neither the patient nor the physician administering the drug will know 
who receives what. In addition, 30 minutes prior to the administration 
of the narcotic analgesic-physostigmine/placebo combination you will 
receive an intramuscular (IM) injection of Robinul to prevent the ap-
pearance of side effects attributable to the administration of phy-
sostigmine. Each patient will participate in this study on three 
days. During this time, you will be asked to complete with the help 
of a research investigator five questionnaires as follows. First, the 
McGill Pain Assessment Questionnaire will be administered on the day 
preceding the first test day. This will require approximately 30 min-
utes of your time. Second, the McGill-Melzack Pain Questionnaire will 
be administered two times each on test days l and 3. You will be asked 
to complete this form following your regularly scheduled dose of nar-
~otic analgesic as well as following the combination regularly sched-
uled dose of narcotic analgesic with physostigmine/placebo on each 
test day (total of 4 times) . No participation is required on test 
day 2. 
8.1.2 Risks and Discomforts 
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There are essentially no life risks involved using physostigmine 
at this dose (0.5 mg); potential adverse side effects are few. Some 
patients report feelings of nausea which can be remedied by admin-
istration of Clozapine or Compazine. Bradycardia (slow heart) consti-
tutes another side effect which has developed in some patients. Your 
heart rate and blood pressure will be monitored and in need can be 
corrected by administration of atropine" The only discomfort associ-
ated with this procedure would be due to the needle for intramuscular 
(IM) injection of Robinul and the intravenous (IV) injection of physo-
stigmine/placebo. 
I understand that biomedical or behavioral research such as that 
in which I have agreed to participate, by its nature, involves risk 
of injury. In the event of physical injury resulting from these re-
search procedures,emergency medical treatment will be provided at no 
cost, in accordance with the policy of Loyola University Medical Cen-
ter. No additional free medical treatment or compensation will be 
provided except as required by Illinois law. 
In the event you believe that you have suffered any physical 
injury as the result of participation in the research program, please 
contact Dr. H.J. Blumenthal, Chairman, Institutional Review Board for 
Protection of Human Subjects at the Medical Center, telephone (312) 
531-3384. 
8.1.3 Potential Benefits 
The benefit to you that we hope for will be a lessening of pain, 
and reduction of untoward side effects due to narcotic drug adminis-
tration (drowsiness and constipation) . We also hope that this partic-
ular therapeutic regimen will prove to be effective and thus establish 
a new procedure for treating patients who require this type of care. 
8.1.4 Alternatives 
The alternative method for management of your pain is to be main-
tained on a narcotic analgesic treatment plan. The side effects and 
risks associated with this therapy are stated previously. 
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Consent 
I have fully explained to (name: patient) the nature 
and purpose of the above described procedure and the risks that are 
involved in its performance. I have answered and will answer all 
questions to the best of my ability. 
(signature: principal investigator) 
I have been fully informed of the above-described procedure with its 
possible benefits and risks. I give permission for my participation 
in this study. I know that Dr. Ketty Badrinath or his associates will 
be available to answer any questions I may have. If, at any time, 
I feel my questions have not been adequately answered, I may request 
to speak with a member of the Medi~al Center Institutional Review 
Board. I understand that I am free to withdraw this consent and 
discontinue participation in this project at any time without prej-
udice to my medical care. I have received a copy of this informed 
consent document. 
(signature: patient) 
(signature: witness to signatures) 
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